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1 INTRODUCTION 
 
The natural product tetrandrine (1, Figure 1) belongs to the class of bisbenzylisoquinoline 
alkaloids, which can be mainly found in the plant families Menispermaceae, Berberidaceae, 
Lauraceae, and Ranunculaceae[2-3].  
Tetrandrine (1) was first isolated by Kondo and Yano in 1928[4-5] from the climbing plant 
Stephania tetrandra S. Moore (Menispermaceae). The root of this herb has been used in 
Chinese and Japanese traditional medicine for treating diverse diseases such as tuberculosis, 
malaria, asthma, hyperglycemia, hypertension and cancer[6]. Apart from the traditional use the 
pharmacological effects of tetrandrine (1) in its isolated form have been extensively studied. In 
this work anticancer, antiviral, chemoresistance reversing and calcium channel blocking 
activities will be emphasized and discussed in the following. 
 
 
 
 
 
Figure 1. Tetrandrine (1) (1S,1’S) and isotetrandrine (2) (1R,1'S) – Numbering of the skeleton according to the 
convention established by Shamma[7] (Reproduced from ref. 1 by permission from The Royal Society of Chemistry). 
Also for the isomer isotetrandrine (2, Figure 1) biological activities such as anticancer[8-10], 
multidrug resistance reversing[11-12], antioxidative[13] and autoimmune disease modifying[14] 
effects are reported.  
 
1.1 BISBENZYLISOQUINOLINE ALKALOIDS – AN OVERVIEW 
 
As the name suggests, bisbenzylisoquinolines consist of two benzylisoquinoline moieties. The 
isoquinoline is mostly saturated to a tetrahydroisoquinoline, but also partially reduced 
dihydroisoquinolines and fully aromatic isoquinoline moieties can be found in natural products. 
Depending on the degree of saturation up to two asymmetric centres (C-1 and C-1’) are 
present. Bisbenzylisoquinolines appear as macrocyclic dimers or in their open chained seco-
form. The monomers are linked through one or more diaryl ether bridges, biphenyl bridges, 
phenyl-benzyl ether bridges or a combination thereof. The monomers can be connected in 
different orientations regarding the isoquinoline unit (referred as “head”) and the benzyl unit 
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(referred as “tail”), resulting in three possible connection patterns “head-to-head”, “head-to-tail” 
and “tail-to-tail”. The diversity of bisbenzylisoquinolines is represented by selected examples 
of some subtypes in Figure 2. Tetrandrine (1) is linked by a “head-to-head” and “tail-to-tail” 
bridge according to this classification. Common substituents of bisbenzylisoquinolines in the 
aromatic moiety are hydroxy, methoxy and methylenedioxy groups.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Seco-bisbenzylisoquinoline dauricine (3) and macrocyclic bisbenzylisoquinolines cycleanine (4), 
cepharanthine (5), tiliaimine (6) and racemosidine A (7). 
 
1.2 BIOLOGICAL ACTIVITIES OF TETRANDRINE (1) 
 
As already mentioned multiple biological activities have been reported for tetrandrine (1). In 
the following part its anticancer, antiviral, chemoresistance reversing and calcium channel 
blocking activities will be emphasized. 
 
1.2.1 TETRANDRINE (1) AS CA2+ CHANNEL BLOCKER 
 
A study in 1982[15] found that tetrandrine (1) is a modulator of Ca2+ channels that blocks in a 
similar manner as verapamil (8, Figure 3), a blocker of voltage-dependent L-type Cav channels. 
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Further studies confirmed inhibitory effects of tetrandrine (1) on L-type Cav channels[16-18] and 
identified also T-type Ca2+ channels as pharmacological target[19-20].  
 
Figure 3. Structure of verapamil (8), a blocker of L-type calcium channels. 
Moreover tetrandrine (1) was found as a blocker of two-pore channels (TPCs)[21], which are 
also members of the superfamily of voltage-gated calcium channels[22]. TPCs are located on 
the membranes of endolysosomes[3, 22-23], which are intracellular acidic calcium stores that are 
important organelles for the endocytotic transport in cells[3, 22, 24] and therefore vital for 
physiological functions in the cell. TPCs are an interesting pharmacological target since they 
play a key role in the pathomechanism of diseases such as cancer[25] and viral infections[21], 
which will be discussed in detail in the following. 
 
1.2.2 ANTIVIRAL ACTIVITY 
 
Recent studies have shown that tetrandrine (1) possesses antiviral properties against Ebola 
virus (EBOV)[21, 26] and the coronaviruses MERS-CoV[27] and SARS-CoV-2[28]. Hereby 
tetrandrine (1) reduced the infectivity by affecting a late entry step of the viruses (or 
pseudoviruses respectively that served as model viruses) into host cells. These studies 
suggest tetrandrine’s (1) TPC blocking property to be the mode of action. The infection 
pathways of these viruses are similar, with TPCs being a vital host cell factor. After binding of 
the virus to cell surface receptors it is internalized through endocytosis to facilitate host cell 
entry. The virus is then translocated via the endolysosomal system before the virus core is 
released to the cell cytoplasma where it replicates. Since TPCs are important players in the 
regulation of endolysosomal trafficking, these channels are a potential target for 
pharmacological intervention.  
Sakurai et al. could halt EBOV infection in vitro in human monocyte-derived macrophages with 
tetrandrine (1) in submicromolar concentrations (IC50 = 55 nM)[21]. In further in vivo studies the 
treatment of infected mice with tetrandrine (1) significantly enhanced the survival rate.  
Another study investigated the inhibitory effect of several bisbenzylisoquinoline alkaloids on 
MERS-CoV infectivity in vitro[27]. Among several tested bisbenzylisoquinolines and a series of 
known ion channel modulators, tetrandrine (1) was one of the most potent inhibitors of MERS-
CoV pseudovirus infectivity with an IC50 of 7.0 µM. 
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Also against the novel coronavirus SARS-CoV-2 tetrandrine (1) showed antiviral activity in 
vitro[28]. The TPC-mediated virus entry could be decreased by blocking the TPC activity. 
Currently, in China a clinical trial (NCT04308317)[29] is announced to investigate orally 
administered tetrandrine (1) as adjuvant treatment of COVID-19 patients. It needs to be stated 
that although this study is officially registered on clinicaltrails.gov, a database provided by the 
U.S. National Library of Medicine, it has to be seen critically. The study is registered as a phase 
4 study, despite this late stage of the approval process is impossible considering the novelty 
of the disease intended to treat. However, it is worth to observe the progress and the possible 
outcome of this study. 
 
1.2.3 ANTICANCER ACTIVITY 
 
The effect of tetrandrine (1) on different types of cancer has been extensively investigated[30].  
As antitumor agent the alkaloid may not have one specific target but several. It modulates 
diverse physiological functions of cancer cells and therefore intervenes in multiple aspects of 
oncogenesis. It was found to affect the proliferation[31], angiogenesis[32], migration[25], 
apoptosis[33-34] and chemoresistance of tumors[35]. TPCs[25], cell cycle regulating kinases[36-37], 
apoptosis inducing caspases[38], tumor suppressor genes[37], death receptors and efflux 
pumps[39-42] are discussed targets to be modulated by tetrandrine (1)[35]. In the following the 
role of TPCs and efflux pumps in cancer will be outlined. 
Recently it was shown that TPCs are an important factor for the migration, angiogenesis and 
growth of tumors[25, 43-44]. As mentioned before, TPCs are located on the membranes of 
endolysosomes[3, 22-23] and thereby regulate multiple functions in cancer cells, such as the 
trafficking and recycling of integrins[45]. Integrins are transmembrane receptors that facilitate 
the adhesion and migration of tumor cells. By the pharmacological inhibiton of TPCs with 
tetrandrine (1) or Ned-19[44] (9, Figure 4), both known blockers of TPCs, the migration and 
vascularization of tumor cells could be impaired in vitro and in vivo[25]. It was further shown that 
TPCs mediate vascular endothelial growth factor (VEGF)-induced neoangiogenesis[46]. 
Through a blockade of TPCs the VEGF-induced formation of new blood vessels could be 
inhibited[47]. This data reveals the role of TPCs in cancer and identifies these cation channels 
as a pharmacological target for tumor therapy. 
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Figure 4. Structure of Ned-19 (9), a blocker of TPC channels. 
 
1.2.4 TETRANDRINE (1) AS A REVERSER OF MULTIDRUG RESISTANCE 
 
Apart from a direct anticancer activity tetrandrine (1) showed synergistic effects on resistant 
cancer cell lines in combination with other common antitumor agents such as vincristine, 
doxorubicine and paclitaxel. Hereby tetrandrine (1) was able to resensitize chemoresistant 
tumors by levering the resistance mechanism. As the mode of action several studies discuss 
the modulation of P-glycoprotein (P-gp)[39, 41-42, 48-49] either by downregulation or by direct 
inhibition. P-gp is a universal efflux pump for xenobiotics, which is a key factor of drug 
resistance[50] causing treatment failure of tumor therapy. The multidrug resistance-associated 
protein 1 (MRP1), another unspecific transporter protein, was also reported as a target of 
tetrandrine (1)[40]. By suppressing the P-gp/MRP1-mediated efflux of chemotherapeutic drugs, 
the intracellular accumulation increases and the anticancer effect is restored consequently.  
Under the name CBT-1™ tetrandrine (1) is investigated in clinical studies[51-52] (NCT03002805/ 
NCT00972205/ NCT00437749) and intended for the therapy of multidrug resistant tumors. 
 
1.2.5 TOXICITY OF TETRANDRINE (1) 
 
This section is reproduced and partly adapted from ref. 53 [53], Copyright Elsevier (2020). 
 
Despite its versatile pharmacological effects the clinical use of tetrandrine (1) as a drug is 
limited by its toxicity. Several toxic side effects have been reported for tetrandrine (1) and other 
bisbenzylisoquinolines so far[54]. In animal models mainly an injury of liver and lung was 
observed[55-58].  
The molecular mechanism of tetrandrine-induced toxicity has not been entirely elucidated yet. 
Li and coworkers[59] hypothesized that an interaction of tetrandrine (1) with p38α MAPK 
(mitogen-activated protein kinase) led to liver injury, whereas several other studies suggest 
the involvement of cytochrome P450 (CYP) enzymes in tetrandrine-induced pulmonary[55-56] 
and hepatic toxicity[60]. Qi et al.[60] considered CYP2E1 as primary reason for mitochondrial 
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dysfunction of rat hepatocytes after tetrandrine (1) exposure, which they related to reactive 
oxygen species (ROS) that were generated in the course of CYP2E1 metabolism. However, it 
is unknown which molecular mechanisms are connected to CYP2E1-mediated toxicity. In a 
metabolic study by Jin et al.[55] a CYP3A4- and CYP3A5-mediated metabolism equally leading 
to a potentially toxic intermediate is described. Hereby one particular structural element is 
suggested to be responsible for tetrandrine’s (1) toxicity. In the hypothesized metabolic 
pathway, the methoxy group at C-12 in para-position to a benzylic methylene group is first 
demethylated to give the corresponding phenol 10. This phenol then undergoes enzymatic 
oxidation to the para-quinone methide 11, which is an electrophilic intermediate prone to attack 
bio-nucleophiles (see Scheme 1). After incubation of tetrandrine (1) with human liver 
mircosomes in the presence of glutathione (GSH), a corresponding GSH conjugate (12) was 
detected via LC-MS, which provides evidence for the formation of the para-quinone methide 
11.  
Scheme 1. CYP-enzyme mediated oxidative metabolism of tetrandrine (1) adopted from Jin et al[55]. 
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1.3 SYNTHETIC APPROACHES  
 
Central structural motifs in the bisbenzylisoquinoline scaffold are the diaryl ether and the 
tetrahydroisoquinoline moiety. For the construction of both moieties a number of methods is 
available. In the following a concise overview focusing on the most prominent methods is 
provided. Furthermore protocols of already published syntheses of tetrandrine (1) and 
derivatives will be discussed briefly.  
 
1.3.1 SYNTHESIS OF DIARYL ETHERS 
 
1.3.1.1 ULLMANN REACTION 
 
The Ullmann-type cross-coupling is the most commonly utilized method for the construction of 
diaryl ethers in the synthesis of natural products[61]. Fritz Ullmann originally invented this 
method in the 20th century reacting aryl halides in the presence of copper to form biaryl 
compounds[62]. He extended this approach to the preparation of diarylamines[63] and diaryl 
ethers[64]. In his first successful attempt in the construction of diaryl ethers aryl halides were 
reacted with phenols in the presence of KOH or elementary potassium, respectively, and neat 
copper at elevated temperatures (> 200 °C)[64]. Harsh reaction conditions (high temperatures 
and strong bases), high catalytist loads and restricted substrate scope limit the application of 
the “classical” Ullmann reactions. To overcome these drawbacks modified protocols for 
copper-catalyzed cross-coupling reactions employing different copper salts, ligands and 
weaker bases were explored[65-66].  
 
 
Scheme 2. Ullman-type cross-coupling reaction of aryl halides and phenols catalyzed by copper/ligand systems. 
The use of auxiliary ligands, which are mostly bidentate, enhances the solubility and stability 
of copper complexes resulting in higher reaction rates, whereas catalyst loadings and reaction 
temperatures could be reduced[67]. Figure 5 displays examples of ligands, which were tested 
for the construction of the diaryl ether bridges in the synthesis of tetrandrine (1) (see chapter 
3.1).  
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Figure 5. Tested ligands for the Ullmann-type cross-coupling reaction in the synthesis of tetrandrine (1) (see Table 
2 in chapter 3.1: N,N-dimethylglycine[68] (13), 1,1'-azobis(cyclohexanecarbonitrile)[69] (14) and picolinic acid[70] (15)). 
 
1.3.1.2 CHAN-EVANS-LAM COUPLING 
 
Not only aryl halides are suitable for the synthesis of diaryl ethers, but also aryl boronic acids 
can be utilized as coupling partners. The cross-coupling of aryl boronic acids and phenols (as 
well as other nucleophiles) was reported by Chan[71] and Evans[72] in 1998. In this approach 
Cu(OAc)2 is used as catalyst in the presence of the amine bases triethylamine or pyridine 
furnishing the desired coupling product already at ambient temperature. To prevent 
competitive side reactions presumably due to the formation of water, the addition of molecular 
sieves (4 Å) is reported[72].  
 
 
Scheme 3. Chan-Evans-Lam cross-coupling reaction of aryl boronic acids and phenols catalyzed by 
copper(II)acetate. 
Furthermore it was observed that the reaction is performed best under oxygen or ambient 
atmosphere instead of an inert argon atmosphere[72], which makes this method very 
convenient.  
 
1.3.1.3 BUCHWALD-HARTWIG CROSS-COUPLING 
 
In this transition metal-mediated synthesis of diaryl ethers reported by Buchwald[73] and 
Hartwig[74] the C–O bond is formed under palladium catalysis at elevated temperatures around 
100 °C. In addition electron-rich, sterically bulky phosphine ligands are used as part of the 
catalytic system. Figure 6 displays the ligands, which were tested for the diaryl ether synthesis 
in tetrandrine (1) (see chapter 3.1).  
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Figure 6. Typical ligands or catalysts respectively, used for Buchwald-Hartwig coupling: tBuXPhos (16), 
Me4tButylXphos (17) and catalyst PEPPSITM-IPr (18), which were tested for the diaryl ether synthesis in tetrandrine 
(1) (see Table 2 in chapter 3.1). 
Mostly Pd2(dba)3/Pd(dba)2 or Pd(OAc)2 are used as palladium source and K3PO4 as base was 
found to be effective for diaryl ether formation[73]. Scheme 4 shows typical conditions for 
Buchwald-Hartwig cross-coupling reactions. 
 
Scheme 4. Buchwald-Hartwig reaction of aryl halides/triflates and phenols catalyzed by a palladium/ligand system. 
With this method not only electron-deficient or electronically neutral but also electron-rich aryl 
halides and aryl triflates readily reacted with a variety of phenols to the corresponding diaryl 
ethers[73]. Drawbacks of this method are the complex ligands, which are often expensive or not 
commercially available at all. 
 
1.3.1.4 O-ARYLATION WITH DIARYLIODONIUM SALTS 
 
In this attempt hypervalent iodine(III) compounds in the form of diaryliodonium salts are used 
as arylating agents. In the presence of inorganic bases diaryliodonium salts react with phenols 
to diaryl ethers at temperatures ranging from ambient temperature to around 100 °C [75-76]. The 
diaryliodonium salts can be prepared by oxidation of either two iodoarenes or elemental iodine 
and two arenes or an aryl iodide and an arene with potassium peroxodisulfate (K2S2O8) or m-
chloroperoxybenzoic acid (mCPBA) in the presence of strong acids such as TFA or TfOH[77-
80]. This method results in either symmetrical or unsymmetrical diaryliodonium salts, which can 
both be used for arylation. In case of symmetric salts only one aryl group can be transferred 
to the nucleophile, although this results in the waste of one iodoarene in consequence. 
Unsymmetric salts consist of one aryl group, which is supposed to be transferred and one 
auxiliary arene, which serves as “dummy group”[80]. Depending on electronic and steric effects 
one aryl group is preferably transferred to the nucleophile in the reductive elimination step. 
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Electron deficient aryl groups are favoured over electron rich arenes, also aryl groups bearing 
ortho-substituents promote reductive elimination[81].  
 
 
Scheme 5. Diaryl ether synthesis with diaryliodonium salts and phenols (some typical counter ions of the 
diaryliodonium are X = -OTf, -OTs, BF4-). R2 = dummy group. 
Considering the fact that the aromatic rings in the target compound tetrandrine (1) are highly 
substituted and mostly electron rich due to the presence of methoxy groups, it might be difficult 
to control the selectivity in the transfer process. This method also requires the synthesis of a 
suitable diaryliodonium salt in the first step, which makes this approach not the method of first 
choice.  
 
1.3.2 SYNTHESES OF THE TETRAHYDOISOQUINOLINE MOIETY 
 
1.3.2.1 BISCHLER-NAPIERALSKI REACTION 
 
The Bischler-Napieralski reaction, discovered in 1893 by the eponymous chemists[82], is a 
commonly used method for the construction of the 1,2,3,4-tetrahydroisoquinoline scaffold in 
several steps. The first step is the intramolecular cyclization of an N-acylated β-
phenethylamine (I) typically catalyzed by a lewis acid furnishing a 3,4-dihydroisoquinoline (II), 
followed by the reduction to the corresponding tetrahydroisoquinoline (III) in a second step. 
As diverse natural (bis)benzylisoquinolines are N-methylated, a subsequent N-methylation is 
typically an additional step.  
 
Scheme 6. Typical conditions for the Bischler-Napieralski reaction and subsequent reduction of the resulting 3,4-
dihydroisoquinoline II to a 1,2,3,4-tetrahydoisoquinoline III.  
To first access an appropriate amide in this approach, a phenethylamine and an arylacetic acid 
are required, which are then condensed to the corresponding amide. These arylacetic acid 
precursors are often difficult to access. Another disadvantage of this method is the 
comparatively long sequence of steps. 
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1.3.2.2 PICTET-SPENGLER REACTION 
 
The Pictet-Spengler reaction[83] is a convenient method for the construction of 
tetrahydroisoquinolines in a one-pot process, typically employing β-phenethylamines and 
aldehydes. Hereby the amine condenses with the aldehyde to form an imine, which then 
undergoes an intramolecular cyclization in the presence of an acid. This method mostly 
requires phenethylamines bearing electron donating groups, strong acids[84] and elevated 
temperatures. In the N-acyl Pictet-Spengler reaction as a variant, acylated amine precursors 
(I) are used instead that react with aldehydes (II) resulting in N-acyl iminium intermediates 
(III), which are excellent electrophiles generally enhancing the cyclization reaction[85]. In a 
nucleophilic attack by the aromatic ring the cyclization takes place under the simultaneous 
formation of the asymmetric centre at C-1 furnishing the N-acyl 1,2,3,4-tetrahydroisoquinolines 
(IV).  
 
Scheme 7. The N-acyl Pictet-Spengler reaction. The aldehyde II and N-acylated phenethylamine I condense to 
the N-acyliminium intermediate III, which then undergoes cyclization in a nucleophilic attack by the aromatic ring 
to give N-acylated 1,2,3,4-tetrahydroisoquinoline IV. 
For the Pictet-Spengler reaction the electrophilic component is not limited to aldehydes, also 
surrogates like acetals[86-87], enamines[88-89], alkynes[90-91] and enol ethers[92] for example can 
be employed[93]. Such masked aldehydes are often more stable than arylacetaldehydes, which 
would be required for the construction of benzyltetrahydroisoquinolines. The high diversity of 
starting material as well as the access of the tetrahydroisoquinoline moiety in only one step 
makes this approach very attractive and will be object of preliminary investigations in the 
following. 
 
1.3.3 PUBLISHED SYNTHESES OF TETRANDRINE (1) AND DERIVATIVES 
 
So far only two synthetic approaches[94-95] to tetrandrine (1) are published apart from the 
synthesis reported in this thesis. In 1968 Inubushi and coworkers accomplished the first total 
synthesis of tetrandrine (1), its enantiomer phaeanthine (33) and its diastereomer 
isotetrandrine (2) [94, 96] in more than 20 steps. Central steps in this approach are two copper-
catalyzed Ullmann couplings for the construction of the diaryl ether moieties and two Bischler-
Napieralski reactions for the formation of the two benzylisoquinoline units. On Scheme 8 the 
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essential steps of Inubushi’s approach are summarized. Aryl acetic acid 19 was condensed 
with phenethylamine 20 to the amide 21 in a yield of 64%, which was then cyclized in a first 
Bischler-Napieralski reaction using POCl3. The resulting dihydroisoquinoline 22 was reduced 
to the racemic tetrahydroisoquinoline 23, which was converted into its (+)-tartaric acid salt and 
resolved into the enantiomers via fractional crystallization. The isolated free base (R)-23, which 
is the precursor for phaeanthine (33) or isotetrandrine (2) respectively, was subsequently N-
methylated by reductive alkylation. The (S)-isomer of 23 represents the corresponding 
precursor for the synthesis of tetrandrine (1). Next, the N-methylated building block 24 was 
further reacted via Ullmann coupling catalyzed by CuO with phenol 25 to give the diaryl ether 
26 in 42% yield. After the debenzylation of 26 the obtained phenol 27 was then coupled in a 
second Ullmann synthesis with methyl p-bromophenylacetate 28 to yield the diaryl ether 29. 
In a sequence of several steps, which involves the conversion of the methyl ester into a p-
nitrophenyl ester and the deprotection of the N-Boc group, the cyclic amide 30 was obtained 
in a yield of 54% over 4 steps. Amide 30 was then reacted in an intramolecular Bischler-
Napieralski cyclization to the 3,4-dihydroisoquinole 31, which was subsequently reduced to the 
tetrahydroisoquinoline 32 using different methods, either by Pt-catalyzed hydrogenation, by 
hydride transfer using NaBH4 or by reduction with Zn/H2SO4. By hydride transfer and the 
reduction with zinc, stereocontrol was achieved to some extent in this step, whereas no 
stereocontrol was observed in the catalytic hydrogenation resulting in a mixture of 
diastereomers. Final step was the N-methylation of intermediate 32 furnishing (iso)tetrandrine 
and the corresponding enantiomers, depending on which isomer of intermediate 23 was 
reacted after resolution. The overall yield in this approach amounts 2.1% (after the combination 
of the building blocks 19, 20, 25 and 28). 
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Scheme 8. First published total synthesis of (iso)tetrandrine (1/2) and phaeanthine (33) by Inubushi et al.[94]. The 
synthesis of tetrandrine (1) is not explicitly shown, but follows the same synthetic route using the corresponding 
(S)-enantiomer of intermediate 23. 
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A very similar approach was recently published in a Chinese patent[95] using the same key 
reactions. Two racemic benzyltetrahydroisoquinoline units, which were synthesized via 
Bischler-Napieralski cyclization using arylacetic acid and phenethylamine building blocks, were 
connected in two consecutive Ullmann couplings as the final steps. Consequently, and in 
contrast to Inubushi’s approach, this approach lacks stereoselectivity. 
Beside the total synthesis of the natural product a number of semi-synthetic tetrandrine 
derivatives and the syntheses hereto are published. Hereby the isolated alkaloid from plant 
sources served as starting material and structural modifications were mainly introduced on C-
5 (e.g. (hetero)aryl[97-99] and alkynyl rests[99]) and C-14 (e.g. sulfonamide[100] and (thio)urea[101-
102] derivatives) by electrophilic substitution reactions on the electron-rich aromatic rings. 
Furthermore quaternary ammonium salts[103] of tetrandrine (1) are published, which were 
obtained via N-alkylation at N-2’.  
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2 OBJECTIVES 
 
2.1 AIM OF THIS THESIS 
 
Aim of this work is to develop a new synthetic route to tetrandrine (1) and isotetrandrine (2), 
which is more efficient than previously published approaches not only in terms of yield but 
primarily regarding the total number of steps. The protocol should allow to employ easily 
accessible building blocks ideally deriving from cheap commercially available starting 
materials. The synthetic route should allow to flexibly implement diverse structure variations in 
particular on the aromatic rings. Several routes are to be established, one starting with the 
construction of rings A-C that are comprising one half of the target molecule and the second 
one starting with rings A’-C’, so that - depending on which aromatic ring is subjected to 
systematic structure variations - the corresponding modified building block can be inserted in 
a late stage of the synthesis. Eventhough the synthesis is planned as a racemic approach in 
the first place, a perspective for controlling the stereochemical outcome via asymmetric 
induction should be provided in a further approach, as high diastereoselectivity of the protocol 
is aimed for. For this purpose an additional variation of each route should be designed, 
resulting in a total of four different routes.  
Once a synthetic route is established, structure variations of the aromatic ring C are intended. 
Since the metabolically labile methoxy group at C-12 in ring C is discussed to be responsible 
for tetrandrine’s (1) toxicity as already mentioned, an elimination or replacement by different 
functional groups is targeted. Furthermore, the synthesis of seco-analogues based on 
intermediates of the tetrandrine route is envisaged, as the design of less complex and therefore 
easier accessible benzylisoquinoline compounds with high biological activity is intended. 
Eventually all obtained analogues are subject of pharmacological evaluation focussing on 
anticancer and multidrug resistance reversing activity as well as their toxicity profile.  
As an additional synthetic challenge, the total synthesis of three more natural products, namely 
the isoquinoline alkaloids muraricine (in its racemic form rac-34), berbanine (35) and berbidine 
(36) is to be accomplished. 
 
Figure 7. Isoquinoline-benzylisoquinoline alkaloid muraricine (34) and isoquinoline-isoquinolone alkaloids 
berbanine (35) and berbidine (36). 
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2.2 STRATEGY OF SYNTHESIS 
 
2.2.1 PRELIMINARY STUDIES FOR THE SYNTHESIS OF THE TETRAHYDROISOQUINOLINE 
SCAFFOLD 
 
In a first step a suitable method for the construction of the tetrahydroisoquinoline moiety is to 
be selected. Due to the fast access of this structural motif via Pictet-Spengler reaction in only 
one step and the high flexibility of starting material, this method seems very promising for the 
synthesis of the targeted natural products. It was decided to focus on N-acyl Pictet-Spengler 
condensation, since N-acyl iminium intermediates as strong electrophiles readily undergo the 
cyclization step as discussed before. Carbamates were chosen as acylated phenethylamine 
building blocks, since they are easily available by treating phenethylamines with acylating 
agents such as alkyl chloroformates to give urethans. An additional benefit of the carbamate 
group is the option to convert it directly into an N-methyl group by reduction with e.g. lithium 
alanate. The phenethylamines required for this approach can be accessed from aromatic 
aldehydes by Henry reaction and subsequent reduction of resulting β-nitrostyrenes.  
Further, an alternative to aldehydes should be investigated, since arylacetaldehydes, which 
would be required for the synthesis of benzyltetrahydroisoquinolines are often laborious to 
access and instable due to their tendency towards polymerization and autocondensation. As 
discussed before also masked aldehydes such as acetals[86-87], enamines[88-89], alkynes[90-91] 
and enol ethers[92] can be employed instead of aldehydes. Alkynes, nitrostyrenes - as precursor 
for the corresponding enamines - and enol ethers are investigated in preliminary model 
reactions in the following. 
For this purpose known N-ethoxycarbonyl-3,4-dimethoxyphenethylamine (39) was chosen as 
N-acyl-arylethylamine building block, which was readily synthesized from commercially 
available 3,4-dimethoxyphenethylamine (37) and ethyl chloroformate (38) according to a 
literature method[104] (Scheme 9). 
 
Scheme 9. Synthesis of N-acyl-arylethylamine building block 39 serving as a model substrate in the following N-
acyl Pictet-Spengler test reactions. 
In a first attempt to investigate alkynes as building blocks for the Pictet-Spengler condensation, 
carbamate 39 was stirred with phenylacetylene (40) in the presence of trifluoroacetic acid 
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(TFA) in DCM following Vercauteren’s approach[90] (Scheme 10, A). Neither at ambient 
temperature nor under reflux conditions the desired cyclization product 41 could be generated, 
but a number of unidentified side products was detected instead (GC-MS and TLC control). 
Next, carbamate 39 was submitted to metal-catalyzed hydroamidation reaction to access the 
enamide 42 in the first place, which should then be cyclized under acidic conditions[105] to give 
41. To generate the enamide 42 two protocols of Gooßen et al.[106-107] were applied (Scheme 
10, B, methods a and b). In this approach a ruthenium catalyst (in situ generated from a 
ruthenium source and phosphine ligands) should promote the addition of carbamate 39 to 
phenylacetylene (40) in the presence of DMAP (and K2CO3 as base). Unfortunately no 
conversion to the desired enamide 42 could be observed (GC-MS control). Also the method of 
Herrero et al.[108] using FeCl3 as catalyst in the presence of Cs2CO3 and pyridine was 
unsuccessful (Scheme 10, B, method c). 
 
Scheme 10. Attempted synthesis of tetrahydroisoquinoline 41 via (A) Pictet-Spengler type reaction using alkyne 
40 as aldehyde equivalent or (B) hydroamidation resulting in the enamide intermediate 42 susceptible for the 
subsequent TFA-catalyzed cyclization. Reaction conditions are listed below.  
Table 1. Conditions for the hydroamidation reaction of carbamate 39 with phenylacetylene (40). 
method conditions conversion 
a[106] 
carbamate 39 (1.0 eq.), alkyne 40 (2.0 eq.), 3 mol% RuCl3·3 H2O, 
9 mol% P(n-Bu)3, 9 mol% DMAP, 15 mol% K2CO3, 40 mol% H2O, 
toluene, 100 °C 
- 
b[107] 
carbamate 39 (1.0 eq.), alkyne 40 (1.3 eq.), 1 mol% ((p-cumene) 
RuCl2)2 , 3 mol% P(p-Cl-C6H4)3, 4 mol% DMAP, toluene, 60 °C 
- 
c[108] 
carbamate 39 (1.0 eq.), alkyne 40 (1.0 eq.), 10 mol% FeCl3, 
Cs2CO3 (1.0 eq.), 40 mol% pyridine, toluene, 150 °C (pressure 
tube) 
- 
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In the next attempt the nitrostyrene 43 as precursor of enamine 44 was examined. β-
Nitrostyrenes are easily available in one step from benzaldehydes and nitromethane via Henry 
reaction and therefore valuable building blocks. The commercially available β-nitrostyrene 43 
was first submitted to a nickel-catalyzed reduction method using polymethylhydrosiloxane 
(PMHS) as reducing agent[109]. Hereby the nitro group should be selectively reduced to an 
amine resulting in the envisaged primary enamine 44 (Scheme 11, A). Although this protocol 
was applied on the identical nitroalkene compound as described in the publication, there was 
no conversion observed (TLC control with the eluent system used by the authors for the 
purification of enamine 44). Even at elevated temperatures (110 °C instead of 80 °C) or under 
microwave irradiation the reaction was unsuccessful. To rule out that the enamine is not 
detectable due to its susceptibility towards hydrolysis or other lability issues, the reaction was 
repeated in presence of carbamate 39 and an acid to instantly react the enamine 44 via N-acyl 
Pictet-Spengler condensation, but there was no reaction observed.  Next, another reduction 
method was tested in which the intermediate is not an enamine but the corresponding 
phenylacetaldehyde (45) using CrCl2 as reducing agent[110] (Scheme 11, B). To avoid any 
possible stability issues of the generated phenylacetaldehyde, the reduction was conducted 
as one-pot approach in presence of carbamate 39. As hydrochloric acid was required for the 
reduction protocol anyways, the acidic condition should promote the subsequent N-acyl Pictet-
Spengler condensation once the aldehyde is generated in situ. Also this attempt did not lead 
to the desired product 41.  
Scheme 11. Attempted synthesis of tetrahydroisoquinoline 41 using β-nitrostyrene 43 after (A) reduction to 
enamine intermediate 44 or (B) conversion to phenylacetaldehyde 45. 
Following Comins’ approach[111] enol ether 46 was now envisaged as aldehyde equivalent in 
the N-acyl Pictet-Spengler condensation with carbamate 39, a method that was already 
applied successfully in our group before[112-113]. When reacting methoxystyrene 46 
(commercially available) with carbamate 39 in the presence of TFA a full conversion within 2 
h was observed and the desired cyclization product 41 was isolated in a yield of 71% (Scheme 
12), reproducing well the results of Dr. Alexandra Kamlah[112].  
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Scheme 12. Successful synthesis of tetrahydroisoquinoline 41 via N-acyl Pictet-Spengler reaction using enol ether 
39 as aldehyde equivalent. 
Once again the robustness of this protocol was demonstrated and the tetrahydroisoquinoline 
41 was accessed in a good yield within a short reaction time. Moreover, ώ-alkoxystyrenes 
represent a benefical starting material as they should be readily available from benzaldehydes 
via Wittig olefination in a single operation. The N-acyl Pictet-Spengler reaction using N-
ethoxycarbonyl-arylethylamine building blocks and ώ-alkoxystyrenes seems a fast and 
straightforward method for the construction of the tetrahydroisoquinoline moiety and therefore 
will be applied in the synthesis of the bisbenzylisoquinolines tetrandrine (1) and isotetrandrine 
(2) in the following. 
 
2.2.2 SYNTHESIS OF TETRANDRINE (1)  
 
 
This section is reproduced and partly adapted from ref. 1 with permission from The Royal Society of Chemistry.  
 
In contrast to the published total syntheses of tetrandrine (1), the retrosynthetic approach 
aimed at utilizing N-acyl Pictet-Spengler cyclizations instead of Bischler-Napieralski protocols. 
This approach would provide tetrahydroisoquinolines directly, and further, by using N-
alkoxycarbonyl residues in the N-acyl-arylethylamine building blocks, the required N-methyl 
groups should be available in only one additional step by lithium alanate reduction of the 
carbamate groups. This should lead to a significant reduction of the required number of steps. 
Alternatively, hydrolysis of the carbamate groups would provide secondary amino groups (N-
2-H, N-2’-H), which in turn could subsequently be N-alkylated to give various tertiary amino 
groups. This should reduce the number of steps further compared to the original method, since 
ώ-alkoxystyrenes are available from the corresponding substituted benzaldehydes in one 
single step, whereas construction of arylacetic acids for Bischler-Napieralski reactions requires 
a number of steps. Further, the exploration of modern alternatives such as Buchwald-Hartwig 
coupling[114] or Chan-Evans-Lam reaction[71] for the construction of the diaryl ether moieties is 
aimed for.   
Based on these considerations several alternative routes to tetrandrine (1) (and its isomers) 
were explored: In route 1 both 1-benzyltetrahydroisoquinoline moieties - meaning both 
stereocenters at C-1 and C-1’ in consequence - were to be built up early in intermolecular N-
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acyl Pictet-Spengler reactions, and the central step for the construction of the macrocycle 
should be an intramolecular diaryl ether synthesis at a late stage. In contrast, in route 2 a late 
intramolecular N-acyl Pictet-Spengler cyclization should provide the macrocycle under 
construction of the second stereocenter. For each route an additional variation was designed, 
considering that either the benzyltetrahydroisoquinoline moiety consisting of rings A-C or the 
one consisting of rings A’-C’ can be constructed first.  Besides the general feasibility of both 
approaches, the stereochemical outcome of all four conceivable variants was of high interest, 
as high diastereoselectivity of the whole protocol was desirable. 
The sequence of the Pictet-Spengler- and C–O coupling steps of the four variants is depicted 
in Figure 8. In detail, in the variants 1a and 1b the retrosynthetic approach for the synthesis of 
the macrocyclic skeleton consists of two alternating N-acyl Pictet-Spengler condensations and 
C–O couplings. Finally the macrocycle is generated in an intramolecular diaryl ether synthesis 
(“D-2”) of a seco-bisbenzylisoquinoline intermediate, connecting rings C and C’. In route 2, 
both diaryl ethers are constructed early (operations “D-1” and “D-2”) and the macrocycle is 
generated in an intramolecular N-acyl Pictet-Spengler condensation. In route 2a ring B’ is 
constructed in this late operation (“P-S-2”), whereas in route 2b this final connection is 
performed for the construction of ring B (“P-S-1”).  
 
 
  
 
   
 
  
    
    
Figure 8. Retrosynthetic analysis of the envisaged routes to the precursor of racemic tetrandrine (rac-1) and 
isotetrandrine (rac-2). 
 
2.2.3 SYNTHESIS OF TETRANDRINE ANALOGUES 
 
Based on the total synthesis of racemic tetrandrine (rac-1) and isotetrandrine (rac-2) the 
synthesis of full synthetic macrocyclic (iso)tetrandrine analogues is targeted. The flexible 
synthetic pathway should allow to implement variations on all of the four aromatic rings in 
tetrandrine (1), although this work will focus on structure variations exclusively on ring C. 
Hereby the general scope and limitation of this synthetic pathway should be investigated and 
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first structure variations should be made for initial structure-relationship studies. In 
pharmacological evaluations the substances will be screened for anticancer and multidrug 
reversing activities and assessed with respect to potential toxic effects.  
As already discussed in the section “Toxicity of tetrandrine (1)” (chapter 1.2.5) the methoxy 
group at C-12 in ring C (highlighted in red) is suspected to be responsible for tetrandrine’s (1) 
toxicity. A modification of ring C should be feasible by following route 1b or 2b. Aim is to either 
eliminate the critical methoxy group or to replace it by metabolically stable groups such as 
trifluoromethoxy or chlorine. Also a replacement of the benzene ring by different heterocycles 
(e.g. thiophene, furan and pyridine) or an alkyne chain is targeted. One intermediate of the 
tetrandrine synthesis that already covers the mutual scaffold (highlighted as bold bonds in 
Figure 9) should be used as starting material. The bottom diaryl ether bridge connecting tail-
to-tail should be constructed via suitable C–O bond forming reactions and the right 
tetradydroisoquinoline moiety via N-acyl Pictet-Spengler reaction using suitable (masked) 
aldehydes. 
 
Figure 9. Structure of racemic tetrandrine (rac-1) & isotetrandrine (rac-2) and targeted macrocyclic compounds 
with variations on ring C. The bold bond indicates the identical scaffold present in both, the lead structure and the 
targeted analogues. 
 
2.2.4 SYNTHESIS OF SECO-ANALOGUES 
 
Besides the design and synthesis of macrocyclic tetrandrine analogues the synthesis of 
simplified seco-analogues is intended as well. Several biological activities of tetrandrine (1) 
are also documented for benzylisoquinolines e.g. anticancer[115-117] and calcium channel 
blocking[118] effects, which makes this class of alkaloids attractive since the synthetic access is 
easier and faster compared to bisbenzylisoquinoline alkaloids.  
Within the scope of this thesis the synthesis of a small series of seco-analogues as exemplary 
truncated variants is planned. The analogues hereby should gradually converge the lead 
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structure tetrandrine (1). As a minimum all analogues comprise one benzylisoquinoline unit 
(rings A-C) as indicated by the bold lines in Figure 10. Suitable intermediates of route 1a of the 
tetrandrine synthesis should serve as starting material. The benzenoid ring A’ (highlighted in 
red) should be introduced via diaryl ether synthesis and ring B’ should be constructed via N-
acyl Pictet-Spengler reaction using different aldehydes (indicated by turquoise bonds). The 
ring C’ should be mimicked by an O-benzyl residue at C-11. 
 
 
 
 
 
 
Figure 10. Synthetic approach for the targeted seco-analogues using suitable intermediates of the tetrandrine 
synthesis as starting material and C–O cross-coupling & N-acyl Pictet-Spengler reaction as key steps. The bold 
bonds indicate the mutual structural scaffold present in both, the lead structure and the targeted seco-analogues. 
 
2.2.5 RELATED ALKALOIDS 
 
Beside the bisbenzylisoquinolines tetrandrine (1) and isotetrandrine (2) the synthesis of further 
alkaloids containing a (tetrahydro)isoquinoline scaffold and a diaryl ether bridge is to be 
accomplished. Once a synthetic protocol for the construction of the central moieties is 
established as part of the synthesis of (iso)tetrandrine, the methods should be applied for the 
(racemic) total synthesis of the natural products muraricine (rac-34), berbanine (35) and 
berbidine (36) as well. 
 
2.2.5.1 MURARICINE 
 
The isoquinoline-benzylisoquinoline alkaloid muraricine (34), recently isolated from Berberis 
vulgaris (Berberidaceae)[119], possesses the same scaffold like tetrandrine (1) as indicated by 
the bold lines in Figure 11. The aromatic rings A and A’ of the tetrahydroisoquinoline moiety 
display the same substitution patterns and an oxygen is present in para-position of the benzylic 
methylene group in both alkaloids. These similarities should allow to synthesize muraricine in 
its racemic form directly using an intermediate of the synthetic pathway of tetrandrine (1).   
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Figure 11. isoquinoline-benzylisoquinoline alkaloid muraricine (rac-34) and the structure of tetrandrine (1) with 
mutual structural elements highlighted as bold bonds. 
 
2.2.5.2 BERBANINE AND BERBIDINE 
 
For the synthesis of the dimeric isoquinoline-isoquinolone alkaloids berbanine (35) and 
berbidine (36), the 1-oxodihydroisoquinoline alkaloid thalifoline (47) should be used as starting 
material. The synthesis of thalifoline (47) was elaborated by Sandra Schmidt within the scope 
of her master’s thesis in our group (for details see the published protocol[120]). The diaryl ether 
bridge should be constructed via a suitable C–O cross-coupling protocol of the phenolic 
compound 47 with either 2-bromo-3,4-dimethoxybenzaldehyde (48) or 8-bromo-6,7-
dimethoxyisoquinoline (49, Figure 12). The latter building block does not seem suitable for this 
type of cross-coupling reaction, as Knabe and coworkers[121] already failed to accomplish 
Ullmann couplings of this compound with a 7-hydroxyisoquinoline in their synthesis of the 
alkaloid phaeantharine. Since the more electron deficient and less sterically hindered 2-bromo-
3,4-dimethoxybenzaldehyde (48) should undergo the conversion, this building block was 
chosen as coupling partner for the diaryl ether synthesis. The construction of the fully aromatic 
isoquinoline unit of alkaloid berbanine (35) should then be accomplished in a subsequent 
Pomeranz-Fritsch reaction. The N-methylation of berbanine (35) and the reduction of the 
resulting isoquinolinium salt should finally provide berbidine (36). 
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Figure 12. (A) 1-Oxodihydroisoquinoline alkaloid thalifoline (47) and the synthetic strategy for the dimeric 
isoquinoline-isoquinolone alkaloids berbanine (35) and berbidine (36). (B) 2-Bromo-3,4-dimethoxybenzaldehyde 
(48) and 8-bromo-6,7-dimethoxyisoquinoline (49) as potential building blocks for the envisaged C–O cross-coupling 
reaction. 
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3 SYNTHESES 
 
The synthesis of racemic tetrandrine (rac-1) and isotetrandrine (rac-2) was already pubslished 
in ref. 1. The synthesis and pharmacological evaluation of the analogues RMS1-RMS10 was 
published in ref. 53., the data of racemic muraricine (rac-34) was published in ref. 122 and the 
synthesis of berbanine (35) and berbidine (36) in ref. 120. 
 
3.1 SYNTHESIS OF TETRANDRINE (1) 
 
This section is reproduced and in part adapted from ref. 1 with permission from The Royal Society of Chemistry. 
 
As mentioned before several synthetic routes to racemic tetrandrine (rac-1) and isotetrandrine 
(rac-2) were elaborated. The two routes 1a and 1b start with the construction of either the one 
or the other benzylisoquinoline monomer, respectively, representing one half of the target 
molecule. The cyclization step in both routes 1a and 1b is an intramolecular diaryl ether 
synthesis. As an additional variation the routes 2a and 2b are to be developed, in which the 
macrocyclic system is constructed via an intramolecular N-acyl Pictet-Spengler. As the second 
asymmetric centre is to be generated simultaneously in this step, an asymmetric induction is 
to be expected generating preferably the one or the other diastereomer in consequence. 
In route 1a the highly substituted 1-benzyltetrahydroisoquinoline 55, which covers rings A-C of 
tetrandrine (1), was prepared from the commercially available aldehydes 5-
bromoveratraldehyde (50) and O-benzylisovanilline. In a Henry reaction 50 was condensed 
with nitromethane[122] to give ß-nitrostyrene 51 in 60% yield. Reduction with zinc/HCl[122] gave 
the corresponding arylethylamine 52, and subsequent reaction with ethyl chloroformate (38) 
led to carbamate 53 in 70% yield over both steps. Known enol ether 54[123] was synthesized in 
a Wittig olefination of O-benzylisovanilline in 87% yield. The following N-acyl Pictet-Spengler 
condensation[111] with carbamate 53, catalyzed by trifluoroacetic acid (TFA), gave racemic 
tetrahydroisoquinoline 55 in 47% yield (Scheme 13). This moderate yield might be due to the 
sterically demanding bromine substituent. When using trifluoromethanesulfonic acid (TfOH) as 
a stronger acidic catalyst[84] instead, 55 was obtained in a comparable yield of 49%. Due to 
easier handling TFA was prefered in the following procedures. The N-acyl Pictet-Spengler 
condensation in this step delivers exclusively the desired regioisomer 55. No by-product was 
identified in which cyclization took place at the para position of the bromine in intermediate 55.  
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Scheme 13. Route 1a: Synthesis of the benzyltetrahydroisoquinoline 55.  
Next, the first C–O coupling was performed in order to obtain diaryl ether 58 (Scheme 14). The 
required phenol 57 was prepared from commercially available 3-methoxytyramine (56; itself 
readily available from the aromatic aldehyde vanilline) and ethyl chloroformate (38). For the 
coupling of 55 with 57 several reaction conditions (Table 2) were explored testing different 
ligand/catalyst systems. Palladium-catalyzed Buchwald-Hartwig cross-coupling reactions 
(Table 2, entries 1-3) using different phosphine ligands[124] or Pd-PEPPSITM-IPr (18) as catalyst 
failed to furnish the desired diaryl ether 58. Next a set of catalytic systems for Ullmann-type 
C–O couplings was explored employing different combinations of copper(I) halides, ligands 
and bases (entries 4-8). When using the combination of copper(I) iodide, N,N-dimethylglycine 
(13) and caesium carbonate in dioxane[68] traces of the desired product 58 (entry 4) were 
detected by LC-MS. Increasing catalyst and ligand to stoichiometric amounts (entry 5) did not 
improve the yield. Employing copper(I) bromide-dimethylsulfide complex with caesium 
carbonate in pyridine[125] without any additional ligand (entry 9) it was possible to isolate minor 
amounts (2%) of the desired diaryl ether 58. A predominant side reaction was debromination 
of the aryl halide 55 at high reaction temperatures. Microwave conditions[126-127] instead of 
conventional heating could not improve the reaction in terms of yield and by-product formation 
(entry 10). To minimize debromination the temperature was decreased to 110 °C and the 
reaction time was prolonged. This modification resulted in a better yield (12%; entry 11). By 
increasing the amount of phenol 57 from 1.1 to 1.5 equivalents the yield was further improved 
to 27% (entry 12). The best result was obtained when performing the reaction at 110 °C with 
2.0 equivalents of the phenol 57 furnishing diaryl ether 58 in 41% yield (entry 13). Considering 
the comparatively low reactivity of electron-rich and sterically hindered aryl halide 55, the 
obtained yield is satisfying and comparable to the yield of 42% in Inubushi’s approach[94] using 
related building blocks. An attempted Chan-Lam-Evans coupling[71] was discarded after the 
synthesis of the corresponding boronic acid from bromoarene 55 was unsuccessful. Diaryl 
ether 58 was then O-debenzylated by standard Pd-catalyzed hydrogenolysis giving phenol 59 
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in 92% yield. The debenzylation had to be performed at this stage, since surprisingly the O-
benzylated intermediate 58 was found to react very sluggishly in an attempted subsequent N-
acyl Pictet-Spengler reaction with enol ether 60. 
 
Scheme 14. Route 1a: First Ullmann coupling.  
 
Table 2. Conditions for Ullmann-type C–O coupling of bromoarene 55 with penol 57. 
entry conditions 
eq. 
phenol 57 
yield (%) 
1 
Pd2(dba)3 (1.5 mol %), tBuXPhos (16, 2.0 mol %), K3PO4 
(2.0 eq.), toluene, 100 °C, 48 h[124] 
1.2 - 
2 
Pd(AcO)2 (5.0 mol %),  Me4tButylXphos (17, 7.0 mol %), 
K3PO4 (2.0 eq.), toluene, 100 °C, 48 h[124] 
1.2 - 
3 
PEPPSI-IPr (18, 2.0 mol %), K3PO4 (2.0 eq.), toluene, 
100 °C, 48 h 
1.2 - 
4 
CuI (0.1 eq.), N,N-dimethylglycine (13, 0.3 eq.), Cs2CO3 
(2.0 eq.), dioxane, 105 °C, 72 h, pressure tube[68] 
1.5 traces 
5 
CuI (1.0 eq.), N,N-dimethylglycine (13, 3.0 eq.), Cs2CO3 
(2.0 eq.), dioxane, 105 °C, 72 h, pressure tube[68] 
1.5 traces 
6 
CuI (0.1 eq.), N,N-dimethylglycine (13, 0.3 eq.), Cs2CO3 
(2.0 eq.), dioxane, 150 - 200 °C, 2.5 h, microwaves[126] 
1.5 - 
7 
CuI (0.1 eq.), picolinic acid (15, 0.2 eq.), K3PO4 (2.0 eq.), 
DMSO, 90 °C, 72 h[70] 
1.2 - 
8 
CuBr (1.0 eq.), 1,1'-azobis(cyclohexanecarbonitrile) (14, 
1.0 eq.), Cs2CO3 (2.0 eq.), DMF, 100 °C, 4 h, 
microwaves[69] 
1.1 - 
9 
CuBr.Me2S (1.0 eq.), Cs2CO3 (3.0 eq.), pyridine, 150 – 
200 °C, 72 h, pressure tube[125] 
1.1 2 
10 
CuBr.Me2S (1.0 eq.), Cs2CO3 (3.0 eq.), pyridine, 220 °C, 
3 h, microwaves 
1.1 - 
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11 
CuBr.Me2S (1.0 eq.), Cs2CO3 (3.0 eq.), pyridine, 110 °C, 
7 d 
1.1 12 
12 
CuBr.Me2S (1.0 eq.), Cs2CO3 (3.0 eq.), pyridine, 110 °C, 
7 d 
1.5 27 
13 
CuBr.Me2S (1.0 eq.), Cs2CO3 (3.0 eq.), pyridine, 110 °C, 
7 d 
2.0 41 
   
For the construction of the second tetrahydroisoquinoline moiety the method of choice was 
again a TFA-mediated N-acyl Pictet-Spengler condensation, connecting intermediate 59 with 
known enol ether 60[128] to give seco-bisbenzylisoquinoline 61 in an excellent yield of 96% 
(Scheme 15) and again with desired regioselectivity. As expected both racemic diastereomers 
in a ratio of 1:1 (determined by HPLC) were obtained. No stereocontrol was observed, since 
the newly formed stereocenter is far away from the stereocenter in the starting material. But 
fortunately, the obtained diastereomers of 61 were easily separated by flash column 
chromatography on a preparative scale. The isolated yields of the racemic diastereomers were 
50% of the (R,R)/(S,S) isomers (61a) and 46% of the (R,S)/(S,R) isomers (61b). The relative 
configurations of these products were determined retrospectively after conversion into racemic 
tetrandrine (rac-1) and racemic isotetrandrine (rac-2), respectively.  
Scheme 15. Route 1a: Synthesis of racemic tetrandrine (rac-1) and racemic isotetrandrine (rac-2) via seco-
bisbenzylisoquinoline 61. 
For the following intramolecular C–O coupling to generate the macrocycle 62 once again a 
screening for reaction conditions was conducted. Pd2(dba)3 in combination with phosphine 
ligand Me4tButylXphos (17)[124], copper(I) iodide combined with ligand N,N-dimethylglycine 
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(13)[68] and copper(I) bromide-dimethylsulfide complex[125] were tested as catalytic systems on 
a mixture of diastereomers 61 (compare entries 2, 4 and 11 in Table 2). All of these reactions 
were carried out under high dilution conditions (0.02 M) in order to suppress intermolecular 
coupling reactions. Again copper(I) bromide-dimethylsulfide complex catalyzed the diaryl ether 
synthesis well, furnishing the desired macrocycle 62 in 62-64% yield (Scheme 15), whereas 
the other catalytic systems were not successful. Surprisingly the separation of diastereomers 
of 62 via flash column chromatography could not be achieved. Thus, for generation of pure 
racemic alkaloids the cyclization had to be conducted with the previously isolated racemic 
diastereomers of the seco-intermediate 61. Both isomers were cyclized in almost identical 
yields of 62 and 64%.  
To complete the total synthesis of the alkaloids, carbamates 62 were reduced using LiAlH4 in 
THF to give racemic tetrandrine (rac-1) and racemic isotetrandrine (rac-2), both in almost 
quantitative yield (98%) (Scheme 15).  The analytical data of racemic tetrandrine (rac-1) was 
identical with those of an authentic natural sample of tetrandrine (1), kindly donated by Prof. 
Peter Pachaly.  
As a variation of this approach route 1b was elaborated, which starts with the synthesis of the 
benzyltetrahydroisoquinoline unit consisting of rings A’-C’. Following the established protocol 
of TFA-catalyzed N-acyl Pictet-Spengler reaction, carbamate 57 was condensed with known 
enol ether 63[129] to give racemic 1-benzyltetrahydroisoquinoline 64 in 96% yield (Scheme 16). 
Enol ether 63 was synthesized by Wittig olefination of commercially available 4-
benzyloxybenzaldehyde in 97% yield. For the Ullmann synthesis of diaryl ether 65 from 
phenolic intermediate 64 and aryl bromide 53 (see Scheme 13) once again the established 
catalytic system was employed (Scheme 16). 
 
Scheme 16. Route 1b: Synthesis of diaryl ether 65. 
This critical key step could significantly be enhanced in this approach compared to route 1a 
(Scheme 14). The diaryl ether was now obtained in a yield of 64% (vs. 41%) in a shorter 
reaction time (3 days vs. 7 days). Also in terms of efficiency this step was improved, since only 
1.0 equivalents of phenol instead of 2.0 equivalents was brought to reaction with 1.2 
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equivalents of aryl bromide 53. The improved yield can be explained by the fact that aryl 
bromide 53 is less sterically hindered than the aryl halide 55 in route 1a. Diaryl ether 65 was 
further debenzylated by hydrogenolysis in methanol to give phenol 66 in 94% (Scheme 16).  
Scheme 17. Route 1b: Synthesis of seco-bisbenzylisoquinoline 68 and cyclization. 
Next seco-bisbenzylisoquinoline 68 was obtained in an N-acyl Pictet-Spengler reaction of 66 
with enol ether 67[130], which was prepared in 80% yield by Wittig olefination of the 
corresponding aromatic aldehyde. Surprisingly the product of this Pictet-Spengler reaction 
following the standard protocol was not an equimolar racemic mixture of diastereomers 
(compared to route 1a), but the (R,R)/(S,S) isomers (68a) were formed preferably (ratio 62:38, 
determined by HPLC) in an isolated yield of 30% (Table 3, entry 1), whereas the (S,R)/(R,S) 
isomers (68b) were obtained in 19% yield. As in route 1a, the diastereomers were easily 
separable using flash column chromatography. Further, a by-product was isolated in 24% 
yield, which was identified as another Pictet-Spengler product with the same mass as the 
desired product. Since the fraction of the by-product was an inseparable mixture of 
diastereomers, exact identification was not possible, but most likely it is a regioisomer of seco-
bisbenzylisoquinoline 68, resulting from cyclization to the other free ortho position of precursor 
66. In order to decrease the amount of this by-product and to improve the diastereomeric ratio, 
the N-acyl Pictet-Spengler reaction was performed under different conditions (Table 3). 
Conducting the reaction at lower temperature (entry 2) had only minor influence in terms of 
diastereomeric ratio and the formation of the by-product. Using trifluoromethanesulfonic acid 
(TfOH) instead of TFA (entry 3) increased the formation of (S,R)/(R,S) isomers, leading to a 
more balanced ratio of 47:53, but did not decrease by-product formation. Following Kayhan’s 
approach[131], the reaction was conducted in the more polar solvent trifluoroethanol (entry 4), 
ending up with an improved regioselectivity of 80:20. A diastereomeric ratio of 54:46 was 
obtained hereby for the desired regioisomer 68. Even though the regioselectivity was best in 
this entry, due to a slow and incomplete conversion it was decided to follow the established 
protocol (entry 1) for the synthesis of seco-bisbenzylisoquinoline 68 (Scheme 17).  
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Table 3. Route 1b: Conditions for the synthesis of seco-bisbenzylisoquinoline 68. 
entry solvent acid 
temperature 
(°C) 
ratio  
(S,S)/(R,R):(S,R)/(R,S) 
product/by-
product 
1 DCM TFA rt 62:38 68:32 
2 DCM TFA -15 66:34 66:34 
3 DCM TfOH rt 47:53 69:31 
4 TFE TFA rt 54:46 80:20 
 
In the following step the macrocycle 62 was generated via intramolecular C–O coupling of 68 
(with previously separated racemic diastereomers) using the protocol as described above, 
yielding 51% of macrocyclic (R,R)/(S,S) isomers (62a) and 35% of (S,R)/(R,S) isomers (62b, 
Scheme 17). Both of these products can be reduced to racemic tetrandrine (rac-1) and racemic 
isotetrandrine (rac-2), respectively, in almost quantitative yields, as shown for route 1a 
(Scheme 15). 
As expected and discussed above, both routes 1a and 1b gave mixtures of diastereomers. 
Fortunately, chromatographic separation of late intermediates was achieved in both routes, so 
both racemic tetrandrine (rac-1) and racemic isotetrandrine (rac-2) are available in pure form 
with these approaches. Nevertheless, it was intended to expand this approach to a protocol 
with preference for the one or other of the diastereomers. Altering the sequence of reaction 
steps, particularly utilizing an intramolecular N-acyl Pictet-Spengler reaction for ring closure 
and construction of the second stereocenter, should presumably lead to an asymmetric 
induction as a result of the influence of the stereochemistry of the already present asymmetric 
center and pre-organization of the chiral starting material. This aim was achieved in routes 2a 
and 2b, as elaborated in detail in the following. 
In route 2a, employing the established diaryl ether synthesis protocol, phenolic intermediate 
59 from route 1a was coupled with 4-bromophenyl enol ether (60) to obtain 69 in 61% yield 
(Scheme 18). Next the reaction conditions for the intramolecular N-acyl Pictet-Spengler 
condensation were examined. The reaction was carried out at different temperatures (Table 
4), expecting that the stereochemical outcome might be controlled by the reaction temperature 
to a certain extent. No conversion was observed below -20 °C using TFA as catalyst (entry 1). 
At -20 °C, catalyzed by TFA, macrocycle 62 was formed in 13% yield under predominant 
formation of the (R,R)/(S,S) isomers 62a (diastereomeric ratio d.r. 84:16; entry 2), hence 
favouring the relative stereoconfiguration of tetrandrine (1) (S,S) and its enantiomer 
phaeanthine (R,R). The best result was obtained at -15 °C (entry 3) in terms of diastereomeric 
ratio (87:13) and yield (28%). When performing the reaction at ambient temperature a 
comparable yield (25%) was obtained and a d.r. of 82:18 (entry 4). With the stronger acid 
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trifluoromethanesulfonic acid (TfOH) macrocycle 62 was generated even at -78 °C, but in a 
very poor yield of 9% in a 78:22 ratio (entry 5). With toluenesulfonic acid (p-TsOH) no 
noteworthy reaction was observed below 40 °C, and at elevated temperature only inferior d.r. 
and poor yield was obtained (entry 6). Eventhough the cyclization step of route 2b suffers from 
low yield, the asymmetric induction in this step is remarkable and motivating to do further 
investigations. 
 
Scheme 18. Route 2a: Cyclization via intramolecular Pictet-Spengler condensation.  
 
Table 4. Conditions for cyclization via N-acyl Pictet-Spengler condensation. 
entry 
temperature 
(°C) 
acid 
ratio  
(R,R)/(S,S):(S,R)/(R,S) 
yield (%) 
1 -78 to -25 TFA - - 
2 -20 TFA 84:16 13 
3 -15 TFA 87:13 28 
4 20 TFA 82:18 25 
5 -78 TfOH 78:22 9 
6 40 p-TsOH 62:38 > 5 
 
Route 2a involved late stage construction of the tetrahydroisoquinoline moiety (rings A’ + B’) 
forming the stereocenter at C-1’, but the same concept can also be applied to C-1 in ring B. 
So, in route 2b, the same building blocks were used as in route 1b, but the Ullmann coupling 
was performed first, followed by an intramolecular Pictet-Spengler reaction.  Diaryl ether 70 
was obtained from phenolic intermediate 66 and brominated enol ether 67 employing the 
established diaryl ether synthesis protocol in a yield of 43% (Scheme 19). Important for this 
step is the use of freshly synthesized enol ether 67, since it tends to decompose quickly 
resulting in minor yields. In attempts to improve this yield once again Pd-catalysis (compare 
entry 2 in Table 1) was examined, but only traces of the desired product 70 were obtained. In 
the subsequent intramolecular Pictet-Spengler reaction, catalyzed by TFA at -15 °C, 
macrocycle 62 was obtained in 79% yield (Scheme 19), but in strong contrast to route 2a, here 
33 
 
the isotetrandrine-type (S,R)/(R,S) isomers 62b were formed predominantly in a ratio of 71:29 
(determined by HPLC). In contrast to route 1b, where regioisomeric products were obtained in 
intermolecular Pictet-Spengler reactions, exclusively the desired cyclization products were 
detected in this intramolecular reaction. Whereas route 2a does not provide an advantage over 
route 1a in terms of yield, the access of isotetrandrine-type isomers in route 2b could be 
improved compared to route 2a.   
 
Scheme 19. Route 2b: Alternative cyclization via intramolecular N-acyl Pictet-Spengler condensation. 
Final step of both routes 2a and 2b was, as in routes 1a and 1b, the reduction of both ethyl 
carbamate moieties in 62 using LiAlH4 in THF to give N-methyl groups, ending up in with 
mixtures of racemic tetrandrine (rac-1) and racemic isotetrandrine (rac-2) (see Scheme 15). 
Separation of these diastereomers is possible using preparative TLC[132] or preparative HPLC, 
so pure racemic alkaloids can also be obtained via routes 2a and 2b. 
In Inubushi’s synthetic approach[96], which included an intramolecular Bischler-Napieralski 
reaction, some stereocontrol was also observed favouring the formation of tetrandrine-type 
(R,R)/(S,S) isomers. In this case the second stereocenter was not built up in the course of the 
cyclization reaction, but in the following reduction of the formed 3,4-dihydroisoquinoline moiety 
to the corresponding tetrahydroisoquinoline. The best d.r. obtained there was 4:1 (determined 
by NMR).  
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3.2 SYNTHESIS OF TETRANDRINE ANALOGUES 
 
Once the synthetic pathway for racemic tetrandrine (rac-1) and isotetrandrine (rac-2) was 
established, fully synthetic analogues of tetrandrine (rac-1) and isotetrandrine (rac-2) were 
designed and synthesized. As mentioned above, structure variations hereby focus on ring C, 
which bears the hypothesized metabolically labile 12-methoxy group. In the targeted 
compounds the critical methoxy group is to be eliminated or replaced by metabolically stable 
functional groups such as trifluoromethoxy or chlorine substituents. These variations should 
already be sufficient for investigating the role of the methoxy group at C-12 for the toxicity of 
tetrandrine (1). If the hypothesized pathway is indeed the underlying mechanism for 
tetrandrine-induced toxicity, a significant reduction of toxic effects should be achieved 
herewith. To further explore structure-activity relationships the synthesis of structure variations 
containing different aromatic heterocycles or a simple alkyl chain instead of ring C is aimed 
for. 
For the synthesis of the targeted compounds a synthetic route is to be selected, in which ring 
C is inserted in a late stage. This is possible in route 1b, in which ring C is introduced by an N-
acyl Pictet-Spengler reaction and a subsequent Ullmann coupling. Also route 2b is basically 
feasible, in which the sequence of these two steps is reversed.  As shown in the synthesis of 
(iso)tetrandrine, preferably macrocyclic intermediates with the stereoconfiguration of 
isotetrandrine (2) via asymmetric induction are formed in this route, whereas in route 1b no or 
just a slight preference for tetrandrine-like intermediates was observed. In this project the 
synthesis of both, tetrandrine- as well as isotetrandrine-type analogues is aimed for, as the 
influence of relative stereochemistry on biological targets is of interest.  In addition, the 
feasibility of route 2b depends on the stability of employed enol ethers, which need to sustain 
the harsh conditions required for the Ullmann coupling reaction. Based on these considerations 
route 1b was chosen for the synthesis of (iso)tetrandrine analogues, especially as the required 
enol ethers turned out to be quickly decomposing, as discussed later.  
As starting material the intermediate 66 of the (iso)tetrandrine synthesis was utilized, which 
was  readily synthesized in a larger scale. Next step was the synthesis of the required enol 
ethers for the construction of ring C. The enol ethers 71-73 and 75-77 were prepared via Wittig 
olefination of the corresponding commercially available aromatic aldehydes (Scheme 20, A) in 
high yields (80-92%) following the established standard protocol. For the planned alkyl 
analogue commercially available 5-bromo-1-pentanol (78) was oxidized using pyridinium 
chlorochromate (PCC)[133] to the corresponding aldehyde (Scheme 20, B).  
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Scheme 20. (A) Synthesis of the enol ethers 71-73 and 75-77 via Wittig olefination. (B) Synthesis of aldehyde 79 
via oxidation of 5-bromo-1-pentanal (78). 
As already mentioned these enol ethers were not as stable as the enol ethers 60 and 67 
previously used for the (iso)tetrandrine synthesis. Eventhough the NMR spectra of the 
compounds recorded right after isolation displayed no or only minor peaks of impurities, in the 
HPLC chromatogram several peaks as a result of decomposition were visible after some time 
and also the visual appearance changed quickly.  
With the building blocks 71-73, 75-77 and 79 in hand an intermolecular N-acyl Pictet-Spengler 
reaction was then conducted with the carbamate intermediate 66 of the (iso)tetrandrine 
synthesis (Scheme 21). Trifluoromethanesulfonic acid (TfOH) was used as catalyst, since as 
observed previously in the synthesis of (iso)tetrandrine, catalysis utilizing TfOH resulted in an 
almost equimolar diasteromeric ratio of tetrandrine/isotetrandrine-like intermediates (d.r. of 
47:53 (S,S)/(R,R):(S,R)/(R,S)). Under TFA-catalysis preferably tetrandrine-like precursors 
were formed in a d.r. of 62:38 (see Table 3) in route 1b of the (iso)tetrandrine synthesis. As 
both tetrandrine- as well as isotetrandrine-like analogues are desired, TfOH was preferentially 
used here.  
 
  
 
 
 
  
Scheme 21. Synthesis of seco-bisbenzylisoquinolines 80-85 via N-acyl Pictet-Spengler reaction. 
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Table 5. Seco-bisbenzylisoquinolines 80-85. *isolated yield (sum of diastereomers). **the stereoconfiguration of 
the bromobutyl intermediates 85 could not be determined.  
entry 
enol ether/ 
aldehyde 
product 
yield* 
(%) 
diastereomeric ratio 
(S,S)/(R,R):(S,R)/(R,S) 
1 
71 
 
80 
64 54:46 
2  
72 
 
81 
63 60:40 
3  
75 
- - - 
4  
76 
 
82 
24 50:50 
5  
77 
 
83 
68 51:49 
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6  
73 
 
84 
53 49:51 
7  
79 
 
85 
59 61:39** 
The intermolecular N-acyl Pictet-Spengler condensation proceeded well in yields ranging from 
48-64% (sum of diasteromers), except for the furan and pyridine variation (entry 3 and 4, Table 
5). TLC control of the N-acyl Pictet-Spengler reaction of carbamate 66 with furanyl enol ether 
76 indicated a notable formation of side products and the yield for both diastereomers in sum 
amounted only 24% (entry 4, Table 5). The diminished yield can be explained by the sensitivity 
of the furan moiety towards acids[134]. The pyridine variation 75 did not react at all under the 
standard reaction conditions using TfOH, although an additional equivalent of acid was used 
(1.1 equivalents in total) on top of the usual catalytic amount (0.1 equivalents), as one 
equivalent is probably consumed by the protonation of the basic pyridine (entry 3, Table 5). 
Neither elevated temperatures (40 °C) nor the use of other acids such as TFA or sulfuric acid 
in excess amounts could bring the enol ether 75 to reaction. The latter attempt was conducted 
in acetic acid employing concentrated sulfuric acid, following Ponnala’s protocol[135], in which 
3-bromo-4-pyridinecarboxaldehyde was reacted likewise with an acylated phenethylamine in 
an N-acyl Pictet-Spengler in good yield. Since this approach didn’t obviously work out in this 
case, the pyridine variation was discarded.  
As already described for route 1b in the synthesis of (iso)tetrandrine, the intermolecular N-acyl 
Pictet-Spengler condensation proceeds racemic and not in a regioselective manner. In 
consequence, a mixture of diastereomers and regioisomers is generated in this step. Luckily, 
the seco-intermediates 80-85 that respresent the desired regioisomers, were always preferably 
formed and it was possible to separate them from the side products by flash column 
chromatography. The undesired regioisomers, which were formed due to two possible 
directions in the cyclization step as aforementioned, were isolated in minor amounts ranging 
from 13-25%. An unambiguous identification of the correct isomers was conducted by NMR 
analysis (HMBC experiments). The diastereomeric mixture of the intermediates 80-85 was 
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successfully separated by FCC as well, so that the open-chain diastereomers could be 
proceeded separately in the next step. 
The isolated diastereomers of seco-intermediates 80-85 were now reacted in an intramolecular 
Ullmann coupling (Scheme 22, A) following the established protocol to construct the diaryl 
ether bridges (connecting rings C and C’) furnishing the macrocyclic bisbenzylisoquinolines 
86-90 in yields from 17-77% as summarized in Table 6. The ω-bromobutyl intermediate 85 
was processed via SN2 reaction in DMF employing K3PO4 as base in the presence of catalytic 
amounts of potassium iodide (Scheme 22, B) to give macrocyclic intermediate 91 in yields of 
29 and 60% respectively (entry 6, Table 6). Again the variation 82 containing a furanyl residue 
led to unsatisfactory results, as only traces of the macrocyclic intermediate 88 could be 
detected by LC-MS (entry 3, Table 6). Since both steps, the synthesis of the seco-intermediate 
82 and its conversion to the macrocyclic compound 88 proceeded very poorly, the furanyl 
variation was discarded.  
In general it was observed that the rate of cyclization strongly depended on the relative 
stereochemistry of the seco-intermediates. In most cases the S,S/R,R intermediates gave 
approximately twice as high yields than the S,R/R,S intermediates.   
 
 
Scheme 22. Reaction conditions for the synthesis of macrocyclic bisbenzylisoquinolines 86-91. (A) Intramolecular 
Ullman-type cross-coupling of seco-intermediates 86-90. (B) SN2 reaction of ω-bromobutyl intermediate 91.  
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Table 6. Yields of the synthesis of macrocyclic bisbenzylisoquinoline intermediates 86-90 via Ullmann coupling or 
SN2 reaction, respectively. *the stereoconfiguration of the butylidene intermediate 91 could not be determined. 
entry 
seco- 
intermediate 
product 
yield (%) 
 
(S,R)/(R,S) (S,S)/(R,R)     
1 80 
86 
40 77 
2 81 
87 
28 64 
3 82 
88 
traces 
4 83 
89 
17 57 
5 84 
90 
25 49 
40 
 
6 85 
 
91 
29* 60* 
 
To obtain the desired N-methylated compounds RMS1-RMS6 and RMS9-RMS10 both 
carbamate groups were simultaneously reduced using lithium alanate in a final step (Scheme 
23). Following the standard protocol established in the synthesis of (iso)tetrandrine the reaction 
proceeded straightforward in good to almost quantitative yields ranging from 62-94% (Table 
7).   
 
Scheme 23. Reaction conditions for the reduction of carbamate groups in the bisbenzylisoquinoline precursors 86-
89 and 91 to give the final compounds RMS1-RMS6 and RMS9-RMS10. 
 
Table 7. Yields of bisbenzylisoquinoline compounds RMS1-RMS6 and RMS9-RMS10 after the reduction of the 
carbamate precursors 86-89 and 91. *the stereoconfiguration of the butylidene intermediates RMS9-RMS10 could 
not be determined. 
entry 
carbamate 
intermediate 
product 
yield (%) 
 
(S,R)/(R,S) (S,S)/(R,R) 
1 86 
 
91 
RMS1 
94 
RMS2 
41 
 
2 87 
 
87 
RMS3 
74 
RMS4 
3 89 
 
62 
RMS5 
77 
RMS6 
4 91 
 
89* 
RMS9 
 
70* 
RMS10 
 
 
Only for the chloroarene variation RMS7/RMS8 this method could not be applied, as it led to  
substantial dechlorination, even when the reaction was carried out at a lower temperature 
(ambient temperature instead of 50 °C) or when using the milder reduction reagent Red-Al® 
(sodium bis(2-methoxyethoxy)aluminium dihydride). As an alternative approach the carbamate 
groups should be first removed to give the secondary amino groups (N-2-H, N-2’-H) followed 
by N-methylation via reductive alkylation in a second step. To explore suitable reaction 
conditions compound 62 (an intermediate of the (iso)tetrandrine synthesis) was employed as 
model substrate (Scheme 24). In a first attempt carbamate 62 was submitted to alkaline 
hydrolysis using KOH as base in ethylene glycol at 170 °C in the presence of hydrazine[136]. 
Neither upon conventional heating nor under microwave irradiation any traces of desired 
product could be detected by TLC-MS or ASAP analysis. Next, trimethylsilyl iodide (in situ 
generated with elemental iodine and hexamethyldisilane) was employed[137]. Since this method 
is also applied for the cleavage of ethers[138] side products resulting from desalkylation of the 
methoxy groups are to be expected, but were not observed (via TLC-MS/ASAP analysis). 
Unfortunately this method did not lead to the desired secondary amine 92 as well. A fast 
method was found using methyllithium[139], in which the starting material was completely 
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consumed within 1.5 h. In TLC-MS and ASAP analysis the mass of desired product 92 was 
detected, but a notable amount of a side product with the mass m/z 637 was also observed. 
Although this side product was not isolated and characterized, the mass peak could be 
assigned to a corresponding mono-amide 93 (depicted in Scheme 24) as a result of incomplete 
reaction. Whereas a prolonged reaction time or elevated temperatures (ambient temperature 
instead of 0 °C) did not lead to a full conversion, the reaction completed after an increase of 
the amount of methyllithium from 6 to 10 equivalents. After the laborious isolation by FCC the 
desired product was obtained in a yield of 37%.  
 
Scheme 24. Screening for reaction conditions for the conversion of the carbamate groups into secondary amines 
using intermediate 62 as model substrate. 
With a protocol in hand for the cleavage of the carbamate groups this method was now 
successfully applied on the chloroarene intermediate 90. Gratefully no side product resulting 
from dechlorination was observed in this approach. It was important that the temperature was 
kept at 0 °C, since above approximately 5 °C a degradation of the starting material occurred. 
It was found benefical to further increase the amount of methyllithium to 15 equivalents. 
Without purification the crude secondary amine 94 was then N-methylated using 
formaldehyde/NaBH3CN and the compounds RMS7 and RMS8 were obtained in almost 
identical yields of 30 and 32% over two steps (Scheme 25).  
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Scheme 25. Cleavage of the carbamate groups of intermediate 90 and subsequent N-methylation. 
As discussed before, the N-acyl Pictet-Spengler condensation proceeds almost racemic. 
Consequently, a mixture of diastereomers was generated accordingly in every variant. A 
separation of the obtained seco-bisbenzylisoquinolines 80-85 was possible by flash column 
chromatography. The bisbenzylisoquinolines RMS1-RMS10 could be therefore eventually 
obtained as racemic compounds with the relative stereoconfiguration of either tetrandrine (rac-
1) or isotetrandrine (rac-2) (see Figure 1) in high diastereomeric ratios (d.r., determined by 
HPLC).  
The relative stereochemistry of compounds RMS1-RMS8 was determined via their NMR 
spectra according to the spectral characteristics of bisbenzylisoquinolines elaborated by 
Guinaudeau et al.[140]. In this study the NMR spectra of more than 100 bisbenzylisoquinolines 
were investigated and it was observed that the chemical shifts of distinctive protons in the 1H-
NMR spectra of bisbenzylisoquinolines correlate with the configuration of the asymmetric 
centres.  Hereby the aromatic proton at C-10 resonates around δ (ppm) = 6.45 – 6.60 in the 
tetrandrine-type alkaloids (R,R)/(S,S) and further upfield around δ (ppm) = 6.20 – 6.45 in the 
isotetrandrine-type (R,S)/(S,R). There is an opposite trend for the signal of H-10’, which is to 
be expected around δ (ppm) = 6.40 for the isotetrandrine-type and more upfield around δ (ppm) 
= 6.25 for the tetrandrine-type. The same applies to the singlet of the 6’-methoxy group that 
appears at around δ (ppm) = 3.60 in the (R,S)/(S,R) isomers and between δ (ppm) = 3.20 – 
3.40 in the (R,R)/(S,S) isomers. In Table 8 the diagnostic chemical shifts of the synthetic 
bisbenzylisoquinolines RMS1-RMS8 are summarized compared to the natural 
bisbenzylisoquinolines alkaloids tetrandrine (1) and isotetrandrine (2). Although the indicative 
signals of H-10, H-10’ and 6’-OCH3 are not always within the range described for tetrandrine- 
and isotetrandrine-like bisbenzylisoquinolines, they follow the trend found for tetrandrine (1) 
and isotetrandrine (2), respectively. 
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Table 8. Chemical shifts in the 1H NMR spectra of bisbenzylisoquinolines of the tetrandrine- and isotetrandrine-type 
that indicate the relative stereochemistry of the alkaloids according to Guinaudeau et al.[140] *the signals of H-10 
and H-10’ overlap. 
alkaloid 
chemical shift [δ (ppm)] 
relative  
stereoconfiguration 
H-10 H-10’ 6’-OCH3 (R,R)/(S,S) (R,S)/(S,R) 
tetrandrine-type 6.45 – 6.60 ~ 6.25 3.20 – 3.40 x  
isotetrandrine-type 6.20 – 6.45 ~ 6.40 ~ 3.60  x 
tetrandrine (1) 6.55 6.30 3.37 x  
isotetrandrine (2) 6.48 – 6.37* 6.48 – 6.37* 3.61  x 
RMS1 6.45 – 6.37* 6.45 – 6.37* 3.60  x 
RMS2 6.55 6.30 – 6.28 3.37 x  
RMS3 6.64 – 6.57 6.45 3.60  x 
RMS4 6.63 6.32 – 6.28 3.38 x  
RMS5 6.02 6.48 – 6.43 3.52  x 
RMS6 6.24 6.26 3.36 x  
RMS7 6.54 6.44 3.61  x 
RMS8 6.59 6.30 3.37 x  
 
Once the relative configurations were determined for the final compounds RMS1-RMS8, the 
stereochemistry of the corresponding (seco-)precursors was then assigned retrospectively. 
For the variations RMS9/RMS10, which contain an alkyl chain instead of the aromatic ring C, 
this method cannot be applied. Unfortunately this variant as free base or as hydrochloride salt 
resisted attempts of crystallization for the determination of the stereoconfiguration by 
crystallographic analysis. The relative stereochemistry of RMS9/RMS10 as well as the 
corresponding precursors is therefore not specified. 
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3.3 SYNTHESIS OF SECO-ANALOGUES 
 
The synthesis of a small series of open-chain analogues of tetrandrine (1) is described in the 
following. Using an appropriately substituted 1-benzyltetrahydroisoquinoline as building block, 
the targeted variants represent truncated compounds gradually resembling tetrandrine (1) in 
their structure, as their complexity increases starting from the simple monomeric 
benzyltetrahydroisoquinoline sc1 to the tetrahydroisoquinoline-benzyltetrahydroisoquinoline 
variants sc4 and sc5. Apart from the benzylisoquinoline unit, all variations contain an O-benzyl 
residue, which is mimicking the aromatic ring C of the lead structure. 
The monomeric 1-benzyltetrahydroisoquinoline sc1 was directly synthesized from the 
intermediate 55 of the (iso)tetrandrine synthesis by lithium alanate reduction to the 
corresponding N-methylated compound. Following the established protocol, the carbamate 
moiety was readily reduced and the aryl bromide was cleaved simultaneously, as this method 
led to substantial debromination (Scheme 26).  
 
Scheme 26. Synthesis of sc1 via reduction and debromination of the intermediate 55 with lithium alanate. 
For the synthesis of seco-analogues sc2-sc5 the intermediate 58 of route 1a of the 
(iso)tetrandrine synthesis was used as starting material. Reduction of the carbamate groups 
in 55 using lithium alanate, gave the N-methylated secondary amine sc2 (Scheme 27) in a 
yield of 93%.  
 
Scheme 27. Synthesis of seco-intermediate sc2 by reduction of intermediate 58 to the secondary amine. 
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The TFA-catalyzed N-acyl Pictet-Spengler condensation of 58 with paraformaldehyde 
furnished intermediate 95 (Scheme 28) in 46% yield.  
Scheme 28. Synthesis of seco-intermediates sc3-sc5. TFA-catalyzed N-acyl Pictet-Spengler reactions with 
intermediate 58 and subsequent carbamate reductions of the intermediates 95-96 gave N-methylated seco-
analogues sc3-sc5. 
Reacting 58 with 3-methylbutyraldehyde following the standard protocol of the intermolecular 
N-acyl Pictet-Spengler yielded almost quantitatively intermediate 96 as an equimolar mixture 
of racemic diastereomers (Scheme 28), which were readily separable by flash column 
chromatography. The N-acyl Pictet-Spengler reaction in this step proceeded in a regioselective 
manner and delivered exclusively the desired isomers, which was confirmed by NMR analysis 
(HMBC). Subsequent reduction of 95 and 96 with LiAlH4 gave the isoquinoline-
benzylisoquinoline seco-compounds sc3-sc5 in good to excellent yields (80-99%). The 
determination of the relative stereochemistry of sc4 and sc5 was attempted by NMR analysis. 
The asymmetric centres in sc4 and sc5 bear bulky residues such as the isobutyl and the 
benzyl group, which have – depending on their relative stereochemistry – a different spatial 
orientation to each other. This might be detectable by NOESY analysis, but unfortunately the 
NOESY spectra of both diastereomers were too similar for any differentiation. Next, 
crystallization was attempted for crystallographic analysis of the diastereomers, but 
unfortunately neither sc4 nor sc5 (as free bases) gave crystals in a sufficient quality. Also after 
conversion into the hydrochloride salts cristalization was unsuccesful. The stereoconfiguration 
of sc4 and sc5 and the corresponding precursors (96) is therefore not further specified. 
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3.4 SYNTHESIS OF RELATED ALKALOIDS 
 
3.4.1 MURARICINE 
 
As aforementioned the carbamate 66, which is an intermediate of route 1b of the tetrandrine 
synthesis (see chapter 3.1) served as starting material for the synthesis of racemic muraricine 
(rac-34). Building block 66 was reacted in an N-acyl Pictet-Spengler condensation with 
paraformaldehyde to give the muraricine precursor 97a (Scheme 29). As already observed in 
the synthesis of (iso)tetrandrine and respective analogues, again a side product with the 
identical mass could be detected, which is most plausibly the regioisomer 97b. The product 
ratio 97a:97b amounted 69:31, as determined by HPLC. To minimize the formation of the 
undesired regioisomer 97b a solvent-directed approach[131, 141] was applied, similarly as already 
examined in the synthesis of tetrandrine (1). According to the protocol of Kayhan et al.[131], the 
N-acyl Pictet-Spengler condensation was carried out in the more polar solvent methanol, which 
should preferentially lead to a cyclization in para-position to the 6’-methoxy group. 
Unfortunately the reaction proceeded very slowly and incomplete under these conditions, just 
as observed in the synthesis of tetrandrine (1), when conducting this step in trifluoroethanol 
instead of DCM as usual. But luckily also in this case the desired isomer 97a could be 
separated from 97b and was isolated in a yield of 68% by flash column chromatography. For 
the unambiguous identification of regioisomer 97a 2D NMR experiments were performed. With 
HMBC experiments of 97a and NOESY experiments of rac-34 respectively, the structure of 
97a could be verified. In the last step bis-carbamate 97a was reduced with LiAlH4 to furnish 
racemic muraricine (rac-34) in 23% yield. The NMR data of synthetic racemic muraricine (rac-
34) were in accordance with the data of the natural alkaloid 34 isolated from Berberis vulgaris 
by Host'álková et al.[119]. 
Scheme 29. Synthesis of racemic muraricine (rac-34).  
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3.4.2 BERBANINE AND BERBIDINE 
 
For the synthesis of the dimeric isoquinoline-isoquinolone alkaloids berbanine (35) and 
berbidine (36) the 1-oxodihydroisoquinoline thalifoline (47) was used as building block. 
Thalifoline (47) was synthesized by Sandra Schmidt as part of her master’s thesis according 
to a newly developed protocol for 1-oxodihydroisoquinoline alkaloids[120].  To access the diaryl 
ether moiety phenolic compound 47 was reacted with 2-bromo-3,4-dimethoxybenzaldehyde 
(48) following the established protocol already used in the synthesis of (iso)tetrandrine. 
Bromoarene 48 was synthesized in one step from commercially available 2-bromo-3-hydroxy-
4-methoxybenzaldehyde (98) via O-methylation with Me2SO4[142]. The Ullmann-type coupling 
furnished the diaryl ether 99 in a yield of 49%. Intermediate 99 was then further processed in 
a Pomeranz-Fritsch reaction using aminoacetaldehyde dimethylacetal and boron 
trifluoride/acetic acid complex as Lewis acid applying the conditions published by Patel for the 
synthesis of related isoquinolines[143] to obtain the alkaloid berbanine (35) in 47% yield. 
Surprisingly, the NMR data of synthetic berbanine (35) were not in accordance with the data 
of isolated berbanine published by Host'álková et al.[144]. Apart from several deviations of 
chemical shifts in the 1H and 13C NMR spectra, most striking was a deviation in the signal of 
proton 1’-H of the isoquinoline moiety. Host'álková et al. report a doublet at 9.23 ppm (J = 5.9 
Hz), whereas a singlet further upfield at 9.16 ppm was found for synthetic berbanine. A 
reasonable explanation for the downfield shift and multiplicity of the 1’-H signal in Host'álková’s 
data might be that not the free base was characterized as reported, but the protonated 
isoquinolinium species of 35. After the conversion of synthetic berbanine into its hydrochloride 
salt, the NMR data thereof was largely identical with the reported data of the isolated alkaloid. 
Next, berbanine (35) was converted into its N-methylated 1,2,3,4-tetrahydro analogue 
berbidine (36) in two steps following a method of Chan et al.[145]. N-Methylation of the aromatic 
isoquinoline 35 using methyl iodide gave an isoquinolinium salt, which was reduced with 
sodium borohydride to furnish alkaloid 36 in a yield of 88% over two steps (Scheme 30).  
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Scheme 30. Synthesis of the alkaloids berbanine (35) and berbidine (36).   
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4 PHARMACOLOGICAL EVALUATION 
 
As mentioned above several biological activities such as anticancer, antiviral, chemoresistance 
reversing and calcium channel blocking properties are known for tetrandrine (1). The 
synthesized (iso)tetrandrine analogues RMS1-RMS10, the seco-analogues sc1-sc5 and 
racemic muraricine (rac-34) were subjected to pharmacological characterization with a focus 
on antitumoral activities. These compounds were therefore screened for their antiproliferative 
and multidrug resistance reversing activity. Moreover the substances were investigated for 
their toxicity as the reduction of tetrandrine’s (1) toxic effects is of central interest. Additionally, 
MTT and standard agar diffusion assays were employed as part of an in-house routine 
screening for assessing cytotoxicity and antimicrobial activity, respectively. The screenings for 
antiproliferative and multidrug resistance reversing activity as well as toxicological evaluation 
were performed by Martin Müller and Franz Geisslinger of the group of Prof. Dr. Angelika 
Vollmar (chair of pharmaceutical biology, LMU Munich). The MTT and agar diffusion assays 
were performed by Martina Stadler of our group. The results were already published in ref. 53 
(tetrandrine analogues RMS1-RMS10) and ref. 122 (rac-34). The seco-analogues sc1-sc5 
were pharmacologically characterized by Franz Geisslinger within the scope of his master’s 
thesis[146]. 
 
  
51 
 
4.1 ANTIPROLIFERATIVE ACTIVITY 
 
The effect of the (iso)tetrandrine analogues RMS1-RMS10 and the seco-analogues sc1-sc5 
on cell proliferation was assessed using vincristine-resistant cells (VCR-R CEM cells). VCR-R 
CEM cells are P-gp overexpressing leukemia cells that are cross-resistant to a variety of 
cytostatic agents[147]. VCR-R CEM cells were treated with increasing concentrations (0.01 – 50 
µM) of the test compounds and cell viability was determined 48 h after exposure to the 
compounds employing a CellTiter-Blue® cell viability assay. Table 9 summarizes the IC50 
values of the tested compounds compared to natural tetrandrine (1, isolated from natural 
sources and kindly donated by Prof. Dr. Peter Pachaly).  
Table 9. Antiproliferative activity of (iso)tetrandrine analogues RMS1-RMS10 and seco-analogues sc1-sc5 
assessed on VCR-R CEM cells. The experiments were performed in triplicates. 
compound IC50 [µM]  compound IC50 [µM] 
tetrandrine (1) 15.8    
(iso)tetrandrine analogues  seco-analogues 
RMS1 4.8  sc1 > 50 
RMS2 4.4  sc2 > 50 
RMS3 3.8  sc3 12 
RMS4 4.2  sc4 8.9 
RMS5 7.1  sc5 7.5 
RMS6 > 50    
RMS7 4.9    
RMS8 4.8    
RMS9 > 50    
RMS10 > 50    
 
Compared to the lead structure tetrandrine (1), the analogues RMS1-RMS5, RMS7-RMS8 and 
the seco-compounds sc3-sc5 showed an increased antiproliferative activity against VCR-R 
leukemia cells. Six of the macrocyclic analogues (RMS1-RMS4, RMS7-RMS8) were three to 
four times more potent than tetrandrine (1). The propylidene analogues containing an alkyl 
residue instead of the aromatic ring C (RMS9-RMS10), as well as the thiophene analogue with 
the relative stereochemistry of tetrandrine (R,R/S,S) (RMS6) were nearly inactive. Surprisingly 
its diastereomer RMS5 did show an antiproliferative effect, although weaker than the other 
active analogues. Except for the diastereomeric compounds RMS5 and RMS6, no relevant 
difference in the antiproliferative potency of diastereomers can be observed. The seco-
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analogues sc1 and sc2, which are lacking a second tetrahydroisoquinoline moiety (ring B’), 
were also inactive.  
The synthetic isoquinoline-benzylisoquinoline alkaloid muraricine (rac-34) was also screened 
for antiproliferative activity using hepatocellular carcinoma (HepG2), colorectal 
adenocarcinoma (HCT-15), and bladder carcinoma (T24) cell lines. The cells were incubated 
with increasing concentrations of rac-34 or tetrandrine (1) (0.1 – 50 µM) for 72 h and cell 
viability was determined by CellTiter-Blue® assay. No cytotoxic activity and only very low 
antiproliferative effects were observed, when compared to tetrandrine (1). Consequently, 
muraricine (rac-34) does not possess a direct anticancer activity. The data is shown as 
supplementary material on Figure 22 (chapter 7.1). 
In terms of structure-activity relationship this data indicates that the aromatic ring C and the 
presence of two tetrahydroisoquinoline units might be important structural elements for 
antiproliferative activity. Moreover, the antiproliferative properties seem to be mainly 
independent of the relative stereochemistry. This needs to be further investigated in SAR 
studies involving a larger number of structure variations, for which these findings provide a first 
basis and give inspiration for the design of new variants.  
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4.2 P-GP INHIBITION 
 
The inhibitory effects of the (iso)tetrandrine analogues RMS1-RMS10, the seco-analogues 
sc1-sc5 and racemic muraricine (rac-34) on the efflux pump P-gp were investigated in VCR-
R CEM cells, the same cell line which was used for assessing antiproliferative effects. Owing 
to the overexpression of P-gp VCR-R CEM cells are a suitable model for the investigation of 
P-gp inhibition. Hereby the effect of the analogues on P-gp was assessed in two assays. In a 
calcein-AM retention assay[52] the direct interaction with the multidrug resistance transporter 
was determined and, in a subsequent Nicoletti assay[148], the cells were treated with the 
cytostatic agent and P-gp substrate vincristine (VCR) in combination with the tested 
compounds. An increase in vincristine susceptibility indicates a reversal of multidrug 
resistance.  
In the calcein-AM retention assay a model substrate of P-gp, calcein-AM, the nonfluorescent 
acetoxymethyl ester of the fluorescent dye calcein, accumulates in cytoplasmatic 
compartments, if P-gp is inhibited. Calcein-AM is then cleaved by cellular esterases to calcein, 
which results in an increase of fluorescence intensities. In this assay, the cells were incubated 
with the tested compounds in increasing concentrations and calcein-AM (200 nM) for 30 min. 
The cells were then washed to remove excess calcein-AM and again incubated with the 
potential P-gp inhibitor for 1 h. Lastly, calcein fluorescence was determined by flow cytometry. 
The seco-analogues sc1-sc5 were tested at 0.1, 1 and 10 µM, as these concentrations were 
well tolerated by the cells. The compounds RMS1-RMS10 could be tested only in 
concentrations up to 1 µM, since the cell viability was strongly affected at higher doses.  
Muraricine (rac-34) was assessed using the same protocol but in generally higher 
concentrations (1, 10, 20 and 50 µM) and the known second-generation P-gp inhibitor 
verapamil (8) was used as a positive control. Verapamil (8) was a suitable positive control for 
muraricine (rac-34), since the cells tolerated high micromolar concentrations of the compound 
(≤ 50 µM). 
All full (iso)tetrandrine analogues, except the propylidene analogues RMS9-RMS10, were able 
to inhibit P-gp to a similar extent as tetrandrine (1) (Figure 13, A). Among the seco-analogues 
sc4 and sc5 exhibited inhibitory activity (Figure 13, B), which was similar compared to that of 
tetrandrine (1). Compounds sc1-sc3 as the least active substances showed no noteworthy 
inhibition below 10 µM. To test whether an improved P-gp inhibition can be achieved by dose 
increase, muraricine (rac-34) was exemplarily employed at higher concentrations (≤ 50 µM), 
at which the alkaloid had only marginal antiproliferative effects. Muraricine (rac-34) did not 
show any activity in concentrations below 10 µM, but in higher concentrations (10-50 µM) a 
dose-dependent inhibition of calcein efflux could be detected (Figure 13, C). 
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Figure 13. Inhibition of P-gp-mediated calcein-AM efflux determined by calcein retention assay in VCR-R CEM 
cells. (A) Inhibition of P-gp by treatment with RMS1-RMS10 and tetrandrine (1). (B) Treatment with seco-analogues 
sc1-sc5 and tetrandrine (1). (C) Treatment with racemic muraricine (rac-34) and verapamil (8). Ctrl: solvent control, 
tet: tetrandrine (1). Geometric means of fluorescence intensities (gMFI) of treated samples were normalized to the 
untreated calcein-AM control. Bar graph indicates means ± SEM of three independent experiments (A,B: two-way 
ANOVA followed by Dunnett’s multiple comparison test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; C: one-
way ANOVA followed by Tukey’s multiple comparison test, **P < 0.01, ***P < 0.001). 
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Next, the cells were treated with increasing concentrations of vincristine (VCR) (0.01, 0.1 and 
1 µM) in combination with the tested compounds in a specified concentration of 1 µM. Only 
muraricine (rac-34) was used in a higher concentration of 25 µM in combination with 0.1 or 1 
µM of vincristine. After an incubation time of 48 h the percentage of apoptotic cells was 
determined via propidium iodide (PI) staining and flow cytometry (Nicoletti assay). Propidium 
iodide staining is performed in a hypotonic buffer, enabling the PI to bind and label DNA and 
to quantify apoptotic, hypodiploid cells[148]. 
Again, all macrocyclic analogues except RMS9-RMS10 were able to resensitize VCR-R CEM 
cells to the vincristine treatment by inhibiting P-gp as evident by strongly increased apoptosis 
rates at 0.1 and 1 µM of vincristine (Figure 14, A). Very similar to the observations made in the 
calcein-AM retention assay, the seco-analogues sc4 and sc5 were the most active substances 
among the seco-series in reversing multidrug resistance similar to tetrandrine (1). As expected 
sc2 and sc3 did not increase apoptosis rates at 1 µM, sc1 suprisingly showed weak activity in 
combination with 1 µM of VCR (Figure 14, B). Muraricine (rac-34), employed at a concentration 
of 25 µM, markedly led to an increase of apoptosis in the combination treatment with vincristine 
in 0.1 and 1 µM concentration (Figure 14, C). As observed for the antiproliferative effects, the 
relative stereochemistry of the compounds is not an important factor for the chemoresistance 
reversing activity as well. 
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Figure 14. Combination treatment of chemoresistant VCR-R CEM cells. (A) Vincristine (VCR) and RMS1-RMS10 
or tetrandrine (1). (B) Vincristine (VCR) and seco-analogues sc1-sc5 or tetrandrine (1). (C) Vincristine (VCR) and 
racemic muraricine (rac-34). Ctrl: solvent control, tet: tetrandrine (1). Bar graph indicates means ± SEM of three 
independent experiments (A,B: two-way ANOVA followed by Dunnett’s multiple comparison test, *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001); C: one-way ANOVA followed by Tukey’s multiple comparison test, *P < 0.05, 
***P < 0.001). 
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4.3 TOXICITY 
 
The toxicity of the macrocyclic (iso)tetrandrine analogues RMS1-RMS10 and the seco-
derivatives sc1-sc5 was evaluated in several cancerous and non-malignant cell lines.  
As the variations RMS1-RMS10 were designed to be less toxic than the lead structure 
tetrandrine (1), the evaluation of their toxicity was of central interest. The compounds RMS1-
RMS10 are lacking the hypothesized metabolically instable methoxy group at C-12, which is 
discussed to undergo a CYP-mediated oxidative metabolism resulting in a potentially toxic 
quinone methide intermediate[55]. Beside the assessment of general toxicity, it should be 
specifically investigated whether the CYP3A4-driven metabolism is in fact the major 
mechanism of tetrandrine-induced toxicity. For this purpose, two cell lines were employed, the 
non-malignant HepaRGTM cells and the liver cancer cell line HepG2. HepaRGTM is a hepatic 
cell system frequently used to study drug metabolism and hepatotoxicity as these cells possess 
several characteristics of human hepatocytes such as the expression of P450 enzymes[149-150], 
including CYP3A4. HepaRGTM cells were treated with the analogues RMS1-RMS10 and 
tetrandrine (1) at 10 and 20 µM (Figure 15, A). After an incubation time of 24 h, cell viability 
was determined via CellTiter-Blue® cell viability assay. Surprisingly, none of the analogues was 
significantly less toxic to HepaRGTM cells than the lead structure tetrandrine (1) at 10 µM, only 
at the higher concentration of 20 µM a decreased toxicity was observed for RMS6 and RMS9 
compared to tetrandrine (1). Unlike expected the compounds RMS2, RMS4 and RMS8 
exhibited even increased toxic effects, whereas the toxicity of all other analogues was similar 
to that of tetrandrine (1) at both concentrations.  
As the hypothesized metabolic pathway requires CYP3A4 enzymatic activity to transform 
tetrandrine (1) into the putatively toxic para-quinone methide, it was additionally investigated 
whether an overexpression of CYP3A4 would further enhance the compounds’ toxicity. 
Therefore, HepaRGTM cells were transiently transfected with a vector coding for CYP3A4 
(pcDNA3-CYP3A4-EGFP) or an empty vector control. The treatment of CYP3A4 
overexpressing cells with compounds RMS1-RMS10 or tetrandrine (1) (10 µM, 24 h) did not 
lead to a considerable increase of cell death compared to the treatment of control HepaRGTM 
cells (Figure 15, B) transfected with the empty vector. 
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Figure 15. Toxicity assessment of RMS1-RMS10 and tetrandrine (1) in HepaRGTM cells. (A) Differentiated 
HepaRGTM cells treated with 10 and 20 µM of RMS1-RMS10 or tetrandrine (1). (B) CYP3A4 overexpressing (thick 
bars) or control (thin bars) HepaRGTM cells with 10 µM of RMS1-RMS10 or tetrandrine (1). Tet: tetrandrine (1). Bar 
graph indicates means ± SEM of three independent experiments (A: one-way ANOVA followed by Dunnett’s 
multiple comparison test, relative cell viabilites were compared with that of tetrandrine (1), *P < 0.05, **P < 0.01, 
***P < 0.001; B: unpaired t-test with Welch’s correction, not significant). 
To further determine the influence of CYP3A4 activity on toxicity, the cancer cell line HepG2 
(hepatocellular carcinoma cells) as an additional standard in vitro model for CYP metabolism 
studies, was employed. To facilitate overexpression of CYP3A4, HepG2 cells were stably 
transfected with a pcDNA3-CYP3A4-EGFP vector. Cells that were stably transfected with an 
empty vector served as control. Also in this cellular model, cytotoxic effects on CYP3A4 
overexpressing cells and on control cells were very similar (Figure 16). Consequently, 
cytotoxicity could again not be correlated to the level of cellular CYP3A4 expression. The 
majority of analogues (RMS1-RMS5 and RMS7-RMS8) showed strongly enhanced cytotoxic 
effects compared to tetrandrine (1), as the specific cell death was twice as high. Only RMS6, 
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RMS9 and RMS10 affected cell viability slightly less than or similarly to tetrandrine (1), as 
already observed in the HepaRGTM cells. 
 
 
 
 
 
 
 
  
Figure 16. Toxicity assessment of RMS1-RMS10, berbamine (100), dauricine (3) and tetrandrine (1) in CYP3A4 
overexpressing (thick bars) or control (thin bar) HepG2 cells with 15 µM of each compound (cells were treated for 
24 h). Tet: tetrandrine (1), bm: berbamine (100), dc: dauricine (3). Bar graph indicates means ± SEM of three 
independent experiments (unpaired t-test with Welch’s correction, not significant). 
In the hypothesized metabolic pathway of tetrandrine (1), the first step is the demethylation of 
the methoxy group at C-12 prior to oxidation to the discussed quinone methide[55]. This O-
demethylation process is catalyzed by not further specified CYP enzymes. Assuming that 
HepG2 cells are lacking these essential enzymes required for initial demethylation, the 
metabolism to the para-quinone methide might not occur. Consequently, this could explain the 
observed similar cytotoxic effects on both CYP3A4 overexpressing and control cells. To rule 
this out, the related bisbenzylisoquinoline alkaloids berbamine (100) and dauricine (3; a seco-
bisbenzylisoquinoline) (see Figure 17) that already bear a free phenol at C-12 instead of a 
methoxy group susceptible to direct oxidation by CYP3A4 enzymes, were also tested using 
HepG2 cells (Figure 16). As observed for tetrandrine (1) and the analogues RMS1-RMS10, 
the cytotoxic effects were again independent of the expression level of CYP3A4.  
 
Figure 17. (Seco)bisbenzylisoquinoline alkaloids dauricine (3) and berbamine (100) with the para-hydroxybenzyl 
structure (highlighted in red) prone to oxidative metabolism.  
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Considering the anticancer properties in relation to toxic effects, RMS3 and RMS5 possess 
the most benefical pharmacological profile among the RMS series, as they exerted strongly 
enhanced antiproliferative and cytotoxic effects, MDR reversing activities similar to that of 
tetrandrine (1), whereas their toxic properties on HepaRGTM were not inferior compared to the 
lead structure. Although a decrease of toxicity could not be achieved directly, an indirect 
reduction of toxic effects by lowering required doses might be possible. To further analyse the 
toxicity of the highly active compounds RMS3 and RMS5, additional studies with human 
umbilical vein endothelial cells (HUVECs) and peripheral blood mononuclear cells (PBMCs), 
both representing non-cancerous primary cell lines, were conducted. Both cell lines were 
treated with RMS3, RMS5 or tetrandrine (1) at increasing concentrations (1, 5 and 10 µM) for 
either 48 h (PBMCs) or 24 h (HUVECs). Viability of HUVECs was determined via CellTiter-
Blue® cell assay and cell death of PBMCs was quantified using flow cytometry after propidium 
iodide staining. In both cell lines the toxic effects of RMS3 and RMS5 were largely equal to 
those of tetrandrine (1). A slight difference was observed in PBMC cells treated with 
compounds at a concentration of 10 µM (Figure 18, A). In this case tetrandrine (1) affected the 
cell viability most, as indicated by the high percentage of cell death. In contrast, RMS3 at the 
same concentration (10 µM) showed slightly higher toxic effects on HUVEC cells compared to 
tetrandrine (1) (Figure 18, B). Combining the data of all toxicity studies, no substantial 
difference in the cytotoxic potencies of the analogues RMS3/RMS5 and tetrandrine (1) can be 
observed. 
 
Figure 18. Toxicity assessment of RMS3, RMS5 and tetrandrine (1) in (A) human umbilical vein endothelial cells 
(HUVECs) and (B) peripheral blood mononuclear cells (PBMCs). Ctrl: solvent control, tet: tetrandrine (1). Bar graph 
indicates means ± SEM of three independent experiments (two-way ANOVA followed by Dunnett’s multiple 
comparison test, *P < 0.05, **P < 0.01, ***P < 0.001). 
The acute toxicity of sc1-sc5 was also determined using HUVEC and PBMC cells. Hereby, 
the assessment of general toxicity compared to tetrandrine (1) and not the metabolic pathway 
leading to potentially toxic intermediates was the primary objective. Like the lead structure 
tetrandrine (1), all seco-analogues sc1-sc5 possess the para-methylene methoxy group at C-
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12, that could potentially be O-demethylated and oxidized to the corresponding quinone 
methide. Similar to the previous section, the cells were treated with sc1-sc5 or tetrandrine (1) 
at increasing concentrations (1, 5, 10 and 20 µM) for either 48 h (PBMCs) or 24 h (HUVECs) 
and the cell viability was determined as mentioned before. The cell viability of PBMCs is only 
slightly affected by the tested compounds in the low concentration range of 1-5 µM (Figure 19, 
A). In higher concentrations of 10 and 20 µM cell death markedly increases upon treatment 
with sc2-sc5 and tetrandrine (1), whereas sc1 barely shows toxic effects (Figure 19, A). On 
HUVEC cells sc1 likewise had only a minor effect on cell viability in the tested concentration 
range, sc2-sc4 showed toxic effects largely similar to tetrandrine (1) and sc5 was the most 
toxic compound especially at higher concentrations (≥ 10 µM) (Figure 19, B). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Toxicity assessment of the seco-analogues sc1-sc5 and tetrandrine (1) in (A) PBMC cells and (B) 
HUVEC cells. Ctrl: solvent control, tet: tetrandrine (1). Bar graph indicates means ± SEM of three independent 
experiments (two-way ANOVA followed by Dunnett’s multiple comparison test. The relative cell viabilites and the 
percentage of cell death were compared with that of tetrandrine (1) in the respective concentrations, *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001). 
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The toxicity assessment of racemic muraricine (rac-34) was determined using HUVEC cells as 
well. The cells were incubated with rac-34 or tetrandrine (1) in increasing concentrations (10, 
20 and 50 µM) for 6 h and the cell viability was measured using CellTiter-Glo® cell assay 
detecting the intracellular adenosine triphosphate (ATP) content as a surrogate of cell viability. 
Whereas tetrandrine (1) exhibited strong toxic effects on HUVEC cells, the cell viability was 
nearly unaffected when applying racemic muraricine (rac-34) in the tested concentration range 
(Figure 20). 
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Figure 20. Toxicity assessment of racemic muraricine (rac-34) in HUVEC cells. Tet: tetrandrine (1), rac-34: racemic 
muraricine. Bar graph indicates means ± SEM of three independent experiments (one-way analysis of variance 
followed by Tukey's multiple comparison test; **p < .01, ***p < .001). 
Summarizing, with most of the structure variations that are present in RMS1-RMS10 no 
considerable reduction of the toxicity of tetrandrine (1) could be achieved as shown by several 
in vitro models. Only the analogues RMS6 and RMS9 (RMS10 slightly) showed decreased 
toxicity to some extent, whereas all other compounds did not substantially differ from 
tetrandrine (1) or exhibited even increased toxic effects. It has to be stated that a decrease of 
toxicity as observed for RMS6, RMS9 and RMS10 is unfortunately accompanied by a 
concurrent reduction of antitumoral activity. Moreover, the cytotoxic potency of tetrandrine (1) 
and the analogues RMS1-RMS10 was mainly unaffected by the extent of cellular CYP3A4 
expression. Therefore it can be concluded that the hypothesized CYP3A4-mediated 
metabolism generating potentially toxic para-quinone methide intermediates[55] is not the major 
cause of tetrandrine-induced hepatotoxicity. Most of the seco-analogues sc1-sc5 and racemic 
muraricine (rac-34) that do contain the putatively problematic methoxy or hydroxy group at C-
12 did not exhibit a notably increased toxicity compared to the RMS compounds, although a 
direct comparison was not made. This provides further evidence, that the proposed metabolic 
pathway is not the underlying mechanism for the alkaloid’s toxicity. 
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4.4 MTT ASSAY 
 
For a rapid and rough evaluation of cytotoxicity the (iso)tetrandrine analogues RMS1-RMS10 
and the seco-analogues sc1-sc5, as well as the natural products muraricine (rac-34), 
berbanine (35) and berbidine (36) were submitted to a routine MTT assay following the 
standard protocol of Mosmann[151]. The assay was performed in human leukemia cell line HL-
60 and Triton® X-100 was used as positive control.  
Table 10. Results of the MTT assay as IC50-values. *The synthetic (racemic) alkaloid was used for testing. 
 
compound IC50 [µM]  compound IC50 [µM] 
(iso)tetrandrine analogues  seco-analogues 
RMS1 2.6  sc1 > 50 
RMS2 10.9  sc2 30.7 
RMS3 7.7  sc3 19.5 
RMS4 6.5  sc4 13.1 
RMS5 15.4  sc5 17.1 
RMS6 >50  natural products 
RMS7 14.6  tetrandrine (1) 21.2 
RMS8 14.6  berbanine (35)* >50 
RMS9 >50  berbidine (36)* >50 
RMS10 24.1  muraricine (rac-34)* >50 
 
As already mentioned the results of this assay only allows an approximate estimation of the 
acute cytotoxicity of a compound. An IC50 value of ≤ 5 µM in the MTT assay can be considered 
as strongly cytotoxic, substances with a value above 50 µM can be usually expected to be 
non-toxic. IC50 values in between can indicate potential cytotoxic properties to a certain extent.  
Since the majority of compounds already exhibited antiproliferative and toxic properties on 
cancerous cell lines (see chapter 4.1 and 4.3), toxic effects on human leukemia (HL-60) cells 
are to be expected as well. The most toxic compounds identified by MTT assay are RMS1, 
RMS3 and RMS4, which are in the range (RMS3 and RMS4 very closely) of strong toxicity. In 
direct comparison to tetrandrine (1) (IC50 = 21.2 µM), two thirds of all synthesized analogues 
exhibit lower IC50 values than the lead structure. The analogues RMS6, RMS9 and sc1 as well 
as the synthetic alkaloids berbanine (35), berbidine (36) and racemic muraricine (rac-34) did 
not show notable cytotoxic effects in this assay (IC50 > 50 µM). This data is approximately in 
line with the observed trend in the assessment of toxicity and antiproliferative activity.  
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4.5 AGAR DIFFUSION ASSAY 
 
As part of a routine screening most of the synthesized analogues as well as the natural 
products muraricine (rac-34), berbanine (35) and berbidine (36) were tested for antimicrobial 
activity in a standard agar diffusion assay. Since there is an antimicrobial effect reported for 
some isoquinoline and benzylisoquinoline alkaloids[152], this sreening was mainly intended for 
the less complex alkaloids muraricine (rac-34), berbanine (35) and berbidine (36) as well as 
the seco-analogues sc1-sc5. Among the macrocyclic analogues RMS1-RMS10 only the 
(R,R/S,S) isomers (RMS2, RMS4, RMS6, RMS8) and RMS10 were tested. As there was 
mostly no substantial difference observed between the diastereomers of RMS1-RMS10 
regarding biological activity in the other afore mentionend assays, it should be sufficient to test 
only one isomer as representative of each variation.  The compounds were tested against 
Gram‐positive (Streptococcus entericus, Staphylococcus equorum) and Gram‐negative 
bacteria (Escherichia coli, Pseudomonas marginalis), and against fungi (Yarrowia lipolytica, 
Saccharomyces cerevisiae). For a positive control tetracycline was used as reference 
substances for antibacterial and clotrimazole for antifungal activity. There was no zone of 
inhibition observed in any experiment, consequently none of the substances exhibits 
antimicrobial activity against the tested germs. 
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5 SUMMARY 
 
Taken together, five natural products were successfully synthesized in this work. The 
bisbenzylisoquine alkaloids tetrandrine (rac-1) and isotetrandrine (rac-2) as well as the 
isoquinoline-benzylisoquinoline alkaloid muraricine (rac-34) were synthesized in their racemic 
form. With the synthetic approaches towards muraricine (rac-34) and the isoquinolon-
isoquinoline alkaloids berbanine (35) and berbidine (36) the first total syntheses of these 
alkaloids were developed.  
In a first step a suitable method for the construction of the tetrahydroisoquinoline moiety, which 
is present in four of the five synthesized alkaloids, was investigated. As an N-acyl Pictet-
Spengler reaction seems most promising and straightforward, this approach was selected as 
method of choice and different alternatives for aldehydes were tested as suitable building 
blocks. Beside the efficiency of this reaction step, the good availability and variability of starting 
material was of interest. For this purporse alkynes, nitrostyrenes (as precursors of in situ 
generated enamines and phenylacetaldehydes) and enol ethers were examined in acid-
catalyzed N-acyl Pictet-Spengler condensations with an N-acylated arylethylamine as model 
reaction partner. Neither the alkyne nor the nitroalkene could be successfully reacted under 
various reaction conditions. When using an enol ether as masked aldehyde an efficient 
cyclization resulting in the desired tetrahydroisoquinoline was accomplished. As this protocol 
was already applied successfully in our group, the feasibility could be once again confirmed. 
This method proved to be a straightforward and fast access for the tetrahydroisoquinoline 
scaffold in the racemic synthesis of tetrandrine (rac-1) and isotetrandrine (rac-2) with yields 
from 47% to almost quantitative conversions of 96%, even for highly substituted starting 
materials. In contrast to Bischler-Napieralski protocols, which require three sequential steps, 
the construction of the tetrahydroisoquinoline moiety was accomplished in only one step via 
N-acyl Pictet-Spengler reaction. The required enol ethers of their part are accessed in a single 
operation from corresponding benzaldehydes via Wittig olefination in high yields. Moreover, 
the acylated phenenthylamines required for this approach are as well accessible from aromatic 
aldehydes via Henry reaction, subsequent reduction and acylation. In consequence, all four 
aromatic rings in the target molecule derive from benzyaldehydes, providing a high synthetic 
flexibility, as a great variety of benzaldehydes is commercially available. 
The primary goal of this thesis was to design a new synthetic approach to the 
bisbenzylisoquine alkaloids tetrandrine (1) and isotetrandrine (2), which is - compared to the 
already published syntheses - shorter in the sequence of required steps and superior in terms 
of yields. From views of a diversity oriented synthetic approach, the development of a flexible 
protocol that allows to implement systematic structure variations on the aromatic rings for 
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subsequent structure-activity relationship studies, was also aimed for. Any aromatic ring, which 
is subject of structure variations can be inserted in a late stage of the synthesis, starting with 
aromatic aldehydes as building blocks. For this purpose the routes 1a and 1b were developed, 
in which either the one or the other benzylisoquinoline unit, each representing one half of the 
target molecule, is synthesized first. Although the synthesis was designed as a primarily 
racemic approach, the achievement of diastereoselectivity to a certain extent via asymmetric 
induction was gained in an intramolecular Pictet-Spengler cyclization step. In addition to the 
main routes 1a and 1b, in which the cyclization takes place in an intramolecular Ullmann-type 
coupling reaction, the variations 2a and 2b were created. Herein the macrocycle is constructed 
via an intramolecular N-acyl Pictet-Spengler reaction under formation of the second 
asymmetric centre. Scheme 31 gives a concise overview of the total synthesis via the four 
different routes. 
 
Scheme 31. Racemic synthesis of the bisbenzylisoquinoline alkaloids tetrandrine (rac-1) and isotetrandrine (rac-2) 
on four different routes. Conditions for a) intermolecular N-acyl Pictet-Spengler reaction (intermol. P-S): TFA, DCM, 
0 °C to rt. b) Intramolecular N-acyl Pictet-Spengler reaction (intramol. P-S): TFA, DCM, -15 °C. c) Intermolecular 
and intramolecular Ullmann-type cross-coupling reaction (intermol./intramol. Ullmann): CuBr.Me2S, Cs2CO3, 
pyridine, 110 °C. d) Carbamate reduction (red.): LiAlH4, THF, 50 °C. 
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The total synthesis of racemic tetrandrine (rac-1) and isotetrandrine (rac-2) was achieved in 
12 steps each, starting from commercially available buildings blocks on four different routes. 
Compared to the published syntheses a significant reduction of steps was achieved as 
Inubushi’s approach implies more than 20 steps and the one published in a Chinese patent, 
19 steps. The aim of an improved synthetic approach was also reached in terms of efficiency 
when comparing the overall yields of both approaches. The overall yields (as sum of both 
alkaloids rac-1 and rac-2) when combining the building blocks 53, 54, 57 and 60 in routes 1a 
and 2a (or building blocks 53, 57, 63 and 67 in routes 1b and 2b respectively) amounts 10.5% 
in route 1a and 3.0% in route 2a, 12.4% in route 1b and 19.2% in route 2b. As in Inubushi’s 
approach the overall yield amounts 2.1% after combination of corresponding building blocks 
the herein presented synthetic method is up to nine times more efficient. The greatest 
enhancement of yields was achieved in the formation of the tetrahydroisoquinoline moiety. 
Following the N-acyl Pictet-Spengler approach this scaffold was constructed in one single 
operation in yields of 47 – 96%, whereas in Inubushi’s synthesis the tetrahydroisoquinoline 
units were generated in yields from 28 – 35% over three steps via Bischler-Napieralski 
reaction. Consequently, a significant reduction of required steps could be achieved in this new 
approach.  
For the construction of the diaryl ether moiety various conditions following Buchwald-Hartwig 
and copper-mediated Ullmann-type protocols using different ligand/catalyst systems were 
explored. The most efficient method by far was the combination of CuBr·Me2S as catalyst 
without an additional ligand and Cs2CO3 as base in pyridine, a protocol that was previously 
applied by Evano and coworkers for the synthesis of a macrocyclic 
phenethyltetrahydroisoquinoline alkaloid[125]. With this method also the yields of diaryl ethers 
could be partly improved, which were afforded in yields of 41 – 64%, compared to 42 – 48% 
yield (according to the experimental section[96]) in Inubushi’s approach. 
Through the routes 2a and 2b in which the macrocyclic (iso)tetrandrine precursor 62 is 
generated via an intramolecular N-acyl Pictet-Spengler cyclization, diastereoselectivity could 
be achieved to a certain degree. Favouring the relative stereoconfiguration of tetrandrine (1) 
in route 2a preferably (R,R)/(S,S) isomers were formed in a diasteremeric ratio of 87:13, 
whereas in route 2b predominantly isotetrandrine-type (S,R)/(R,S) isomers were obtained in a 
diasteremeric ratio of 71:29. Inubushi obtained prefereably tetrandrine-type isomers in the 
reduction step of a macrocyclic 3,4-dihydroisoquinoline intermediate to the corresponding 
tetrahydroisoquinoline with a d.r. of 4:1. 
With an efficient synthetic protocol in hand, the synthesis of novel bisbenzylisoquinolines of 
the (iso)tetrandrine-type were realized. Following route 1b and using the intermediate 66 of the 
tetrandrine synthesis as starting material, five structure variations could be synthesized as 
analogues of racemic tetrandrine (rac-1) and isotetrandrine (rac-2) respectively. Hereby the 
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variation focused on the methoxy group at C-12 in ring C, which is discussed for being 
responsible for the alkaloid’s toxicity by being transformed to a quinone methide intermediate 
in an oxidative metabolism pathway. The methoxy group was successfully eliminated resulting 
in variations RMS1 and RMS2 or replaced by metabolically stable trifluoromethoxy (RMS3 and 
RMS4) or chlorine substituents (RMS7 and RMS8). In RMS5 and RMS6 the complete benzene 
ring C was replaced by a thiophene ring and in RMS9 and RMS10 the aromatic system was 
completely exchanged for an alkyl chain. In Scheme 32 the synthetic approach to the 
analogues RMS1-RMS10 is summarized.  
 
 
Scheme 32. Synthesis of macrocyclic (iso)tetrandrine analogues RMS1-RMS10. Conditions for a) N-acyl Pictet-
Spengler reaction: TfOH, DCM, 0 °C to rt. b) Ullmann-type cross-coupling reaction (for the intermediates of variants 
RMS1-RMS8): CuBr.Me2S, Cs2CO3, pyridine, 110 °C. c) SN2 reaction (for the intermediates of variants 
RMS9/RMS10): KI, K3PO4, DMF, 100 °C. d) Carbamate reduction (for RMS1-RMS6, RMS9/RMS10): LiAlH4, THF, 
50 °C. e) Cleavage of carbamates and subsequent reductive N-methylation (compounds RMS7/RMS8): 1) MeLi, 
THF, 0 °C, 2) aq. formaldehyde solution (37%), NaBH3CN, MeOH, rt. 
The syntheses were conducted following the standard protocols established in the synthesis 
of (iso)tetrandrine except for the variations RMS7/RMS8 and RMS9/RMS10. For RMS7/RMS8, 
in which a chlorine substituent is present, an alternative method for the conversion of the 
carbamate to N-methyl groups was required, as the use of LiAlH4 led to substantial 
dechlorination. Cleavage of the carbamate groups using MeLi and subsequent reductive N-
methylation of the resulting secondary amines furnished the desired N-methylated 
bisbenzylisoquinolines RMS7 and RMS8. For the construction of the aliphatic ether bridge in 
variants RMS9/RMS10 an SN2 reaction was applied instead of the standard copper-catalyzed 
protocol for Ullmann cross-coupling. The relative stereoconfigurations of RMS1-RMS8 could 
be determined by NMR according to a method of Guinaudeau et al.[140]. The stereochemistry 
of the variants RMS9-RMS10 unfortunately remains obscure, since an analysis via NMR or X-
ray christallography due to unsuccessful christallization failed. 
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For the synthesis of the seco-analogues sc2-sc5 intermediate 58 of the tetrandrine synthesis 
served as starting material. The O-benzyl residue of 58 mimicks the second diaryl ether bridge 
present in the parental molecule. The reduction of 58 following the standard reduction protocol 
gave compound sc2. The condensation of 58 via standard N-acyl Pictet-Spengler 
condensation with either paraformaldehyde or isovaleraldehyde and subsequent reduction 
gave sc3-sc5 (Scheme 33). As a second asymmetric centre is built in the reaction of 
intermediate 58 with isovaleraldehyde, two diastereomers are generated in this reaction 
consequently. Although the separation of the two diastereomeric intermediates via FCC was 
possible, the determination of the relative stereoconfiguration of sc4 and sc5 by NMR or 
christallographic methods could not be achieved.  
Scheme 33. Synthesis of seco-analogues sc1-sc5. 
The monomeric benzylisoquinoline sc1 was obtained from intermediate 55 in one step by 
lithium alanate reduction (Scheme 33).  
As an additional synthetic challenge, the related alkaloids berbanine (35), berbidine (36) and 
muraricine (34) (in its racemic form) were synthesized. Racemic muraricine (rac-34) was 
obtained in two steps from 66 (an intermediate of the tetrandrine synthesis) via N-acyl Pictet- 
Spengler condensation with paraformaldehyde and subsequent reduction following standard 
protocols (Scheme 34, A). This represents the first total synthesis of racemic muraricine (rac-
34) in a total of 10 steps from commercially available building blocks in an overall yield of 3.8% 
along the longest sequence. 
The isoquinolone-isoquinoline alkaloids berbanine (35) and berbidine (36) (Scheme 34, B) 
were synthesized in one sequence starting with thalifoline (47) and 2-bromo-3,4-
dimethoxybenzaldehyde (48), which were reacted in an Ullmann cross-coupling applying the 
established protocol for diaryl ether synthesis. In a Pomeranz-Fritsch reaction diaryl ether 99 
was converted into the isoquinoline alkaloid berbanine (35), which was then N-methylated at 
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the pyridine ring and reduced to berbidine (36). The overall yields amount 18% for berbanine 
(35) and 16% for berbidine (36) along the longest sequence of steps. With this synthetic 
protocol, the first total synthesis of both alkaloids was developed. 
 
Scheme 34. First total syntheses of (A) racemic muraricine (rac-34) and (B) berbanine (35) and berbidine (36). 
The successful syntheses of the alkaloids berbanine (35), berbidine (36) and racemic 
muraricine (rac-34) demonstrated the general applicability and robustness of these protocols 
for the diaryl ether synthesis and the N-acyl Pictet-Spengler reaction. Both reaction types were 
previously established for the synthesis of racemic tetrandrine (rac-1) and isotetrandrine (rac-
2).  
As anticancer effects and multidrug resistance reversing activities are well documented for 
several (bis)benzylisoquinoline alkaloids, among them tetrandrine (1)[39, 41, 52, 153] and 
isotetrandrine (2)[12], the successfully synthesized macrocyclic analogues RMS1-RMS10, the 
seco-analogues sc1-sc5 and racemic muraricine (rac-34) were submitted to a screening for 
antiproliferative and P-gp inhibitory activity. The compounds were also evaluated with regard 
to their toxic potency through extensive in vitro toxicity assessment, as undesired cytotoxic 
side effects are described for several bisbenzylisoquinoline alkaloids including tetrandrine 
(1)[54]. Although the analogues RMS1-RMS10 that were specifically designed for the reduction 
of tetrandrine’s (1) toxicity by replacement or amendment of the putatively metabolic instable 
methoxy group at C-12, these variants were not found to possess a considerably improved 
toxicity profile in several cellular models. In contrast, several analogues exhibited even 
increased toxic effects. The hypothesized CYP-mediated metabolic pathway was therefore not 
found to be the major cause of tetrandrine-induced toxicity and the underlying molecular 
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mechanism remains to be elucidated. Consequently, a different strategy for the reduction of 
the alkaloid’s toxicity needs to be investigated. 
Whereas the chemoresistance reversing activity by the inhibition of the efflux pump P-gp was 
largely equal to the lead structure tetrandrine (1) in the majority of compounds, several 
analogues exhibited markedly increased antiproliferative potency, especially among the series 
of macrocyclic analogues. Taking the results of pharmacological characterization and the 
toxicity assessment together, RMS3 and RMS5 emerged as promising compounds, as they 
showed strongly enhanced antiproliferative activity, possess chemoresistance reversing 
properties in low doses and do not display an unfavourable toxicity profile compared to 
tetrandrine (1). Due to their higher potency, a reduction of required dose might in turn lead to 
diminished side effects when applying the substances in vivo.   
Also among the seco-analogues sc1-sc5 compounds with antitumoral properties could be 
identified. Especially sc4 and sc5 showed increased antiproliferative activity and significant 
multidrug resistance reversing properties, albeit toxic effects similar or - depending on the used 
in vitro model - stronger compared to that of tetrandrine (1) were observed.  
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Most promising analogues of (iso)tetrandrine with antitumoral activity synthesized in this work.  
The natural product muraricine in its racemic form (rac-34) could be identified as a moderate 
but non-toxic inhibitor of P-gp. These results show that not only complex 
bisbenzylisoquinolines but also simplified analogues are capable of relevant pharmacological 
activity.  
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As the number of structure variations synthesized in this project is comparably small, further 
systematic structure variations for the investigation of structure-activity relationships are 
required. The modular and effective synthetic approach to the bisbenzylisoquinolines of the 
tetrandrine-type developed in this thesis should pave the way for the access of diverse 
structure variations with modifications at nearly all positions. Consequently, this work enables 
to significantly extend the chemical diversity of libraries of bisbenzylisoquinolines, a class of 
pharmacologically interesting alkaloids that is far away from being exploited. Early 
pharmacological evaluation of exemplarly synthesized variations provided encouraging data 
as a good starting point for future medicinal chemistry projects. 
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6 EXPERIMENTIAL SECTION 
 
6.1 GENERAL SPECIFICATIONS AND PARAMETERS 
 
6.1.1 INSTRUMENTS 
 
Nuclear magnetic resonance spectroscopy 
NMR spectra were recorded with a 400 MHz (400 MHz for 1H and 101 MHz for 13C), 500 MHz 
(500 MHz for 1H and 126 MHz for 13C), 600 MHz (599 MHz for 1H and 151 MHz for 13C) or 800 
MHz (800 MHz for 1H and 201 MHz for 13C) Avance III HD Bruker Biospin spectrometer 
(Bruker, USA). Peak assignments were based on 2D NMR experiments using standard pulse 
programs (COSY, HSQC/HMQC, DEPT, HMBC and if required NOESY). Chemical shifts were 
referenced to the residual solvent signal (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm; CD3OD: δH 
= 3.31 ppm, δC = 49.0 ppm). For the characterization of rotamers a temperature program was 
employed for recording both 1D and 2D spectra. Hereby chemical shifts were referenced to 
the signal of tetramethylsilane in deuterated tetrachloroethane (Tcl2 [100 °C]:  δH = 5.92 ppm, 
δC = 74.0 ppm). The spin multiplicity is expressed as: s (singlet), br s (broad singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet) or combinations thereof. 
 
Mass spectrometry 
High resolution mass spectra (HR-MS) were recorded using a Thermo Finnigan MAT 95 or 
Thermo Q Exactive GC Orbitrap (Thermo Fisher Scientific, USA) instrument for electron impact 
ionisation (EI). Thermo Finnigan LTQ FT (Thermo Fisher Scientific, USA) was used for 
electrospray ionisation (ESI). 
For reaction monitoring low resolution mass spectra were recorded on an expressionL CMS 
device (Advion, USA) by atmospheric pressure solids analysis probe (ASAP) and atmospheric-
pressure chemical ionization (APCI) for the analysis of samples in solution or neat solids. For 
the analysis of spots on a TLC plate, the measurement was carried out in combination with a 
Plate Express® TLC Plate Reader device (Advion, USA) using APCI or ESI ionization method. 
Additionally, reaction monitoring was performed via GC-MS using a Hewlett Packard 5989A 
instrument (Hewlett Packard, USA). 
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Infrared spectroscopy 
IR spectra were recorded using a Jasco FT/IR-4100 (type A) instrument (Jasco, Germany) 
equipped with a diamond ATR unit (Jasco PRO450-S). 
 
Melting points 
Melting points were determined by open capillary method on a Büchi B-540 apparatus (Büchi). 
All values are given in °C and are uncorrected. 
 
High pressure liquid chromatography 
For quantitative analysis and for the determination of purity HPLC was performed on a HP 
Agilent 1100 system (Agilent Technologies, Germany) equipped with an Agilent G1315A 
1100/1200 diode array detector, a G1311A QuatPump pump system and a G1316A ColComp 
column oven. Following columns and parameters were used for separation: 
Agilent InfinityLab Poroshell 120 EC-C18 (2.7 µm, 100 x 3.0 mm) (1)  
Agilent Zorbax Eclipse Plus C18 (5.0 µm, 150 x 4.6 mm) (2) 
Table 11. Parameters for analytical HPLC. 
method column eluent 
flowrate 
[mL/min] 
temp. 
[°C] 
a 1 50% ACN, 49.9% water, 0.1% THF 0.8 50 
b 2 70% ACN, 30% water 0.8 50 
c 2 80% MeOH, 20% water, NaOH-buffer pH 9 0.8 50 
d 2 70% ACN, 30% water, formic acid 1.0 35 
e 2 50% ACN, 50% water 0.8 50 
 
The diastereomeric ratios of compounds 61, 62, 68 and 97 were determined using method a. 
 
Preparative HPLC was performed on a VWR LaPrep P110 system (VWR, USA) equipped with 
a UV Detector P311 using a Nucleodur® 100-5 column (5.0 µm, 250 x 10.0 mm; Macherey-
Nagel, Germany).  
 
Microwave assisted synthesis 
Microwave assisted synthesis was carried out in a Discover (S-Class Plus) SP (CEM, USA) 
microwave reactor. 
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6.1.2 BIOLOGICAL ASSAYS 
 
Agar diffusion assay 
The bacteria and fungi, purchased from DSMZ (Deutsche  Sammlung  von Mikroorganismen 
und Zellkulturen GmbH, Germany), were cultivated on an AC agar (Sigma‐Aldrich, Germany) 
in a cell density of 108 bacteria cells per mL and 5 x 106 fungi cells per mL. Six‐millimeter paper 
discs (Macherey-Nagel, Germany), impregnated with 30 μg of the tested compound or 
reference drug (tetracyclin/clotrimazol; both as a 1% [m/V] stock solution in DMSO) were 
placed on the agar. One disc served as control, which was impregnated with 3.0 µL of DMSO. 
The bacteria media were incubated for 24 hr at 32 °C, the fungi media for 48 hr at 28 °C under 
sterile conditions and the diameter of the zone of inhibition (mm) was evaluated. The diameter 
of the zones of inhibition was manually measured.  
 
MTT assay 
The MTT assay was performed using human leukemia cell line HL-60 purchased from DSMZ 
(Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Germany). The cells 
were seeded on a 96-well plate (99 µL cell suspension per well) in a cell density of 9 x 105 cells 
per mL and incubated for 24 h at 37 °C.  
The compounds were tested in increasing concentrations ranging from 1.25 to 400 µM 
dissolved in DMSO. The positive control was performed using Triton® X-100 in a concentration 
of 1 µg/mL, the zero value was determined with DMSO (1 µL per well). 1 µL of each test 
solution, Triton® X-100 solution or DMSO was added to one well and the cells were incubated 
for 24 h at 37 °C and 5% CO2. Subsequently, 10 µL of a MTT-solution (5 mg MTT in 1 mL of 
phosphate buffered saline (PBS) pH 7.4) were added per well and the culture was incubated 
for another 2 h under the same conditions. To each well 190 μL of DMSO was then added and 
the plate left for 1 h. Photometric quantification was performed on an ELISA MRX II Microplate 
reader (Dynex, Germany) at a wavelength of λ = 570 nm. The statistical analysis and the 
calculation of the corresponding IC50 values was done using Prism 5.0 software (GraphPad, 
USA). 
 
Calcein retention assay, Nicoletti assay and toxicity assays 
These assays were performed by Martin Müller and Franz Geisslinger from the group of Prof. 
Dr. Angelika Vollmar (chair of pharmaceutical biology, LMU Munich). For the detailed protocols 
see references no. 53, 122 and 147. 
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6.1.3 MATERIALS 
 
Chemicals and solvents 
All chemicals and anhydrous solvents (septum sealed & stored on molecular sieves) were 
purchased from Sigma Aldrich (Germany), abcr GmbH (Germany), VWR (Germany), Acros 
(Belgium), Alfa Aesar/Thermo Fisher Scientific GmbH (Germany), Th. Geyer GmbH & Co. KG 
(Germany) or TCI Deutschland GmbH. Solvents used for analytical and preparative HPLC 
were HPLC grade, all solvents used for FCC or any other purpose were p.a. grade (if required) 
or purified by destillation. 
 
Thin layer chromatography (TLC) 
TLC was carried out on polyester plates coated with 0.2 mm silica gel and a fluorescence 
indicator (POLYGRAM SIL G/UV254, Macherey-Nagel, Germany). For preparative TLC 1 mm 
PLC silica gel 60 F254 plates (20 x 20 cm) with a concentrating zone (Merck, Germany) were 
used. Visualization was enabled by UV-light using wavelength λ = 254 nm or 365 nm or a 
suitable dye (Dragendorff reagent, Ehrlich reagent, ceric ammonium sulfate (CAM)-stain, 
Dinitrophenylhydrazine (DNPH)-stain). 
 
Flash column chromatography (FCC) 
Flash chromatography was performed using silica gel 60 (0.040 - 0.063 mm, 230-400 mesh 
ASTM, Merck, Germany) and the solvent systems indicated in the compound characterization 
section. 
 
Software 
ChemDraw Professional® 16.0 (PerkinElmer, USA) was used for drawing structures or reaction 
schemes. MestReNova® 10.0 (Mestrelab Research, Spain) was used for processing and 
analysis of NMR spectra. Chromeleon® 7.2.9. (Thermo Fisher Scientific Dionex, USA) was 
used for processing and analysis of HPLC spectra. GraphPad Prism® 5.0 and 8.4.3 (GraphPad 
Software Inc., USA) was used for data visualization and statistical analysis. 
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6.2 GENERAL PROCEDURES 
 
General procedure 1 - Wittig olefination 
A suspension of (methoxymethyl)triphenylphosphonium chloride (1.2 eq.) in anhydrous THF 
(2 mL per mmol aromatic aldehyde) was cooled to 0 °C under nitrogen atmosphere. A solution 
of lithium diisopropylamide (1.4 eq., 2.0 M solution in THF) was added dropwise and the 
resulting mixture stirred for 45 min. A solution of the aromatic aldehyde (1.0 eq.) in anhydrous 
THF (2 mL per mmol) was added while stirring. The mixture was allowed to warm up to ambient 
temperature and was stirred for 4 h. The reaction was then quenched with deionized water and 
extracted 3x with ethyl acetate. The combined organic phases were washed with brine, dried 
over anhydrous Na2SO4 and concentrated in vacuo to afford the crude product, which was 
purified by column chromatography. 
 
General procedure 2 - N-acyl Pictet-Spengler condensation  
A solution of carbamate (1.0 eq.) and enol ether (1.2 – 2.0 eq.) in dichloromethane (for 
intermolecular reactions 10 mL per mmol carbamate) was cooled to 0 °C under nitrogen 
atmosphere. Trifluoroacetic acid (10 eq.) or trifluoromethanesulfonic acid (TfOH, 0.1 eq., 0.113 
mol/L in acetonitrile) was added dropwise. The reaction mixture was allowed to warm up to 
ambient temperature and was stirred for 6 - 12 h. The intramolecular reactions were conducted 
at a carbamate concentration of 0.01 mM and cooled to -15 °C. After adding TFA (10 eq.) the 
temperature was kept at -15 °C until the reaction was completed (typically after 12 h; TLC 
control). A saturated NaHCO3 solution was then added for neutralization and the aqueous 
phase extracted 3x with dichloromethane. The combined organic phases were dried over 
anhydrous Na2SO4 and concentrated in vacuo to afford the crude product, which was purified 
by column chromatography. 
 
General procedure 3 - Ullmann-type C–O coupling reaction  
According to a modified procedure of Wang et al.[125], bromoarene (1.0 – 1.2 eq.), phenol (1.0 
– 2.0 eq.), CuBr·Me2S (1.0 eq.) and Cs2CO3 (3.0 eq.) were placed in a pressure tube or a flask 
closed with a screwcap with septum inlet and sealed with PTFE tape. Anhydrous pyridine (for 
intermolecular C–O coupling reactions 10 mL per mmol bromoarene, for intramolecular 
reaction a concentration of 0.02 mM was chosen) was added and after 5 min of pre-stirring the 
reaction was heated to 110 °C for 2 – 7 days under nitrogen atmosphere. The reaction mixture 
was concentrated in vacuo, diluted with ethyl acetate and filtered over a small plug of silica gel 
78 
 
in order to remove the catalyst and the excess base, followed by washing with ethyl acetate. 
The filtrate was concentrated in vacuo to afford a brown oil as crude product, which was 
purified by column chromatography. 
 
General procedure 4 - carbamate reduction  
Lithium alanate (10 eq.) was suspended in anhydrous THF (1.0 mL per 0.02 mmol carbamate) 
under nitrogen atmosphere. A solution of carbamate (1.0 eq.) in anhydrous THF was added 
dropwise and the resulting mixture was heated at 50 °C for 4 – 12 h. The reaction was cooled 
to 0 °C and slowly quenched with water. After alkalizing to pH 12 – 14 with a 2.0 M sodium 
hydroxide solution, the aqueous phase was then extracted 3x with ethyl acetate. The combined 
organic phases were dried over anhydrous Na2SO4 and concentrated in vacuo to afford the 
crude product, which was purified by column chromatography. 
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6.3 CHARACTERIZATION OF COMPOUNDS 
 
N-Ethoxycarbonyl-6,7-dimethoxy-1-benzyl-1,2,3,4-tetrahydroisoquinoline (41) 
 
 
C21H25NO4 
MW = 355.18 g/mol 
 
Carbamate 39 (500 mg, 1.97 mmol) and enol ether 46 (530 mg, 3.95 mmol) were condensed 
following General Procedure 2 (for intermolecular N-acyl Pictet-Spengler reaction) to give 
tetrahydroisoquinoline 41. The reaction was completed after 2 h. The crude product was 
purified by flash column chromatography (dichloromethane, Rf = 0.12) and the title compound 
obtained as a white solid. 
yield: 489 mg, 1.40 mmol, 71%, white solid 
mp: 116.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.26 – 7.20 (m, 2H, 5'-H, 3'-H), 7.20 – 7.15 (m, 1H, 
4'-H), 7.10 – 7.05 (m, 2H, 6'-H, 2'-H), 6.58 (s, 1H, 5-H), 6.24 (s, 1H, 8-H), 5.19 (t, J=6.9, 1H, 
1), 4.09 – 3.93 (m, 3H, 3-H, OCH2CH3), 3.79 (s, 3H, 6-OCH3), 3.60 (s, 3H, 7-OCH3), 3.31 (ddd, 
J=13.6, 9.5, 4.6, 1H, 3-H), 3.11 (dd, J=13.4, 6.6, 1H, α-H), 2.95 (dd, J=13.3, 7.0, 1H, α-H), 2.79 
(ddd, J=15.6, 9.5, 5.9, 1H, 4-H), 2.58 (dt, J=15.9, 4.5, 1H, 4-H), 1.17 (t, J=7.1, 3H, OCH2CH3) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 (C=O), 148.6 (C-6), 147.8 (C-7), 138.6 (C-
1'), 129.8 (C-6', C-2'), 129.1 (C-8a), 128.2 (C-5', C-3'), 126.8 (C-4a), 126.4 (C-4'), 113.1 (C-5), 
112.2 (C-8), 61.2 (OCH2CH3), 56.4, 56.3, 56.3 (7-OCH3, 6-OCH3 and C-1) 43.1 (C-α), 38.8 (C-
3), 28.1 (C-4), 14.6 (OCH2CH3) 
IR (ATR): ṽ [cm-1] = 2918, 1677, 1519, 1465, 1434, 1229, 1208, 1100, 858, 762, 698 
Purity (HPLC, method d) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C21H25NO4 + H]+ 356.1856, found: 356.1859 
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(E)-3-Bromo-4,5-dimethoxy-1-(2-nitrovinyl)benzene (51)  
 
C10H10BrNO4 
MW = 286.98 g/mol 
Synthesized according to a procedure of Maresh et al.[122]:   
To a mixture of 3-bromo-4,5-dimethoxybenzaldehyde (50, 10.5 g, 42.8 mmol) and ammonium 
acetate (3.30 g, 42.8 mmol, freshly recrystallized from glacial acetic acid) a small number of 
3Ǻ molecular sieves were added as well as glacial acetic acid (35 mL) and nitromethane (11.5 
mL, 214 mmol) under nitrogen atmosphere. After heating the reaction at 95°C for 16 h, the 
molecular sieves were removed and the resulting dark solution was quenched with 100 mL of 
brine. The aqueous phase was extracted with ethyl acetate (3x 500 mL), the combined organic 
phases washed with deionized water (3x 500 mL), dried over MgSO4 and concentrated in 
vacuo to afford a yellow crystalline solid. The crude product can be recrystallized from 
methanol as well as purified by flash column chromatography (50% dichloromethane in 
hexanes, Rf  = 0.25). For recrystallization the nitrostyrene was dissolved in a minimal amount 
of methanol at 50°C. After cooling to 0 °C the solid was vacuum filtered over Buchner funnel 
and washed with few chilled methanol (0 °C) until the crystals appear bright yellow. 
yield: 7.37 g, 25.7 mmol, 60 %, bright yellow crystalline solid 
mp: 153.5 °C (lit.[122]: 150.0 – 153.2 °C) 
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.88 (d, J = 13.6 Hz, 1H, 1'-H), 7.51 (d, J = 13.6 Hz, 1H, 
2'-H), 7.37 (d, J = 2.1 Hz, 1H, 2-H), 6.98 (d, J = 2.0 Hz, 1H, 6-H), 3.92 (s, 3H,  4-OCH3), 3.92 
(s, 3H, 5-OCH3) 
13C NMR (126 MHz, CDCl3) δ [ppm] = 154.2 (C-5), 149.9 (C-4), 137.7 (C-1'), 137.3 (C-2'), 
127.0 (C-1), 126.4 (C-2), 118.7 (C-3), 111.6 (C-6), 61.0 (4-OCH3), 56.4 (5-OCH3) 
IR (ATR): ṽ [cm-1] = 2919, 1628, 1414, 1352, 1279, 1151, 1044, 962, 831 
Purity (HPLC, method a) = 92% (λ = 210 nm) 
HRMS (EI): m/z calcd for [C10H1079BrNO4]•+ 286.9788, found: 286.9801 
 
81 
 
3-Bromo-4,5-dimethoxy-phenethylamine (52) 
 
C10H14BrNO2 
MW = 259.02 g/mol 
Synthesized according to a procedure of Maresh et al.[122]:   
In an open round bottom flask 50 mL of methanol were cooled to 0 °C. Over a period of 60 
min. the nitrostyrene 51 (7.37 g, 25.7 mmol), 37% HCl (48.2 mL, 514 mmol) and zinc (16.8 g, 
257 mmol) were added alternately, each in small portions while vigorously stirring and 
maintaining the temperature at 0° C. The reaction was allowed to stir for 12 h at 0 °C.  The 
disappearance of the yellow colour indicates complete reduction, which was confirmed by TLC 
analysis (Rf = 0.26, 10% methanol in dichloromethane). The excess solid zinc was removed 
by filtration through filter paper. To the filtrate 160 mL of saturated methanolic sodium 
hydroxide solution were added to alkalize the solution to pH 12, which results in a white 
precipitation. After adding 260 mL chloroform, the mixture was vacuum filtered over a Buchner 
funnel. The remaining paste was extracted with chloroform (3x 250 mL) and filtered under 
vacuum. To avoid compound decomposition the temperature was kept below 5 °C during all 
extraction and filtration steps. The combined organic phases were dried over MgSO4, filtrated 
and concentrated in vacuo to afford an orange oil (6.59 g). The crude product was used in the 
following step without purification. 
1H NMR (500 MHz, MeOD) δ [ppm] = 7.06 (d, J = 2.0 Hz, 1H, 2-H), 6.94 (d, J = 1.9 Hz, 1H, 6-
H), 3.88 (s, 3H, 5-OCH3), 3.78 (s, 3H, 4-OCH3), 3.09 (t, J = 8.1, 6.8 Hz, 2H, NCH2-CH2), 2.86 
(t, 2H, NCH2-CH2) 
13C NMR (126 MHz, MeOD) δ [ppm] = 155.3 (C-5), 146.6 (C-4), 136.5 (C-1), 125.7 (C-2), 118.4 
(C-3), 113.8 (C-6), 60.8 (4-OCH3), 56.6 (5-OCH3), 42.6 (NCH2-CH2), 35.6 (NCH2-CH2) 
IR (ATR): ṽ [cm-1] = 3326, 1645, 1488, 1415, 1279, 1238, 1140, 1040, 999 
HRMS (ESI): m/z calcd for [C10H1479BrNO2 + H]+ 260.0286, found: 260.0282 
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3-Bromo-N-ethoxycarbonyl-4,5-dimethoxyphenethylamin (53) 
 
C13H18BrNO4 
MW = 331.04 g/mol 
Phenethylamine 52 (6.48 g, 25.0 mmol) was dissolved in dichloromethane (100 mL) under 
nitrogen atmosphere and the solution cooled to 0 °C. Triethylamine (14.1 mL, 101 mmol) was 
added followed by ethyl chloroformate (6.06 mL, 63.4 mmol) in a dropwise fashion. The 
reaction was allowed to warm to ambient temperature and was stirred for 14 h.  
TLC analysis showed conversion to a less polar product (Rf = 0.33, 25% ethyl acetate in 
hexanes). The reaction was then quenched with saturated NaHCO3 solution (50 mL) and 
extracted with dichloromethane (3x 80 mL). The combined organic phases were dried over 
anhydrous Na2SO4, filtrated and concentrated in vacuo to afford a yellow oil.  
Purification was accomplished by flash column chromatography (25% ethyl acetate in 
hexanes, Rf = 0.33). 
yield: 5.89 g, 17.5 mmol, 70%, pale yellow oil 
1H NMR (400 MHz, CDCl3) δ [ppm] = 6.96 (d, J = 1.9 Hz, 1H, 2-H), 6.69 – 6.66 (m, 1H, 6-H), 
4.68 (s, 1H, NH), 4.11 (q, J = 7.1 Hz, 2H, OCH2-CH3), 3.85 (s, 3H, 5-OCH3), 3.83 (s, 3H, 4-
OCH3), 3.40 (q, J = 6.8 Hz, 2H, NCH2-CH2), 2.73 (t, J = 7.0 Hz, 2H, NCH2-CH2), 1.23 (t, J = 
7.1 Hz, 3H, OCH2-CH3) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 156.7 (C=O), 153.8 (C-5), 145.2 (C-4), 136.2 (C-1), 
124.8 (C-2), 117.8 (C-3), 112.4 (C-6), 61.0 (OCH2-CH3), 60.7 (4-OCH3), 56.2 (5-OCH3), 42.1 
(NCH2-CH2), 35.9 (NCH2-CH2), 14.8 (OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 3354, 2937, 2826, 1697, 1488, 1271, 1235, 1140, 1044, 1001, 817 
Purity (HPLC, method a) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C13H1879BrNO4 + H]+ 332.0497, found: 332.0493 
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(E/Z)-3-(Benzyloxy)-4-methoxy-1-(2-methoxyvinyl)benzene (54) 
 
C17H18O3 
MW = 270.13 g/mol 
3-Benzyloxy-4-methoxybenzaldehyde (6.01 g, 24.8 mmol) was reacted following General 
Procedure 1 (Wittig olefination). The reaction was completed after 4 h. Purification was 
accomplished by flash column chromatography (10% ethyl acetate in hexanes, Rf = 0.30) and 
the product obtained as white solid (yield 5.89 g, 21.8 mmol, 88%). The major product is the 
E-isomer (E,Z-isomer ratio 1:0.82, estimated by NMR-integrals).  
yield: 5.89 g, 21.8 mmol, 88%, white solid 
mp: 95.5 – 96.0 °C 
NMR data of the major E-isomer:   
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.50 – 7.43 (m, 2H, 6''-H, 2''-H), 7.41 – 7.27 (m, 3H, 5''-
H, 4''-H, 3''-H), 6.86 (d, J = 13.1 Hz, 1H, 2'-H), 6.84 – 6.76 (m, 3H, 2-H, 5-H, 6-H), 5.72 (d, J 
= 12.9 Hz, 1H, 1'-H), 5.16 (s, 2H, OCH2-Ph), 3.87 (s, 3H, 4-OCH3), 3.65 (s, 3H, 2'-OCH3)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 148.2 (C-3), 147.9 (C-4), 147.9 (C-2'), 137.4 (C-1''), 
129.4 (C-1), 128.7 (C-5'', C-3''), 128.0 (C-4''), 127.5 (C-6'', C-2''), 118.4 (C-6), 112.4 (C-5), 
111.4 (C-2), 104.9 (C-1'), 71.3 (OCH2-Ph), 56.6 (2'-OCH3), 56.3 (4-OCH3)  
IR (ATR): ṽ [cm-1] = 3060, 2931, 1638, 1514, 1254, 1134, 1010, 746, 698  
Purity (HPLC, method a) = > 99% (λ = 210 nm) 
HRMS (EI): m/z calcd for [C17H18O3]•+ 270.1251, found: 270.1251 
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(±)-8-Bromo-N-ethoxycarbonyl-6,7-dimethoxy-1-(3’-benzyloxy-4’-methoxybenzyl)-
1,2,3,4-tetrahydroisoquinoline (55) 
 
 
 
 
C29H32BrNO6 
MW = 569.14 g/mol 
Carbamate 53 (5.89 g, 17.8 mmol) and enol ether 54 (5.76 g, 21.3 mmol) were condensed 
following General Procedure 2 (for intermolecular N-acyl Pictet-Spengler reaction) using TFA 
as catalyst to give tetrahydroisoquinoline 55. The reaction was completed after 12 h. The crude 
product was purified by flash column chromatography (20% acetone in hexanes, Rf = 0.17) 
and the title compound obtained as a pale yellow solid (4.66 g, 8.19 mmol, 46%). 
yield: 4.66 g, 8.19 mmol, 46%, pale yellow solid 
mp: 40.5 – 42.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.46 – 7.41 (m, 2H, 6''-H, 2''-H), 7.38 – 7.32 (m, 
2H, 5''-H, 3''-H), 7.31 – 7.26 (m, 1H, 4''-H), 6.79 (d, J = 8.1 Hz, 1H, 5'-H), 6.74 (d, J = 2.0 Hz, 
1H, 2'-H), 6.70 (dd, J = 8.1, 2.0 Hz, 1H, 6'-H), 6.60 (s, 1H, 5-H), 5.58 – 5.48 (m, 1H, 1-H), 5.02 
(s, 2H, OCH2-Ph), 4.03 – 3.84 (m, 3H, H-3, OCH2-CH3), 3.83 (s, 3H, 7-OCH3), 3.82 (s, 3H, 6-
OCH3), 3.81 (s, 3H, 4'-OCH3), 3.43 (ddd, J = 13.2, 8.8, 5.5 Hz, 1H, 3-H), 3.15 (dd, J = 14.3, 
3.9 Hz, 1H, α-H), 2.84 – 2.70 (m, 2H, 4-H, α-H), 2.53 (d, J = 13.9 Hz, 1H, 4-H), 1.07 (br s, 3H, 
OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 (C=O), 152.3 (C-6), 149.3 (C-4'), 148.8 (C-
3'), 145.7 (C-7), 137.9 (C-1''), 131.7 (C-4a), 131.6 (C-1'), 129.9 (C-8a), 128.4 (C-3'', C-5''), 
127.7 (C-4''), 127.5 (C-2'', C-6''), 122.9 (C-6'), 118.3 (C-8), 117.5 (C-2'), 113.7 (C-5'), 112.9 (C-
5), 72.0 (OCH2-Ph), 61.2 (OCH2-CH3), 60.5 (7-OCH3), 56.8 (4’-OCH3 or 6-OCH3),  56.5 (4’-
OCH3 or 6-OCH3), 56.1 (C-1), 39.1 (C-α), 38.0 (C-3), 28.1 (C-4), 14.5 (OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 2934, 2836, 1691, 1596, 1513, 1425, 1318, 1246, 1137, 1101, 1024, 741, 
697 
Purity (HPLC, method a) = 98% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C29H3279BrNO6 + H]+ 570.1486, found: 570.1489 
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N-Ethoxycarbonyl-4-hydroxy-3-methoxyphenethylamine (57)  
 
C12H17NO4 
MW = 239.12 g/mol 
3-Methoxytyramine hydrochloride (56, 3.46 g, 17.2 mmol) was suspended in dichloromethane 
(100 mL) under nitrogen atmosphere and the mixture cooled to 0 °C. Triethylamine (9.58 mL, 
68.7 mmol) was added, followed by ethyl chloroformate (4.11 mL, 43.0 mmol) in a dropwise 
fashion. The reaction was allowed to warm to ambient temperature and stirred for 15 h. After 
this time TLC analysis showed complete conversion to a less polar product (Rf = 0.26, 
dichloromethane), which is the ethoxycarbonylated phenol intermediate. For chemoselective 
cleavage of the phenol ester, an ethanolic sodium hydroxide solution (1.0 M, 100 mL) was 
added to the reaction and the mixture stirred for 2 h at ambient temperature. After addition of 
hydrochloric acid (2 M, 60 mL) the organic solvents were removed in vacuo and the remaining 
aqueous solution was extracted with dichloromethane (3 x 100 mL). The combined organic 
phases were dried over anhydrous Na2SO4 and concentrated in vacuo to afford a beige oil. 
Purification by flash column chromatography (30% ethyl acetate in hexanes, Rf = 0.20) gave 
the title compound as a white solid. 
yield: 3.70 g, 15.5 mmol, 90%, white solid 
mp: 95.0 – 95.5 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 6.84 (d, J = 8.2 Hz, 1H, 5-H), 6.70 – 6.65 (m, 2H, 6-H, 2-
H), 5.62 (s, 1H, OH), 4.69 (s, 1H, NH), 4.10 (q, J = 7.1 Hz, 2H, OCH2-CH3), 3.86 (s, 3H, OCH3), 
3.39 (q, J = 6.7 Hz, 2H, NCH2-CH2), 2.73 (t, J = 7.0 Hz, 2H, NCH2-CH2), 1.22 (t, J = 7.1 Hz, 
3H, OCH2-CH3) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 156.8 (C=O), 146.7 (C-3), 144.4 (C-4), 130.7 (C-1), 
121.5 (C-2), 114.6 (C-5), 111.4 (C-6), 60.9 (OCH2-CH3), 56.0 (OCH3), 42.4 (NCH2-CH2), 35.9 
(NCH2-CH2), 14.8 (OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 3368, 3273, 1687, 1518, 1237, 1125, 1033, 824, 781 
Purity (HPLC, method a) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C12H17NO4 - H]- 238.1085, found: 238.1087 
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 (±)-8-(4-(2-((Ethoxycarbonyl)amino)ethyl)-2-methoxyphenoxy)-N-ethoxycarbonyl-6,7-
dimethoxy-1-(3’-benzyloxy-4’-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (58) 
 
C41H48N2O10 
MW = 728.33 g/mol 
Tetrahydroisoquinoline 55 (3.00 g, 5.26 mmol) and phenol 57 (2.52 g, 10.5 mmol) were 
coupled following General Procedure 3 (intermolecular Ullmann-type C–O coupling reaction). 
The reaction was completed after 7 days. Purification was accomplished by flash column 
chromatography (10% ethyl acetate in dichloromethane, Rf = 0.26) and the product obtained 
as a beige solid. 
yield: 1.57 g, 2.16 mmol, 41%, beige solid 
mp: 58.5 – 60.0 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] =  7.41 – 7.37 (m, 2H, 6'''-H, 2'''-H), 7.36 – 7.30 (m, 
2H, 5'''-H, 3'''-H), 7.30 – 7.25 (m, 1H, 4'''-H), 6.79 (d, J = 2.0 Hz, 1H, 2''-H), 6.73 (d, J = 8.1 Hz, 
1H, 5'-H), 6.66 (d, J = 2.0 Hz, 1H, 2'-H), 6.62 – 6.59 (m, 1H, 6'-H), 6.59 – 6.57 (m, 1H, 6''-H), 
6.55 (d, J = 8.2 Hz, 1H, 5''-H), 6.50 (s, 1H, 5-H), 5.42 – 5.32 (m, 1H, 1-H), 4.92 (s, 2H, OCH2-
Ph), 4.56 (s, 1H, NH), 4.07 (q, J = 7.1 Hz, 2H, 'OCH2-CH3), 4.03 – 3.92 (m, 1H, 3-H), 3.89 (s, 
3H, 3''-OCH3), 3.81 (s, 3H, 6-OCH3), 3.91 – 3.69 (m, 2H, OCH2-CH3), 3.78 (s, 3H, 4'-OCH3), 
3.60 (s, 3H, 7-OCH3), 3.36 (q, J = 6.9 Hz, 2H, NCH2-CH2), 3.33 – 3.25 (m, 1H, 3-H), 3.13 (dd, 
J = 14.0, 3.8 Hz, 1H, α-H), 2.80 (dd, J = 14.1, 9.0 Hz, 2H, H-4, α-H), 2.72 (t, J = 7.1 Hz, 2H, 
NCH2-CH2), 2.50 (d, J = 16.4 Hz, 1H, H-4), 1.20 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.93 (br s, 3H, 
OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] =  156.5 ('C=O), 155.4 (C=O), 152.6 (C-6), 149.5 
(C-3''), 149.0 (C-4'), 148.7 (C-3'), 146.9 (C-4''), 145.4 C-8), 140.6 (C-7), 137.9 (C-1'''), 133.3 
(C-1''), 132.3 (C-1'), 130.3 (C-4a), 128.4 (C-5''', C-3''', 127.7 (C-4'''), 127.6 (C-6''', C-2'''), 124.2 
(C-8a), 122.9 (C-6'), 121.0 (C-6''), 117.4 (C-2'), 115.6 (C-5''), 114.7 (C-2''), 113.6 (C-5'), 109.6 
(C-5), 71.8 (OCH2-Ph), 60.9 (OCH2-CH3), 60.7 ('OCH2-CH3), 60.7 (7-OCH3), 56.9 (4'-OCH3 or 
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3''-OCH3), 56.8 (4'-OCH3 or 3''-OCH3), 56.4 (6-OCH3), 52.1 (C-1), 42.3 (NCH2-CH2), 39.9 (C-
α), 37.7 (C-3), 35.9 (NCH2-CH2), 28.1 (C-4), 14.6 ('OCH2-CH3), 14.4 (OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 2936, 2832, 1690, 1606, 1509, 1424, 1330, 1255, 1212, 1154, 1131, 
1108, 1069, 1023, 758 
Purity (HPLC, method a) = 97% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C41H48N2O10 + H]+ 729.3382, found: 729.3385 
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(±)-8-(4-(2-((Ethoxycarbonyl)amino)ethyl)-2-methoxyphenoxy)-N-ethoxycarbonyl-6,7-
dimethoxy-1-(3’-hydroxy-4’-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (59) 
 
C34H42N2O10 
MW = 638.28 g/mol 
To a solution of diaryl ether 58 (1.00 g, 1.37 mmol) in methanol (50 mL) palladium (10% on 
carbon, 100 mg, Pd 0.094 mmol) was added. The reaction was stirred for 12 h at ambient 
temperature under hydrogen atmosphere (1 atm). The catalyst was removed by passing the 
mixture through a small plug of celite, followed by washing with methanol (50 mL). The filtrate 
was concentrated in vacuo to give a white solid as desired product with no side products. The 
isolated product was used without purification for the following Pictet-Spengler cyclization. 
yield: 805 mg, 1.26 mmol, 92%, white solid 
mp: 61.5 – 62.0 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.81 (d, J = 2.0 Hz, 1H, 2''-H), 6.66 (d, J = 8.2 Hz, 
1H, 5'-H), 6.61 (d, J = 2.1 Hz, 1H, 2'-H), 6.57 (dd, J = 8.2, 2.0 Hz, 1H, 6''-H), 6.52 (d, J = 8.2 
Hz, 1H, 5''-H), 6.52 – 6.48 (m, 2H, 5-H, 6'-H), 5.42 (s, 1H, OH), 5.36 (dd, J = 9.4 Hz, 1H, 1-H), 
4.64 (s, 1H, NH), 4.07 (q, J = 7.1 Hz, 2H, 'OCH2-CH3), 4.08 – 3.94 (m, 1H, 3-H), 3.92 (s, 3H, 
3''-OCH3), 3.82 (s, 3H, 6-OCH3), 3.79 (s, 3H, 4'-OCH3), 3.87 – 3.66 (m, 2H, OCH2-CH3), 3.61 
(s, 3H, 7-OCH3), 3.37 (q, J = 7.0 Hz, 2H, NCH2-CH2), 3.39 – 3.28 (m, 1H, 3-H), 3.10 (dd, J = 
14.0, 3.8 Hz, 1H, α-H), 2.89 – 2.78 (m, 1H, 4-H), 2.79 – 2.70 (m, 1H, α-H), 2.73 (t, J = 7.0 Hz, 
2H, NCH2-CH2), 2.59 (d, J = 16.4 Hz, 1H, 4-H), 1.20 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.92 (br 
s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 156.5 ('C=O), 155.4 (C=O), 152.6 (C-6), 149.5 (C-
3''), 146.7 (C-4''), 145.5 (C-8), 145.4 (C-4'), 145.3 (C-3'), 140.7 (C-7), 133.2 (C-1''), 132.6 (C-
1'), 130.1 (C-4a), 124.4 (C-8a), 121.0 (C-6'), 120.8 (C-6''), 116.1 (C-2'), 115.4 (C-5''), 114.4 (C-
2''), 111.1 (C-5'), 109.8 (C-5), 60.9 (OCH2-CH3), 60.7 (7-OCH3, 'OCH2-CH3, 56.7 (3''-OCH3), 
56.4 (6-OCH3 or 4'-OCH3), 56.3 (6-OCH3 or 4'-OCH3), 52.0 (C-1), 42.3 (NCH2-CH2), 39.8 (C-
α), 37.5 (C-3), 35.9 (NCH2-CH2), 28.0 (C-4), 14.6 ('OCH2-CH3), 14.2 (OCH2-CH3) 
89 
 
IR (ATR): ṽ [cm-1] = 3354, 2939, 1686, 1594, 1508, 1419, 1331, 1244, 1211, 1129, 1109, 1023, 
960, 761 
Purity (HPLC, method a) = 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C34H41N2O10]- 637.2767, found: 637.2785 
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(E/Z)-4-Bromo-1-(2-methoxyvinyl)benzene (60) 
 
C9H9BrO 
MW = 211.98 g/mol 
Prepared from 4-Bromobenzaldehyde (2.00 g, 10.8 mmol) following General Procedure 1 
(Wittig olefination). Purification was accomplished by flash column chromatography (2.5% 
ethyl acetate in hexanes, Rf = 0.23/0.30) to give the title compound as a colourless oil (2.06 g, 
9.72 mmol, 90%, E,Z-isomer ratio 1:0.85, estimated by NMR integrals). 
yield: 2.06 g, 9.67 mmol, 90%, colourless oil 
NMR data of the major E-isomer:   
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.40 – 7.35 (m, 2H, 3-H, 5-H), 7.11 – 7.07 (m, 2H, 2-H, 
6-H), 7.03 (d, J = 13.0 Hz, 1H, 2'-H), 5.74 (d, J = 13.0 Hz, 1H, 1'-H), 3.68 (s, 3H, OCH3)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 149.5 (C-2'), 135.5 (C-1), 131.3 (C-3, C-5), 126.8 (C-2, 
C-6), 119.1 (C-4), 104.2 (C-1'), 56.7 (OCH3) 
IR (ATR): ṽ [cm-1] = 2929, 2832, 1589, 1488, 1405, 1120, 1069, 1010, 816 
Purity (HPLC, method a) = 76% (λ = 210 nm) 
HRMS (EI): m/z calcd for [C9H979BrO]•+ 211.9831, found: 211.9827 
  
91 
 
(±)-8-((1-(4-Bromobenzyl)-N-(ethoxycarbonyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-
7-yl)oxy)-N-ethoxycarbonyl-6,7-dimethoxy-1-(3’-hydroxy-4’-methoxybenzyl)-1,2,3,4-
tetrahydroisoquinoline (61) 
 
C42H47BrN2O10 
MW = 818.24 g/mol 
Carbamate 59 (600 mg, 0.939 mmol) and enol ether 60 (240 mg, 1.13 mmol) were condensed 
following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) using TFA as 
catalyst. The reaction was completed after 12 h. For separation of the racemic diastereomers 
of 61 15% ethyl acetate in dichloromethane (Rf = 0.21 for the (1R,1’R)/(1S,1’S) isomers (61a) 
and 0.30 for the (1R,1’S)/(1S,1’R) isomers (61b)) was used.  
(1R,1’R)/(1S,1’S) isomers 61a:  
yield: 385 mg, 0.471 mmol, 50%, white solid 
mp: 73.0 – 75.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = δ 7.23 – 7.18 (m, 2H, 13'-H, 11'-H), 6.86 – 6.80 (m, 
2H, 14'-H, 10'-H), 6.70 (s, 1H, 5'-H), 6.67 (d, J = 8.1 Hz, 1H, 13-H), 6.63 (d, J = 2.0 Hz, 1H, 10-
H), 6.55 (s, 1H, 5-H), 6.50 (dd, J = 8.2, 2.1 Hz, 1H, 14-H), 6.22 (s, 1H, 8'-H), 5.35 (s, 2H, 1-H, 
OH), 5.05 (t, J = 6.3 Hz, 1H, 1'-H), 4.13 – 4.04 (m, 1H, 3-H), 4.01 (q, J = 7.1 Hz, 2H, 'OCH2-
CH3), 3.97 – 3.89 (m, 1H, 3'-H), 3.91 (s, 3H, 6'-OCH3), 3.85 (s, 3H, 6-OCH3), 3.87 – 3.66 (m, 
2H, OCH2-CH3), 3.80 (s, 3H, 12-OCH3), 3.61 (s, 3H, 7-OCH3), 3.40 – 3.30 (m, 1H, 3-H), 3.23 
– 3.12 (m, 1H, 3'-H), 2.98 (dd, J = 14.0, 3.6 Hz, 1H, α-H), 2.92 – 2.81 (m, 1H, 4-H), 2.86 (dd, 
J = 6.4, 3.5 Hz, 2H, α'-H), 2.81 – 2.73 (m, 1H, 4'-H), 2.70 (dd, J = 13.9, 10.0 Hz, 1H, α-H), 2.62 
(d, J = 16.3 Hz, 1H, 4-H), 2.53 (dt, J = 16.0, 4.6 Hz, 1H, 4'-H), 1.14 (t, J = 7.1 Hz, 3H, 'OCH2-
CH3), 0.92 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.4 (C=O), ('C=O), 152.5 (C-6), 148.4 (C-6'), 
146.2 (C-7'), 145.5 (C-11), 145.4 (C-12), 145.0 (C-8), 140.6 (C-7), 137.4 (C-9'), 132.6 (C-9), 
131.2 (C-14', C-10'), 131.1 (C-13', C-11'), 130.0 (C-4a), 128.8 (C-8a'), 128.3 (C-4a'), 124.3 (C-
8a), 121.0 (C-14), 120.2 (C-12'), 116.0 (C-10), 114.0 (C-8'), 113.7 (C-5'), 111.0 (C-13), 110.1 
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(C-5), 61.2 ('OCH2-CH3), 60.9 (OCH2-CH3), 60.7 (7-OCH3), 56.6 (6'-OCH3), 56.5 (6-OCH3), 
56.4 (12-OCH3), 55.6 (C-1'), 52.0 (C-1), 42.6 (C-α'), 39.8 (C-α), 38.9 (C-3'), 37.3 (C-3), 28.2 
(C-4'), 28.0 (C-4), 14.6 ('OCH2-CH3), 14.2 (OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 3527, 2923, 2853, 1686, 1607, 1508, 1426, 1330, 1237, 1196, 1120, 1068, 
1024, 804, 760  
Purity (HPLC, method a) = 92% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H4779BrN2O10 + H]+ 819.2487, found: 819.2479 
 
(1R,1’S)/(1S,1’R) isomers 61b:  
yield: 354 mg, 0.433 mmol, 46%, white solid  
mp: 89.0 – 90.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.24 – 7.18 (m, 2H, 13'-H, 11'-H), 6.88 – 6.82 (m, 
2H, 14'-H, 10'-H), 6.69 (s, 1H, 5'-H), 6.68 (d, J = 2.1 Hz, 1H, 10-H), 6.67 (d, J = 8.2 Hz, 1H, 
13-H), 6.55 (s, 1H, 5-H), 6.53 (dd, J = 8.4, 1.9 Hz, 1H, 14-H), 6.16 (s, 1H, 8'-H), 5.38 (s, 1H, 
OH), 5.32 (dd, J = 9.7, 3.2 Hz, 1H, 1-H), 5.03 (t, J = 6.2 Hz, 1H, 1'-H), 4.13 – 3.93 (m, 4H, 3-
H, 3'-H, 'OCH2-CH3), 3.90 (s, 3H, 6'-OCH3), 3.84 (s, 3H, 6-OCH3), 3.86 – 3.74 (m, 2H, OCH2-
CH3), 3.80 (s, 3H, 12-OCH3), 3.62 (s, 3H, 7-OCH3), 3.42 – 3.31 (m, 1H, 3-H), 3.22 – 3.08 (m, 
2H, α-H, 3'-H), 2.98 – 2.87 (m, 1H, 4-H), 2.85 (dd, J = 6.3, 3.4 Hz, 2H, α'-H), 2.84 – 2.71 (m, 
2H, α-H, 4'-H), 2.64 (d, J = 16.2 Hz, 1H, 4-H), 2.53 (dt, J = 16.0, 4.4 Hz, 1H, 4'-H), 1.14 (t, J = 
7.1 Hz, 3H, 'OCH2-CH3), 0.95 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.4 (C=O, 'C=O), 152.4 (C-6), 148.3 (C-6'), 
146.1 (C-7'), 145.5 (C-8), 145.4 (C-12), 145.0 (C-11), 140.7 (C-7), 137.6  (C-9'), 132.6 (C-9), 
131.2 (C-14', C-10'), 131.1 (C-13', C-11'), 130.0 (C-4a), 128.9 (C-8a'), 128.1 (C-4a'), 124.2 
(C-8a), 121.1 (C-14), 120.1 (C-12'), 116.1 (C-10), 113.6 (C-5', C-8'), 111.0 (C-13), 110.2 (C-
5), 61.2 ('OCH2-CH3), 60.9 (OCH2-CH3), 60.7 (7-OCH3), 56.6 (6-OCH3 or 6'-OCH3), 56.5 (6-
OCH3 or 6'-OCH3), 56.3 (12-OCH3), 55.7 (C-1'), 52.0 (C-1), 42.7 (C-α'), 39.8 (C-α), 38.7 (C-
3'), 37.5 (C-3), 28.3 (C-4'), 28.1 (C-4), 14.6 ('OCH2-CH3), 14.3 (OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 3438, 2931, 2840, 1692, 1609, 1510, 1427, 1332, 1237, 1201, 1122, 
1069, 1026, 804, 760  
Purity (HPLC, method a) = 96% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C42H4779BrN2O10 + H]+ 819.2487, found: 819.2480 
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(±)-N,N’-Bis-(ethoxycarbonyl)-nortetrandrine and isomers (62) 
 
 
 
 
 
C42H46N2O10 
MW = 738.32 g/mol 
Via routes 1a and 1b – Preparation cyclization via intramolecular Ullmann-type C–O coupling 
reaction: 
Previously separated diastereomers of bisbenzylisoquinoline 61 (200 mg, 0.244 mmol of pure 
diastereomer) or of bisbenzylisoquinoline 68, respectively (200 mg, 0.244 mmol of pure 
diastereomer) were reacted following General Procedure 3 (intramolecular C–O coupling). The 
reactions were completed after 52 h. Purification was accomplished by flash column 
chromatography (35% acetone in hexanes, Rf = 0.29) and the products obtained as beige 
solids.  
Yields obtained from bisbenzylisoquinoline 61: (1R,1’R)/(1S,1’S) isomers: 115 mg, 0.156 
mmol, 64%; (1R,1’S)/(1S,1’R) isomers: 112 mg, 0.152 mmol, 62%.  
Yields obtained from bisbenzylisoquinoline 68: (1R,1’R)/(1S,1’S) isomers: 91.9 mg, 0.124 
mmol, 51%; (1R,1’S)/(1S,1’R) isomers: 63.1 mg, 0.0854 mmol, 35%. 
Via routes 2a and 2b – Preparation by intramolecular N-acyl Pictet-Spengler reaction: 
Enol ether 69 or enol ether 70, respectively (50.0 mg, 0.0649 mmol) were reacted following 
General Procedure 2 (intramolecular N-acyl Pictet-Spengler reaction). The reactions were 
completed after 12 h. Purification was accomplished by flash column chromatography (35% 
acetone in hexanes, Rf = 0.29). Yield obtained from enol ether 69: 13.5 mg, 0.0183 mmol, 
28%; yield obtained from enol ether 70: 38.0 mg, 0.0514 mmol, 79%. 
(1R,1’R)/(1S,1’S) isomers 62a:  
mp: 132.0 – 134.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.38 (d, J = 8.2 Hz, 1H, 14'-H or 10'-H), 7.12 (dd, J 
= 8.2, 2.5 Hz, 1H, 13'-H or 11'-H), 6.79 (d, J = 8.1 Hz, 1H, 13-H), 6.67 (s, 1H, 13'-H or 11'-H), 
6.64 (s, 1H, 5'-H), 6.56 (dd, J = 8.1, 2.0 Hz, 1H, 14-H), 6.47 (d, J = 1.9 Hz, 1H, 10-H), 6.32 (s, 
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1H, 5-H), 6.19 (dd, J = 8.4, 2.2 Hz, 1H, 14'-H or 10'-H), 6.16 (s, 1H, 8'-H), 5.26 (t, J = 6.1 Hz, 
1H, 1-H), 5.04 (s, 1H, 1'-H), 4.36 – 4.20 (m, 3H, H-3, 'OCH2-CH3), 4.03 – 3.95 (m, 1H, 3'-H), 
3.87 (s, 3H, 12-OCH3), 3.73 (s, 3H, 6-OCH3), 3.89 – 3.59 (m, 2H, OCH2-CH3), 3.53 – 3.37 (m, 
3H, 3-H, 3'-H, α'-H), 3.34 (s, 3H, 6'-OCH3), 3.26 (s, 3H, 7-OCH3), 3.19 – 3.07 (m, 1H, 4'-H), 
2.94 – 2.75 (m, 2H, H-4, 4'-H), 2.71 (d, J = 5.9 Hz, 2H, α-H), 2.69 – 2.59 (m, 2H, 4-H, α'-H), 
1.36 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.86 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.9 ('C=O), 155.6 (C=O), 154.3 (C-12'), 152.0 
(C-6), 150.2 (C-11), 149.1 (C-6'), 147.9 (C-12), 147.0 (C-8), 144.9 (C-7'), 138.9 (C-7), 134.6 
(C-9'), 133.8 (C-9), 132.2 (C-14' or C-10'), 130.1 (C-14' or C-10'), 130.0 (C-4a'), 128.8 (C-8a'), 
128.1 (C-4a), 122.9 (C-8a), 122.0 (C-13' or C-11'), 121.9 (C-14), 121.5 (C-13' or C-11'), 119.6 
(C-8'), 116.8 (C-10), 114.1 (C-5'), 113.6 (C-13), 107.4 (C-5), 61.4 , ('OCH2-CH3), 60.7 (OCH2-
CH3), 60.3 (7-OCH3), 57.7 (C-1'), 57.1 (12-OCH3 or 6'-OCH3), 57.0 (12-OCH3 or 6'-OCH3), 56.3 
(6-OCH3), 53.5 (C-1), 41.9 (C-3', C-α'), 40.9 (C-α), 36.6 (C-3), 28.0 (C-4), 27.8 (C-4'), 14.8 
('OCH2-CH3), 14.2 (OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 2940, 2832, 1687, 1585, 1507, 1417, 1330, 1277, 1252, 1230, 1207, 1123, 
1097, 1024, 841, 768  
Purity (HPLC, method a) = 94% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H46N2O10 + H]+ 739.3225, found: 739.3223 
 
(1R,1’S)/(1S,1’R) isomers 62b:  
mp: 142.5 – 144.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.40 – 7.33 (m, 1H, 14'-H or 10'-H), 7.07 (dd, J = 
8.2, 2.5 Hz, 1H, 13'-H or 11'-H), 6.76 (d, J = 8.0 Hz, 1H, 13-H), 6.66 – 6.60 (m, 2H, 5', 13'-H or 
11'-H), 6.57 (dd, J = 8.0, 2.0 Hz, 1H, 14-H), 6.42 – 6.36 (m, 1H, 14'-H or 10'-H), 6.32 (s, 1H, 
10-H), 6.28 (s, 1H, 5-H), 6.17 (s, 1H, 8'-H), 5.26 (d, J = 8.7 Hz, 1H, 1-H), 5.10 (dd, J = 10.5, 
6.2 Hz, 1H, 1'-H), 4.33 – 4.07 (m, 3H, 3-H, 'OCH2-CH3), 3.96 – 3.89 (m, 1H, 3'-H), 3.87 (s, 3H, 
12-OCH3), 3.85 – 3.77 (m, 2H, OCH2-CH3), 3.73 (s, 3H, 6-OCH3), 3.61 (s, 3H, 6'-OCH3), 3.57 
– 3.42 (m, 2H, 3'-H, α'-H), 3.38 – 3.25 (m, 1H, 3-H), 3.16 (s, 3H, 7-OCH3), 3.15 – 3.08 (m, 2H, 
α-H, 4'-H), 2.82 (dt, J = 15.8, 4.7 Hz, 1H, 4'-H), 2.77 – 2.67 (m, 2H, 4-H, α'-H), 2.55 (dd, J = 
13.9, 9.5 Hz, 1H, α-H), 2.50 – 2.35 (m, 1H, 4-H), 1.33 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 1.00 (br 
s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.8 (C=O), 155.5 ('C=O), 154.4 (C-12'), 152.5 
(C-6), 150.4 (C-11), 150.1 (C-6'), 147.9 (C-12), 144.4 (C-7'), 137.9 (C-7), 134.8 (C-9'), 134.0 
(C-9), 131.5 (C-14' or C-10'), 130.4 (C-4a'), 130.0 (C-14' or C-10'), 129.6 (C-4a), 128.3 (C-8a'), 
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122.1 (C-14, C-13' or 11'), 122.0 (C-13' or C-11'), 120.6 (C-8a), 119.6 (C-8'), 117.1 (C-10), 
113.3 (C-13), 111.9 (C-5'), 106.9 (C-5), 61.3 ('OCH2-CH3), 60.9 (OCH2-CH3), 60.5 (7-OCH3), 
57.1 (12-OCH3), 1', 56.3 (6-OCH3), 56.1 (6'-OCH3), 54.1 (C-1), 41.7 (C-3'), 41.6 (C-α'), 39.0 
(C-α), 28.2 (C-4), 28.1 (C-4'), 14.8 ('OCH2-CH3), 14.3 (OCH2-CH3). The resonances of C-3 and 
C-8 could not be identified.  
IR (ATR): ṽ [cm-1] = 2929, 2839, 1693, 1584, 1505, 1417, 1330, 1276, 1255, 1231, 1204, 1124, 
1101, 1020, 842, 770  
Purity (HPLC, method a) = 95% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H46N2O10 + H]+ 739.3225, found: 739.3225 
  
96 
 
(E/Z)-4-(Benzyloxy)-1-(2-methoxyvinyl)benzene (63) 
 
C16H16O2 
MW = 240.11 g/mol 
Obtained from 4-benzyloxybenzaldehyde (5.00 g, 23.6 mmol) following General Procedure 1 
(Wittig olefination). Purification by flash column chromatography (5% ethyl acetate in hexanes, 
Rf = 0.32) gave the title compound as a white solid (E,Z-isomer ratio 1:1.4, estimated by NMR-
integrals).  
yield: 5.50 g, 22.9 mmol, 97%, white solid 
mp: 37.5 °C  
NMR data of the major Z-isomer:   
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.55 – 7.48 (m, 2H, 6-H, 2-H), 7.46 – 7.41 (m, 2H, 2''-H, 
6''-H), 7.41 – 7.35 (m, 2H, 3''-H, 5''-H), 7.35 – 7.29 (m, 1H, 4''-H), 6.93 – 6.87 (m, 2H, 3-H, 5-
H), 6.06 (d, J = 7.0 Hz, 1H, 2'-H), 5.18 (d, J = 7.0 Hz, 1H, 1'-H), 5.06 (s, 2H, OCH2-Ph), 3.76 
(s, 3H, OCH3)  
13C NMR (101 MHz, CDCl3): δ [ppm] = 156.9 (C-4), 146.6 (C-2'), 137.3 (C-1''), 129.5 (C-6, C-
2), 129.2 (C-1), 128.7 (C-3'', C-5''), 128.0 (C-4''), 127.6 (C-2'', C-6''), 114.8 (C-3, C-5), 105.3 
(C-1'), 70.1 (OCH2-Ph), 60.6 (OCH3)  
IR (ATR): ṽ [cm-1] = 3034, 2834, 2080, 1639, 1606, 1236, 1093, 836, 739  
Purity (HPLC, method a) = 96% (λ = 210 nm) 
HRMS (EI): m/z calcd for [C16H16O2]•+ 240.1145, found: 240.1140 
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(±)-N-Ethoxycarbonyl-7-hydroxy-6-methoxy-1-(4’-benzyloxybenzyl)-1,2,3,4-
tetrahydroisoquinoline (64) 
 
 
 
 
C27H29NO5 
MW = 447.20 g/mol  
Carbamate 57 (0.950 g, 3.97 mmol) and enol ether 63 (1.43 g, 5.96 mmol) were condensed 
following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) using TFA as 
catalyst. The reaction was completed after 12 h. Purification by flash column chromatography 
(5% ethyl acetate in dichloromethane, Rf = 0.29) gave 64 as a white solid.  
yield: 1.71 g, 3.81 mmol, 96%, white solid 
mp: 45.5 – 48.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.41 – 7.37 (m, 2H, 2''-H, 6''-H), 7.37 – 7.31 (m, 
2H, 3''-H, 5''-H), 7.30 – 7.25 (m, 1H, 4''-H), 7.00 – 6.94 (m, 2H, 2'-H, 6'-H), 6.88 – 6.83 (m, 2H, 
3'-H, 5'-H), 6.58 – 6.52 (m, 2H, 8-H, 5-H), 5.33 (s, 1H, OH), 5.14 (t, J = 6.7 Hz, 1H, 1-H), 5.02 
(s, 2H, OCH2-Ph), 4.04 – 3.88 (m, 3H, H-3, OCH2-CH3), 3.84 (s, 3H, 6-OCH3), 3.22 (ddd, J = 
13.7, 9.9, 4.6 Hz, 1H, 3-H), 2.97 (d, J = 6.6 Hz, 2H, α-H), 2.76 (ddd, J = 15.9, 9.9, 5.9 Hz, 1H, 
4-H), 2.51 (dt, J = 15.8, 4.4 Hz, 1H, 4-H), 1.10 (t, J = 7.1 Hz, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 157.8 (C-4'), 155.5 (C=O), 145.7 (C-6), 144.1 (C-
7),  137.6 (C-1''), 131.1 (C-1'), 130.6 (C-2', C-6'), 130.0 (C-8a), 128.5 (C-3'', C-5''), 127.8 (C-
4''), 127.4 (C-2'', C-6''), 126.1 (C-4a), 115.2 (C-3', C-5'), 113.4 (C-8), 111.3 (C-5), 70.5 (OCH2-
Ph), 61.1 (OCH2-CH3), 56.3 (6-OCH3), 56.1 (C-1), 42.1 (C-α), 38.5 (C-3), 28.2 (C-4), 14.6 
(OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 3032, 2929, 2360, 1683, 1509, 1428, 1232, 1201, 1098, 1014, 696  
Purity (HPLC, method a) = 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C27H29NO5 + H]+ 448.2118, found: 448.2120 
 
 
98 
 
(±)-7-(5-(2-((Ethoxycarbonyl)amino)ethyl)-2,3-dimethoxyphenoxy)-N-ethoxycarbonyl-6-
methoxy-1-(4’-benzyloxybenzyl)-1,2,3,4-tetrahydroisoquinoline (65) 
 
 
 
C40H46N2O9 
MW = 698.32 g/mol 
Phenol intermediate 64 (1.70 g, 3.80 mmol) and aryl bromide 53 (1.51 g, 4.56 mmol) were 
coupled following General Procedure 3 (intermolecular C–O coupling reaction). The reaction 
was completed after 3 days. Purification by flash column chromatography (30% acetone in 
hexanes, Rf  = 0.30) affording the product as a beige solid.  
yield: 1.69 g, 2.42 mmol, 64%, beige solid 
mp: 46.5 – 48.0 °C  
1H NMR, COSY (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.40 – 7.36 (m, 2H, 2'''-H, 6'''-H), 7.33 (t, J 
= 7.3 Hz, 2H, 3'''-H, 5'''-H), 7.30 – 7.24 (m, 1H, 4'''-H), 6.94 – 6.90 (m, 2H, 2'-H, 6'-H), 6.82 – 
6.77 (m, 2H, 3'-H, 5'-H), 6.68 (s, 1H, 5-H), 6.50 (s, 1H, 8)-H, 6.45 (d, J = 1.9 Hz, 1H, 2''-H), 
6.20 (d, J = 1.9 Hz, 1H, 6''-H), 5.12 (t, J = 6.5 Hz, 1H, 1-H), 4.98 (s, 2H, OCH2-Ph), 4.49 (s, 
1H, NH), 4.04 (q, J = 7.1 Hz, 2H, 'OCH2-CH3), 4.03 – 3.92 (m, 3H, 3-H, OCH2-CH3), 3.83 (s, 
3H, 3''-OCH3), 3.79 (s, 3H, 4''-OCH3), 3.78 (s, 3H, 6-OCH3), 3.30 (q, J = 6.8 Hz, 2H, NCH2-
CH2), 3.23 (ddd, J = 13.6, 9.7, 4.6 Hz, 1H, 3-H), 2.94 (tt, J = 13.7, 7.2 Hz, 2H, α-H), 2.81 (ddd, 
J = 15.8, 9.7, 5.9 Hz, 1H, 4-H), 2.64 (t, J = 7.1 Hz, 2H, NCH2-CH2), 2.61 – 2.52 (m, 1H, 4-H), 
1.18 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 1.13 (t, J = 7.0 Hz, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 157.8 (C-4'), 156.4 ('C=O), 155.5 (C=O), 154.0 
(C-3''), 151.1 (C-5''), 149.9 (C-6), 144.4 (C-7), 139.0 (C-4''), 137.5 (C-1'''), 134.1 (C-1''), 130.8 
(C-1'), 130.6 (C-2', C-6'), 130.5 (C-8a), 129.8 (C-4a), 128.5 (C-3''', C-5'''), 127.8 (C-4'''), 127.4 
(C-2''', C-6'''), 119.0 (C-8), 115.1 (C-3', C-5'), 114.1 (C-5), 111.5 (C-6''), 108.6 (C-2''), 70.5 
(OCH2-Ph), 61.2 (OCH2-CH3), 60.9 (4''-OCH3), 60.7 (‘OCH2-CH3), 56.7 (3''-OCH3), 56.6 (6-
OCH3), 55.9 (C-1), 42.2 (NCH2-CH2), 42.1 (C-α), 38.5 (C-3), 36.2 (NCH2-CH2), 28.4 (C-4), 14.6 
('OCH2-CH3, OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 2923, 2849, 1686, 1583, 1508, 1424, 1231, 1102, 1012, 824, 764, 736  
Purity (HPLC, method a) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C40H46N2O9+ H]+ 699.3276, found: 699.3277  
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(±)-7-(5-(2-((Ethoxycarbonyl)amino)ethyl)-2,3-dimethoxyphenoxy)-N-ethoxycarbonyl-6-
methoxy-1-(4’-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline (66) 
 
 
 
 
C33H40N2O9 
MW = 608.27 g/mol  
To a solution of diaryl ether 65 (1.69 g, 2.42 mmol) in methanol (50 mL) palladium (10% on 
carbon, 169 mg, Pd 1.59 mmol) was added. The mixture was stirred for 12 h at ambient 
temperature under hydrogen atmosphere (1 atm). The catalyst was removed by filtration 
through a small plug of celite, followed by washing with methanol (50 mL). The filtrate was 
concentrated in vacuo. Purification by flash column chromatography (35% acetone in hexanes, 
Rf  = 0.22) gave the title compound as a white solid.  
yield: 1.38 g, 2.27 mmol, 94%, white solid 
mp: 63.0 – 65.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.85 – 6.80 (m, 2H, 2'-H, 6'-H), 6.68 (s, 1H, 5-H), 
6.66 – 6.62 (m, 2H, 3'-H, 5'-H), 6.45 (d, J = 1.9 Hz, 1H, 2''-H), 6.30 (s, 1H, 8-H), 6.19 (d, J = 
1.9 Hz, 1H, 6''-H), 5.49 (s, 1H, OH), 5.04 (t, J = 6.6 Hz, 1H, 1-H), 4.61 (t, J = 5.7 Hz, 1H, NH), 
4.08 (q, J = 7.1 Hz, 4H, OCH2-CH3, 'OCH2-CH3), 3.95 – 3.85 (m, 1H, 3-H), 3.84 (s, 3H, 3''-
OCH3), 3.78 (s, 3H, 6-OCH3), 3.76 (s, 3H, 4''-OCH3), 3.36 – 3.27 (m, 3H, H-3, NCH2-CH2), 2.99 
(dd, J = 13.5, 5.9 Hz, 1H, α-H), 2.86 – 2.76 (m, 2H, 4-H, α-H), 2.68 – 2.61 (m, 3H, 4-H, NCH2-
CH2), 1.23 – 1.17 (m, 6H, OCH2-CH3, 'OCH2-CH3) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 156.8 ('C=O), 155.5 (C=O), 154.7 (C-4'), 154.0 
(C-3''), 150.8 (C-5''), 149.7 (C-6), 144.7 (C-7), 139.2 (C-4''), 133.9 (C-1''), 130.7 (C-2', C-6'), 
130.1 (C-4a, C-1'), 129.5 (C-8a), 118.6 (C-8), 115.3 (C-3', C-5'), 114.0 (C-5), 112.2 (C-6''), 
108.9 (C-2''), 61.2 ('OCH2-CH3 or OCH2-CH3), 61.0 ('OCH2-CH3 or OCH2-CH3), 60.8 (4''-
OCH3), 56.7 (3''-OCH3), 56.6 (6-OCH3), 56.3 (C-1), 42.2 (C-α, NCH2-CH2), 39.1 (C-3), 36.2 
(NCH2-CH2), 28.4 (C-4), 14.7 (OCH2-CH3 or ‘OCH2-CH3), 14.6 (OCH2-CH3 or ‘OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 2927, 2833, 2362, 1689, 1508, 1425, 1230, 1100, 1007, 773  
Purity (HPLC, method a) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C33H40N2O9+ H]+ 609.2807, found: 609.2810  
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(E/Z)-3-Bromo-4-methoxy-1-(2-methoxyvinyl)benzene (67) 
 
C10H11BrO2 
MW = 241.99 g/mol 
Obtained from 3-bromo-4-methoxybenzaldehyde (0.500 g, 2.33 mmol) following General 
Procedure 1 (Wittig olefination). Purification by flash column chromatography (5% ethyl acetate 
in hexanes, Rf = 0.30) affording the product as a colourless oil (E,Z-isomer ratio 1:0.91 
estimated by NMR-integrals).  
yield: 0.455 g, 1.87 mmol, 80%, colourless oil 
NMR data of the major E-isomer:   
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.46 – 7.41 (m, 1H, 2-H), 7.11 (dd, J = 8.5, 2.2 Hz, 1H, 
6-H), 6.93 (d, J = 12.9 Hz, 1H, 2'-H), 6.82 (d, J = 5.1 Hz, 1H, 5-H), 5.71 (d, J = 12.9 Hz, 1H, 1'-
H), 3.87 (s, 3H, 4-OCH3), 3.67 (s, 3H, 2'-OCH3)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 154.1 (C-4), 148.6 (C-2'), 130.7 (C-1), 129.9 (C-2), 125.3 
(C-6), 112.3 (C-5), 111.5 (C-3), 103.6 (C-1'), 56.7 (2'-OCH3), 56.5 (4-OCH3) 
IR (ATR): ṽ [cm-1] = 2937, 2837, 2074, 1640, 1496, 1253, 1095, 1053, 816  
Purity (HPLC, method a) = 92% (λ = 210 nm) 
HRMS (EI): m/z calcd for [C10H1179BrO2]•+ 241.9937, found: 241.9938 
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 (±)-8-((1-(4-Hydroxybenzyl)-N-(ethoxycarbonyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinolin-7-yl)oxy)-N-ethoxycarbonyl-6,7-dimethoxy-1-(3’-bromo-4’-
methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (68)  
 
 
 
 
C42H47BrN2O10 
MW = 818.24 g/mol 
Intermediate 66 (200 mg, 0.329 mmol) and enol ether 67 (96.0 mg, 0.394 mmol) were 
condensed following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) 
using TFA as catalyst to give a racemic mixture of diastereomers of tetrahydroisoquinoline 68 
in a ratio of 62:38 (R,R)/(S,S):(S,R)/(R,S). The reaction was completed after 12 h. Purification 
and separation of the diastereomers was accomplished by flash column chromatography (20% 
ethyl acetate in dichloromethane, Rf = 0.17 ((1R,1’S)/(1S,1’R) isomers (68b) and 0.13 
(1R,1’R)/(1S,1’S) isomers (68a)) to give both diasereomers as white solids. 
(1R,1’R)/(1S,1’S) isomers 68a:  
yield: 113 mg, 0.138 mmol, 42%, white solid 
mp: 68.5 – 70.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.18 (d, J = 2.1 Hz, 1H, 10-H), 6.91 (dd, J = 8.3, 
2.1 Hz, 1H, 14-H), 6.81 – 6.76 (m, 2H, 14'-H, 10'-H), 6.74 – 6.68 (m, 2H, 13-H, 5'-H), 6.58 – 
6.52 (m, 3H, 5-H, 13'-H, 11'-H), 6.21 (s, 1H, 8'-H), 5.30 (d, J = 10.1 Hz, 1H, 1-H), 5.02 (t, J = 
6.5 Hz, 1H, 1'-H), 4.86 (s, 1H, OH), 4.14 – 4.04 (m, 1H, 3-H), 4.00 (q, J = 7.3 Hz, 2H, 'OCH2-
CH3), 3.91 (s, 3H, 6'-OCH3), 3.96 – 3.89 (m, 1H, 3'-H), 3.85 (s, 3H, 6-OCH3), 3.87 – 3.71 (m, 
2H, OCH2-CH3), 3.79 (s, 3H, 12-OCH3), 3.63 (s, 3H, 7-OCH3), 3.37 – 3.28 (m, 1H, 3-H), 3.18 
(ddd, J = 13.4, 9.5, 4.4 Hz, 1H, 3'-H), 3.05 (dd, J = 14.1, 3.7 Hz, 1H, α-H), 2.88 (d, J = 6.4 Hz, 
1H, 4-H), 2.84 (t, J = 6.4 Hz, 2H, α'-H), 2.75 (td, J = 16.2, 14.4, 9.9 Hz, 2H, α-H, 4'-H), 2.61 (d, 
J = 6.3 Hz, 1H, 4-H), 2.55 (td, J = 11.3, 5.5 Hz, 1H, 4'-H), 1.14 (t, J = 7.0 Hz, 3H, 'OCH2-CH3), 
0.89 (br s, 3H, OCH2-CH3)  
13C NMR, HSQC, HMBC (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 (‘C=O), 155.4 (C=O), 154.8 
(C-12), 154.3 (C-12'), 152.6 (C-6), 148.2 (C-6'), 146.0 (C-7'), 145.0 (C-8), 140.8 (C-7), 134.2 
(C-10), 133.2 (C-9), 130.5 (C-14', C-10'), 130.4 (C-9'), 130.0 (C-8a), 129.4 (C-14), 129.2 (C-
8a'), 128.5 (C-4a'), 123.9 (C-4a), 115.3 (C-13', C-11'), 114.1 (C-8'), 113.5 (C-5'), 112.5 (C-13), 
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111.7 (C-11), 110.1 (C-5), 61.2 ('OCH2-CH3), 61.1 (OCH2-CH3), 60.7 (7-OCH3), 56.7 (6-, 6’- or 
12-OCH3), 56.6 (6-, 6’- or 12-OCH3), 56.6 (6-, 6’- or 12-OCH3), 55.9 (C-1'), 52.0 (C-1), 42.1 (C-
α'), 39.2 (C-α), 38.7 (C-3'), 37.4 (C-3), 28.3 (C-4'), 28.0 (C-4), 14.6 (‘OCH2-CH3), 14.2 (OCH2-
CH3)  
IR (ATR): ṽ [cm-1] = 2918, 2850, 2366, 1668, 1612, 1497, 1427,1331, 1255, 1120, 1020, 887, 
742  
Purity (HPLC, method a) = 75% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H4779BrN2O10 + H]+ 819.2492, found: 819.2500 
 
(1R,1’S)/(1S,1’R) isomers 68b:  
yield: (70.5 mg, 0.0856 mmol, 26%.  
mp: 71.5 – 73.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.24 (d, J = 2.1 Hz, 1H, 10-H), 6.94 (dd, J = 8.3, 
2.1 Hz, 1H, 14-H), 6.77 (d, J = 8.4 Hz, 2H, 14'-H, 10'-H), 6.74 (d, J = 8.3 Hz, 1H, 13-H), 6.70 
(s, 1H, 5'-H), 6.56 (d, J = 8.3 Hz, 2H, 13'-H, 11'-H), 6.51 (s, 1H, 5-H), 6.11 (s, 1H, 8'-H), 5.27 
(d, J = 8.3 Hz, 1H, 1-H), 5.10 (s, 1H, OH), 4.99 (t, J = 6.5 Hz, 1H, 1'-H), 4.01 (q, J = 7.1 Hz, 
2H, 'OCH2-CH3), 4.07 – 3.89 (m, 2H, 3-H, 3'-H), 3.90 (s, 3H, 6'-OCH3), 3.86 – 3.78 (m, 2H, 
OCH2-CH3), 3.83 (s, 3H, 6-OCH3), 3.80 (s, 3H, 12-OCH3), 3.59 (s, 3H, 7-OCH3), 3.40 – 3.31 
(m, 1H, 3'-H), 3.25 (d, J = 15.6 Hz, 1H, 3-H), 3.17 (dd, J = 14.1, 3.9 Hz, 1H, α-H), 2.92 – 2.73 
(m, 5H, 4-H, α-H, 4'-H, α'-H), 2.62 – 2.52 (m, 2H, 4-H, 4'-H), 1.15 (t, J = 7.1 Hz, 3H, 'OCH2-
CH3), 0.97 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.6 (C=O), 155.5 (‘C=O), 154.8 (C-12), 154.4 
(C-12'), 152.6 (C-6), 148.2 (C-6'), 145.8 (C-7'), 145.2 (C-8), 140.7 (C-7), 134.3 (C-10), 133.2 
(C-9), 130.6 (C-14', C-10'), 130.3 (C-9'), 130.1 (C-4a), 129.5 (C-14), 129.2 (C-8a'), 128.4 (C-
4a'), 123.5 (C-8a), 115.3 (C-13', C-11'), 114.4 (C-8'), 113.4 (C-5'), 112.5 (C-13), 111.7 (C-11), 
109.8 (C-5), 61.2 (‘OCH2-CH3, OCH2-CH3), 60.7 (7-OCH3), 56.7 (6-, 6’- or 12-OCH3), 56.6 (6-
, 6’- or 12-OCH3), 56.6 (6-, 6’- or 12-OCH3), 56.1 (C-1'), 52.1 (C-1), 42.2 (C-α'), 39.4 (C-α) 38.8 
(C-3), 37.9 (C-3'), 28.3 (C-4'), 28.1 (C-4), 14.6 ('OCH2-CH3), 14.4 (OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 2945, 2344, 1686, 1613, 1497, 1431, 1331, 1255, 1120, 1019, 949, 889, 
743  
Purity (HPLC, method a) = 67% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H4779BrN2O10 + H]+ 819.2492, found: 819.2502 
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(±)-8-(4-(2-((Ethoxycarbonyl)amino)ethyl)-2-methoxyphenoxy)-N-ethoxycarbonyl-6,7-
dimethoxy-1-(4’-methoxy-3’-(4-(2-methoxyvinyl)phenoxy)benzyl)-1,2,3,4-
tetrahydroisoquinoline (69) 
  
C43H50N2O11 
MW = 770.34 g/mol 
Phenol 59 (100 mg, 0.157 mmol) and enol ether 60 (36.7 mg, 0.172 mmol) were coupled 
following General Procedure 3 (intermolecular Ullmann-type C–O coupling reaction). The 
reaction was completed after 5 days. Purification by flash column chromatography (15% ethyl 
acetate in dichloromethane, Rf = 0.26) gave 69 as a white solid.  
yield: 74 mg, 0.096 mmol, 61%, white solid 
mp: 59.5 – 61.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) Z-isomer: δ [ppm] = 7.45 – 7.38 (m, 1H, 2'''-H or 6'''-H), 7.11 
– 7.05 (m, 1H, 2'''-H or 6'''-H), 6.86 (d, J = 12.9 Hz, 1H, 2''''-H), 6.81 (d, J = 8.3 Hz, 1H, 5'-H), 
6.78 (d, J = 2.0 Hz, 1H, 6'-H), 6.77 – 6.71 (m, 3H, 2''-H, 3'''-H, 5'''-H), 6.67 (d, J = 1.9 Hz, 1H, 
2'-H), 6.55 (dt, J = 8.3, 1.6 Hz, 1H, 6''-H), 6.50 (d, J = 8.2 Hz, 1H, 5''-H), 6.48 (s, 1H, 5-H), 5.80 
(d, J = 12.8 Hz, 1H, 1''''-H), 5.32 (d, J = 8.7 Hz, 1H, 1-H), 4.58 (s, 1H, NH), 4.07 (q, J = 7.1 Hz, 
2H, 'OCH2-CH3), 3.97 (d, J = 9.9 Hz, 1H, H-3), 3.91 – 3.75 (m, 2H, OCH2-CH3), 3.81 (s, 6H, 6-
OCH3, 3''-OCH3), 3.72 (s, 3H, 4'-OCH3), 3.64 (s, 3H, 2''''-OCH3), 3.59 (s, 3H, 7-OCH3), 3.35 (q, 
J = 6.9 Hz, 2H, NCH2-CH2), 3.32 – 3.24 (m, 1H, 3-H), 3.13 (dd, J = 14.1, 3.9 Hz, 1H, α-H), 2.85 
– 2.73 (m, 2H, 4-H, α-H), 2.71 (t, J = 7.1 Hz, 2H, NCH2-CH2), 2.51 (d, J = 16.2 Hz, 1H, 4-H), 
1.20 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.96 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) Z-isomer: δ [ppm] = 156.5 ('C=O), 156.4 (C-4'''), 152.6 (C-
6), 150.4 (C-4'), 149.4 (C-3''), 148.1 (C-2''''), 146.6 (C-4''), 145.1 (C-3'), 140.7 (C-7), 133.2 (C-
1''), 132.6 (C-1'), 130.4 (C-1'''), 130.2 (C-4a), 129.4 (C-2''' or C-6'''), 126.2 (C-2''' or C-6'''), 125.8 
(C-6'), 124.1 (C-8a), 122.8 (C-2'), 120.8 (C-6''), 117.3 (C-3''' or C-5'''), 116.6 (C-3''' or C-5'''), 
115.4 (C-5''), 114.3 (C-2''), 114.2 (C-5'), 109.7 (C-5), 105.4 (C-1''''), 61.0 (OCH2-CH3), 60.7 
('OCH2-CH3), 60.4 (7-OCH3), 56.9 (2''''-OCH3), 56.8 (4'-OCH3), 56.6 (3''-OCH3), 56.4 (6-OCH3), 
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52.1 (C-1), 42.3 (NCH2-CH2), 39.6 (C-α), 37.7 (C-3), 35.9 (NCH2-CH2), 28.0 (C-4), 14.6 ('OCH2-
CH3), 14.4 (OCH2-CH3). The resonances of C-8 and C=O could not be identified.  
IR (ATR): ṽ [cm-1] = 2911, 1693, 1603, 1504, 1423, 1329, 1262, 1213, 1152, 1125, 1108, 1026, 
839, 766  
Purity (HPLC, method a) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C43H50N2O11 + H]+ 771.3487, found: 771.3497 
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(±)-7-(5-(2-((Ethoxycarbonyl)amino)ethyl)-2,3-dimethoxyphenoxy)-N-ethoxycarbonyl-6-
methoxy-1-(4’-(2-methoxy-5-(2-methoxyvinyl)phenoxy)benzyl)-1,2,3,4-
tetrahydroisoquinoline (70) 
 
 
 
 
 
C43H50N2O11 
MW = 770.34 g/mol 
Phenol intermediate 66 (200 mg, 0.329 mmol) and enol ether 67 (87.9 mg, 0.361 mmol) were 
coupled following General Procedure 3 (intermolecular Ullmann-type C–O coupling reaction). 
The reaction was completed after 48 h. Purification by flash column chromatography (15% 
ethyl acetate in dichloromethane, Rf = 0.23) affording the product as a beige solid.  
yield: 114 mg, 0.141 mmol, 43%, beige solid 
mp: 47.0 – 50.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.95 – 6.84 (m, 4H, 5'''-H, 6'''-H, 2'-H, 6'-H), 6.81 – 
6.74 (m, 4H, 2'''-H, 3'-H, 5'-H, 2''''-H), 6.68 (s, 1H, 5-H), 6.56 (s, 1H, 8-H), 6.46 (s, 1H, 2''-H), 
6.21 (s, 1H, 6''-H), 5.71 (d, J = 12.8 Hz, 1H, 1''''-H), 5.14 (s, 1H, 1-H), 4.51 (s, 1H, NH), 4.04 
(q, J = 7.1 Hz, 2H, 'OCH2-CH3), 4.04 – 3.90 (m, 3H, 3, OCH2-CH3), 3.84 (s, 3H, 3''-OCH3), 3.80 
(s, 3H, 4''-OCH3), 3.78 (s, 3H, 6-OCH3), 3.73 (s, 3H, 4'''-OCH3), 3.60 (s, 3H, 2''''-OCH3), 3.30 
(q, J = 6.9 Hz, 2H, NCH2-CH2), 3.27 – 3.18 (m, 1H, 3-H), 2.95 (d, J = 6.6 Hz, 2H, α-H), 2.81 
(ddd, J = 16.0, 9.5, 6.6 Hz, 1H, 4-H), 2.64 (t, J = 7.1 Hz, 2H, NCH2-CH2), 2.61 – 2.52 (m, 1H, 
H-4), 1.17 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 1.13 (t, J = 8.0 Hz, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 156.8 (C-4'), 156.4 ('C=O), 155.5 (C-3'''), 154.0 
(C-3''), 151.1 (C-5''), 149.9 (C-4'''), 149.9 (C-6), 148.4 (C-2''''), 144.6 (C-7), 139.0 (C-4''), 134.2 
(C-1''), 132.2 (C-1'), 130.6 (C-2', C-6'), 130.4 (C-4a), 130.0 (C-8a), 129.7 (C-1'''), 121.5 (C-6'''), 
118.9 (C-8), 118.1 (C-2'''), 117.1 (C-3', C-5'), 114.8 (C-5'''), 114.1 (C-5), 111.6 (C-6''), 108.7 
(C-2''), 105.0 (C-1''''), 61.2 (OCH2-CH3), 60.9 (4''-OCH3), 60.7 (‘OCH2-CH3), 56.8 (2''''-OCH3), 
56.7 (4''-OCH3 or 3''-OCH3), 56.7 (4''-OCH3 or 3''-OCH3), 56.6 (6-OCH3), 55.8 (C-1), 42.2 
(NCH2-CH2, C-α), 38.6 (C-3), 36.2 (NCH2-CH2), 28.4 (C-4), 14.6 (OCH2-CH3, 'OCH2-CH3). The 
resonance of C=O could not be identified.  
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IR (ATR): ṽ [cm-1] = 2930, 2851, 1692, 1584, 1505, 1424, 1229, 1085, 1028, 941, 830, 767  
Purity (HPLC, method a) = 85% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C43H50N2O11 + K]+ 809.3052, found: 809.3045 
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(±)-Tetrandrine (rac-1) and (±)-isotetrandrine (rac-2) 
 
 
 
 
 
C38H42N2O6 
MW = 622.30 g/mol 
Carbamate 62 (45.0 mg, 0.0609 mmol of either (1R,1’R)/(1S,1’S) (62a) or (1R,1’S)/(1S,1’R) 
(62b) diastereomer) was reduced following General Procedure 4. The reaction was completed 
after 6 h. Purification was accomplished by flash column chromatography (dichloromethane → 
1% triethylamine and 2% methanol in dichloromethane, Rf = 0.18). Racemic tetrandrine (rac-
1) was obtained from 62a as colourless needles (37.0 mg, 0.0594 mmol, 98%) and racemic 
isotetrandrine (rac-2) from 62b as pale yellow prisms (37.3 mg, 0.0599 mmol, 98%), both after 
recrystallization from acetone. For the separation of the mixtures of diastereomers resulting 
from intramolecular N-acyl Pictet-Spengler reactions of 69 and 70 a preparative TLC method 
described by Lu et al.[132] was used with some modifications (0.5% triethylamine and 7.5% 
methanol in chloroform, Rf (rac-1) = 0.32; Rf (rac-2) = 0.22). Alternatively, preparative HPLC 
was performed on a Macherey-Nagel Nucleodur® 100-5 column (5 µm, 250 x 10 mm), eluent 
1% methanol and 0.1% diethylamine in chloroform; flow rate 7.0 mL/min; temperature 25 °C; 
UV-detection at λ = 283 nm; (Rt (rac-1) = 4.11 min; Rt (rac-2) = 4.93 min). 
(±)-Tetrandrine (rac-1):  
yield: 37.0 mg, 0.0594 mmol, 98%, colourless needles 
mp: 217.0 – 220.0 °C (lit.[154]: 252.0 – 253.0 °C (racemic tetrandrine (rac-1))  
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.34 (dd, J = 8.2, 2.2 Hz, 1H, 14'-H or 10'-H), 7.14 (dd, J 
= 8.2, 2.5 Hz, 1H, 13'-H or 11'-H), 6.88 (dd, J = 8.2, 1.6 Hz, 1H, 14-H), 6.86 (d, J = 8.1 Hz, 1H, 
13-H), 6.80 (dd, J = 8.2, 2.6 Hz, 1H, 13'-H or 11'-H), 6.55 (d, J = 1.7 Hz, 1H, 10-H), 6.51 (s, 
1H, 5'-H), 6.30 (s, 1H, 5-H), 6.30 (dd, J = 8.3, 2.2 Hz, 1H, 14'-H or 10'-H), 5.99 (s, 1H, 8'-H), 
3.93 (s, 3H, 12-OCH3), 3.87 (dd, J = 11.0, 5.6 Hz, 1H, 1'-H), 3.75 (s, 3H, 6-OCH3), 3.73 (s, 1H, 
1-H), 3.55 – 3.48 (m, 1H, 3-H), 3.43 (ddd, J = 12.6, 10.0, 5.9 Hz, 1H, 3'-H), 3.37 (s, 3H, 6'-
OCH3), 3.25 (dd, J = 12.5, 5.7 Hz, 1H, α'-H), 3.19 (s, 3H, 7-OCH3), 2.99 – 2.89 (m, 3H, 3-H, 4-
H, 4'-H), 2.89 – 2.84 (m, 1H, 3'-H), 2.80 (t, J = 11.7 Hz, 1H, α'-H), 2.75 – 2.72 (m, 1H, 4'-H), 
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2.70 (dd, J = 14.2, 10.2 Hz, 1H, α-H), 2.62 (s, 3H, 2'-NCH3), 2.52 (d, J = 13.7 Hz, 1H, α-H), 
2.45 – 2.39 (m, 1H, 4-H), 2.33 (s, 3H, 2-NCH3)  
13C NMR (151 MHz, CDCl3) δ [ppm] = 153.9 (C-12'), 151.5 (C-6), 149.5 (C-11), 148.7 (C-6'), 
148.6 (C-8), 147.2 (C-12), 143.9 (C-7'), 138.0 (C-7), 135.4 (C-9'), 135.1 (C-9), 132.8 (C-14' or 
C-10'), 130.3 (C-14' or C-10'), 128.3 (C-4a), 128.2 (C-8a'), 128.1 (C-4a'), 123.1 (C-8a), 122.9 
(C-14), 122.1 (C-13' or 11'), 122.0 (C-13' or 11'), 120.3 (C-8'), 116.4 (C-10), 112.9 (C-5'), 111.7 
(C-13), 105.9 (C-5), 64.1 (C-1'), 61.6 (C-1), 60.4 (7-OCH3), 56.3 (12-OCH3), 56.0 (6'-OCH3), 
56.0 (6-OCH3), 45.4 (C-3'), 44.3 (C-3), 42.8 (2'-NCH3), 42.5 (2-NCH3), 42.1 (C-α), 38.4 (C-α’), 
25.4 (C-4'), 22.2 (C-4). The NMR data are identical with those of an authentic sample of 
tetrandrine.  
IR (ATR): ṽ [cm-1] = 2940, 2838, 1579, 1506, 1446, 1410, 1355, 1268, 1213, 1121, 1023, 844, 
767, 744  
Purity (HPLC, method c) = 98% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C38H42N2O6 + H]+ 623.3116, found: 623.3111 
 
(±)-Isotetrandrine (rac-2):  
yield: 37.3 mg, 0.0599 mmol, 98%, pale yellow solid 
mp: 175.5 – 182.0 °C (lit.[96]: 166.0 – 168.0 °C (enantiopure isotetrandrine (2)) A melting point 
of racemic isotetrandrine (rac-2) is not published yet).  
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.27 (dd, J = 8.4, 2.3 Hz, 1H, 14'-H or 10'-H), 7.10 (dd, J 
= 8.2, 2.5 Hz, 1H, 13'-H or 11'-H), 6.83 – 6.77 (m, 2H, 13-H, 14-H), 6.67 – 6.63 (m, 1H, 13'-H 
or 11'-H), 6.53 (s, 1H, 5'-H), 6.48 – 6.37 (m, 2H, 10-H, 14'-H or 10'-H), 6.27 (s, 1H, 5-H), 5.98 
(s, 1H, 8'-H), 3.92 (s, 3H, 12-OCH3), 3.88 – 3.81 (m, 2H, 1-H, 1'-H), 3.75 (s, 3H, 6-OCH3), 3.61 
(s, 3H, 6'-OCH3), 3.44 – 3.36 (m, 1H, 3'-H), 3.33 – 3.21 (m, 2H, 3-H, α'-H), 3.13 (s, 3H, 7-
OCH3), 3.03 (d, J = 14.2 Hz, 1H, α-H), 2.96 – 2.86 (m, 3H, 4-H, 4'-H, α'-H), 2.85 – 2.76 (m, 3H, 
3-H, 4'-H, 3'-H), 2.60 (d, J = 10.4 Hz, 1H, α-H), 2.57 (s, 3H, 2'-NCH3), 2.45 – 2.31 (m, 1H, 4-
H), 2.26 (s, 3H, 2-NCH3)  
13C NMR (151 MHz, CDCl3) δ [ppm] = 154.2 (12'), 152.0 (C-6), 150.0 (C-6'), 149.7 (C-11), 
148.5 (C-4a), 147.1 (C-12), 143.8 (C-7'), 137.3 (C-7), 135.4 (C-9'), 132.2 (C-14' or C-10'), 
130.3 (C-14' or 10'), 129.0 (C-4a'), 127.9 (C-8a'), 122.9 (C-14), 122.2 (C-13' or C-11'), 121.8 
(C-13' or C-11'), 120.7 (C-8a), 120.0 (C-8'), 116.0 (C-9), 111.5 (C-13), 111.4 (C-5'), 105.7 (C-
5), 64.0 (C-1'), 62.1 (C-1), 60.6 (7-OCH3), 56.2 (12-OCH3), 55.9 (6-OCH3), 55.7 (6'-OCH3), 
46.3 (C-3'), 43.0 (2'-NCH3), 42.8 (2-NCH3), 38.9 (C-α), 37.9 (C-α'), 25.9 (C-4'), 23.2 (C-4). The 
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resonances of C-3 and C-8 could not be identified. The NMR data are in accordance with 
published data[140]. 
IR (ATR): ṽ [cm-1] = 2933, 2834, 1582, 1506, 1445, 1413, 1260, 1229, 1114, 1030, 973, 865, 
837, 772  
Purity (HPLC, method c) = 97% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C38H42N2O6 + H]+ 623.3116, found: 623.3108  
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(E/Z)-3-Bromo-1-(2-methoxyvinyl)benzene (71) 
 
 
 
 
C9H9BrO 
MW = 211.98 g/mol 
Prepared from 3-bromobenzaldehyde (1.00 g, 5.41 mmol) following General Procedure 1 
(Wittig olefination). Purification was accomplished by flash column chromatography (2.5% 
ethyl acetate in hexanes, Rf = 0.25) to give the title compound as a colourless oil (E,Z-isomer 
ratio 0.92:1, estimated by NMR integrals). The compound is literature known[155-156]. 
yield: 940 mg, 4.41 mmol, 82%, colourless oil 
NMR data of the major Z-isomer:  
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.77 (t, J = 1.8 Hz, 1H, 2-H), 7.43 (dt, J = 7.8, 1.4 Hz, 
1H, 6-H), 7.28 – 7.23 (m, 1H, 4-H), 7.16 – 7.09 (m, 1H, 5-H), 6.17 (d, J = 7.0 Hz, 1H, 2'-H), 
5.15 (d, J = 7.0 Hz, 1H, 1'-H), 3.80 (s, 3H, 2'-OCH3)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 149.2 (C-2'), 138.1 (C-1), 131.0 (C-2), 129.8 (C-5), 128.7 
(C-4), 126.8 (C-6), 122.5 (C-3), 104.5 (C-1'), 61.1 (2'-OCH3)  
IR (ATR): ṽ [cm-1] = 3063, 2932, 2833, 1726, 1569, 1474, 1427, 1206, 1070, 782  
HRMS (EI): m/z calcd for [C9H979BrO]•+ 211.9831, found: 211.9829 
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(E/Z)-3-Bromo-1-(2-methoxyvinyl)-4-(trifluoromethoxy)benzene (72) 
 
 
 
C10H8BrF3O2 
MW = 295.97 g/mol 
Prepared from 3-bromo-4-(trifluoromethoxy)benzaldehyde (300 mg, 1.12 mmol) following 
General Procedure 1 (Wittig olefination). Purification was accomplished by flash column 
chromatography (2.5% ethyl acetate in hexanes, Rf = 0.30) to give the title compound as a 
light yellow oil (E,Z-isomer ratio 1:0.71, estimated by NMR integrals).  
yield: 266 mg, 0.895 mmol, 80%, light yellow oil 
NMR data of the major E-isomer:  
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.48 (d, J = 2.1 Hz, 1H, 2-H), 7.19 (dd, J = 8.4, 1.4 Hz, 
1H, 5-H), 7.15 (dd, J = 8.5, 2.1 Hz, 1H, 6-H), 7.03 (d, J = 13.0 Hz, 1H, 2'-H), 5.71 (d, J = 12.9 
Hz, 1H, 1'-H), 3.70 (s, 3H, 2'-OCH3)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 150.6 (C-2'), 144.2 (d, J = 2.0 Hz, C-4), 137.2 (C-1), 
130.1 (C-2), 125.1 (C-6), 122.6 (C-5), 120.7 (q, J = 258.7 Hz, OCF3), 116.5 (C-3), 102.9 (C-
1'), 56.9 (2'-OCH3)  
IR (ATR): ṽ [cm-1] = 2940, 2838, 1641, 1492, 1247, 1156, 1096, 932, 833  
HRMS (EI): m/z calcd for [C10H879BrF3O2]•+ 295.9654, found: 295.9651 
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(E/Z)-3-Bromo-4-chloro-1-(2-methoxyvinyl)benzene (73) 
 
 
 
 
C9H8BrClO 
MW = 245.95 g/mol 
Prepared from 3-bromo-4-chlorobenzaldehyde (500 mg, 2.28 mmol) following General 
Procedure 1 (Wittig olefination). Purification was accomplished by flash column 
chromatography (2.5% ethyl acetate in hexanes, Rf = 0.36) to give the title compound as a 
light yellow oil (E,Z-isomer ratio 1.08:1, estimated by NMR integrals).  
yield: 490 mg, 1.98 mmol, 87%, light yellow oil 
NMR data of the major E-isomer:  
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.47 (d, J = 2.1 Hz, 1H, 2-H), 7.30 (d, J = 7.2 Hz, 1H, 5-
H), 7.08 (dd, J = 8.3, 2.1 Hz, 1H, 6-H), 7.03 (d, J = 13.0 Hz, 1H, 2'-H), 5.69 (d, J = 13.0 Hz, 
1H, 1'-H), 3.69 (s, 3H, OCH3)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 150.3 (C-2'), 137.0 (C-1), 131.0 (C-4), 130.4 (C-5), 130.1 
(C-2), 125.1 (C-6), 122.7 (C-3) 103.1 (C-1'), 56.9 (OCH3)  
IR (ATR): ṽ [cm-1] = 2934, 2833, 1701, 1640, 1467, 1192, 1120, 1023, 822  
HRMS (EI): m/z calcd for [C9H879Br35ClO]•+ 245.9442, found: 245.9444 
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(E/Z)-2-Bromo-4-(2-methoxyvinyl)pyridine (75) 
 
C8H8BrNO 
MW = 212.98 g/mol 
Prepared from 2-bromoisonicotinaldehyde (74, 300 mg, 1.61 mmol) following General 
Procedure 1 (Wittig olefination). Purification was accomplished by flash column 
chromatography (20% ethyl acetate in hexanes, Rf = 0.32) to give the title compound as a light 
yellow oil (E,Z-isomer ratio 1:0.79, estimated by NMR integrals).  
yield: 290 mg, 1.35 mmol, 84%, yellow oil 
NMR data of the major E-isomer:  
1H NMR (400 MHz, CDCl3) δ [ppm] = 8.16 (d, J=5.3, 1H, 6-H), 7.28 – 7.28 (m, 1H, 3-H), 7.26 
(d, J=13.0, 1H, 2'-H), 7.04 (ddd, J=5.3, 1.6, 0.5, 1H, 5-H), 5.63 (d, J=13.0, 1H, 1'-H), 3.73 (s, 
3H, OCH3) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 153.5 (C-2'), 150.0 (C-6), 147.6 (C-4), 142.9 (C-2), 123.6 
(C-3), 118.8 (C-5), 101.9 (C-1'), 57.2 (OCH3) 
IR (ATR): ṽ [cm-1] = 2937, 2082, 1635, 1522, 1378, 1278, 1076, 984, 936, 846, 716 
HRMS (EI): m/z calcd for [C8H879BrNO]•+ 212.9784, found: 212.9785 
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(E/Z)-4-Bromo-2-(2-methoxyvinyl)furan (76) 
 
 
 
 
C7H7BrO2 
MW = 201.96 g/mol 
Prepared from 4-bromo-2-furaldehyde (300 mg, 1.71 mmol) following General Procedure 1 
(Wittig olefination). Purification was accomplished by flash column chromatography (2.5% 
ethyl acetate in hexanes, Rf = 0.19) to give the title compound as a light yellow oil (E,Z-isomer 
ratio 1:0.81, estimated by NMR integrals).  
yield: 280 mg, 1.38 mmol, 81%, light yellow oil 
NMR data of the major E-isomer:  
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.23 (d, J=0.8, 1H, 5-H), 7.07 (d, J=12.9, 1H, 2'-H), 6.06 
– 6.05 (m, 1H, 3-H), 5.58 (d, J=12.8, 1H, 1'-H), 3.66 (s, 3H, OCH3) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 152.9 (C-2), 150.2 (C-2'), 138.4 (C-5), 107.2 (C-3), 101.0 
(C-4), 94.7 (C-1'), 56.8 (OCH3) 
IR (ATR): ṽ [cm-1] = 2931, 1780, 1645, 1453, 1362, 1212, 1118, 1019, 922, 790 
HRMS (EI): m/z calcd for [C7H779BrO2]•+ 201.9624, found: 201.9621 
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(E/Z)-4-Bromo-2-(2-methoxyvinyl)thiophene (77) 
 
 
 
 
C7H7BrOS 
MW = 217.94 g/mol 
Prepared from 4-bromothiophene-2-carboxaldehyde (0.500 g, 2.62 mmol) following General 
Procedure 1 (Wittig olefination). Purification was accomplished by flash column 
chromatography (hexanes, Rf = 0.28) to give the title compound as a light yellow oil (E,Z-
isomer ratio 1:1.13, estimated by NMR integrals).  
yield: 471 mg, 2.15 mmol, 82%, light yellow oil 
NMR data of the E-isomer:  
1H NMR (400 MHz, CDCl3) δ [ppm] = 6.97 (d, J = 12.9 Hz, 1H, 2'-H), 6.89 (d, J = 1.4 Hz, 1H, 
5-H), 6.70 – 6.68 (m, 1H, 3-H), 5.87 (d, J = 12.8 Hz, 1H, 1'-H), 3.67 (s, 3H, OCH3)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 149.9 (C-2'), 141.4 (C-2), 125.0 (C-3), 118.5 (C-5), 109.8 
(C-4), 98.6 (C-1'), 57.0 (OCH3)  
IR (ATR): ṽ [cm-1] = 3110, 2933, 2849, 2053, 1727, 1637, 1221, 1093, 819, 722  
HRMS (EI): m/z calcd for [C7H779BrOS]•+ 217.9395, found: 217.9395 
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5-Bromo-1-pentanal (79) 
 
 
C5H9BrO 
MW = 163.98 g/mol 
Pyridinium chlorochromate (503 mg, 2.33 mmol, 1.3 eq.) was suspended in 10 mL anhydrous 
dichloromethane under nitrogen atmosphere. Then 5-bromo-1-pentanol (78, 300 mg, 1.80 
mmol) was added and the mixture was stirred for 6 h at ambient temperature. The volatiles 
were removed in vacuo and purification of the residue by flash column chromatography (25% 
diethyl ether in hexanes, Rf  = 0.43) gave the product as a colourless oil. The 1H NMR data is 
in good agreement with literature[157]. 
yield: 191 mg, 1.16 mmol, 64%, colourless oil 
1H NMR (400 MHz, CDCl3) δ [ppm] = 9.78 (t, J = 1.5 Hz, 1H, 1-H), 3.42 (t, J = 6.5 Hz, 2H, 5-
H), 2.49 (td, J = 7.1, 1.5 Hz, 2H, 2-H), 1.95 – 1.86 (m, 2H, 4-H), 1.84 – 1.75 (m, 2H, 3-H)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 201.7 (C-1), 42.9 (C-2), 33.0 (C-5), 31.9 (C-4), 20.6 (C-
3)  
IR (ATR): ṽ [cm-1] = 2954, 2865, 2840, 1725, 1437, 1358, 1122, 1058  
HRMS (EI): m/z calcd for [C5H979BrO]•+ 162.9753, found: 162.9752 
  
117 
 
(±)-8-((1-(4-Hydroxybenzyl)-N-(ethoxycarbonyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinolin-7-yl)oxy)-N-ethoxycarbonyl-6,7-dimethoxy-1-(3’-bromobenzyl)-
1,2,3,4-tetrahydroisoquinoline (80; separable mixture of racemic diastereomers) 
 
 
 
 
 
C41H45BrN2O9 
MW = 788.23 g/mol 
Carbamate 66 (250 mg, 0.411 mmol) and enol ether 71 (160 mg, 0.751 mmol) were condensed 
following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) using TfOH as 
catalyst. The reaction was completed after 4 h. Purification by flash column chromatography 
(20% ethyl acetate in dichloromethane, Rf = 0.13 (1R,1’R)/(1S,1’S) isomers and 0.23 
(1R,1’S)/(1S,1’R) isomers) gave the title compounds as white solids.  
(1R,1’R)/(1S,1’S) isomers:  
yield: 111 mg, 0.141 mmol, 34%, white solid  
mp: 112.0 – 113.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.30 – 7.22 (m, 1H, 12-H), 7.18 (t, J = 1.8 Hz, 1H, 
10-H), 7.03 (t, J = 7.7 Hz, 1H, 13-H), 6.95 (d, J = 7.6 Hz, 1H, 14-H), 6.81 – 6.76 (m, 2H, 10'-H, 
14'-H), 6.70 (s, 1H, 5'-H), 6.58 – 6.51 (m, 3H, 5-H, 11'-H, 13'-H), 6.20 (s, 1H, 8'-H), 5.34 (d, J 
= 9.6 Hz, 1H, 1-H), 5.02 (t, J = 6.5 Hz, 1H, 1'-H), 4.68 (s, 1H, OH), 4.16 – 4.05 (m, 1H, 3-H), 
4.00 (q, J = 7.1 Hz, 2H, 'OCH2-CH3), 3.96 – 3.85 (m, 1H, 3'-H), 3.90 (s, 3H, 6'-OCH3), 3.85 (s, 
3H, 6-OCH3), 3.88 – 3.70 (m, 2H, OCH2-CH3), 3.63 (s, 3H, 7-OCH3), 3.33 (ddd, J = 13.2, 10.4, 
5.0 Hz, 1H, 3-H), 3.18 (ddd, J = 13.3, 9.5, 4.4 Hz, 1H, 3'-H), 3.10 (dd, J = 13.9, 3.6 Hz, 1H, α-
H), 2.93 – 2.85 (m, 1H, 4-H), 2.84 (t, J = 6.8 Hz, 2H, α'-H), 2.81 – 2.72 (m, 2H, α-H, 4'-H), 2.60 
(d, J = 16.4 Hz, 1H, 4-H), 2.54 (dt, J = 16.0, 4.6 Hz, 1H, 4'-H), 1.14 (t, J = 7.0 Hz, 3H, 'OCH2-
CH3), 0.90 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 ('C=O), 155.3 (C=O), 154.2 (C-12'), 152.7 
(C-6), 148.2 (C-6'), 145.9 (C-7'), 141.6 (C-9), 140.9 (C-7), 132.5 (C-10), 130.5 (C-10', C-14'), 
130.5 (C-9'), 130.0 (C-8a'), 129.4 (C-13), 129.2 (C-12), 128.5 (C-4a'), 128.2 (C-14), 123.8 (C-
8a), 122.1 (C-11), 115.4 (C-11', C-13'), 114.1 (C-8'), 113.4 (C-5'), 110.1 (C-5), 61.2 ('OCH2-
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CH3), 61.1 (OCH2-CH3), 60.7 (7-OCH3), 56.7 (6'-OCH3 or 6-OCH3), 56.6 (6'-OCH3 or 6-OCH3), 
55.9 (C-1'), 51.9 (C-1), 42.1 (C-α'), 40.1 (C-α), 38.8 (C-3'), 37.4 (C-3), 28.3 (C-4'), 27.9 (C-4), 
14.6 ('OCH2-CH3), 14.2 (OCH2-CH3). The resonances of C-8 and C-4a could not be identified  
IR (ATR): ṽ [cm-1] = 2930, 1693, 1513, 1426, 1332, 1199, 1112, 1021, 835, 765  
Purity (HPLC, method e) = 90% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C41H4579BrN2O9 + H]+ 789.2381, found: 789.2383 
 
(1R,1’S)/(1S,1’R) isomers:  
yield: 95.0 mg, 0.121 mmol, 29%, white solid 
mp: 99.0 – 101.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.28 (dt, J = 7.8, 1.6 Hz, 1H, 12-H), 7.24 (s, 1H, 
10-H), 7.05 (t, J = 7.7 Hz, 1H, 13-H), 6.99 (d, J = 7.6 Hz, 1H, 14-H), 6.81 – 6.74 (m, 2H, 10'-H, 
14'-H), 6.70 (s, 1H, 5'-H), 6.60 – 6.53 (m, 2H, 11'-H, 13'-H), 6.52 (s, 1H, 5-H), 6.11 (s, 1H, 8'-
H), 5.32 (s, 1H, 1-H), 5.18 (s, 1H, OH), 4.99 (t, J = 6.5 Hz, 1H, 1'-H), 4.15 – 4.06 (m, 1H, 3-H), 
4.01 (q, J = 7.3 Hz, 2H, 'OCH2-CH3), 3.96 – 3.87 (m, 1H, 3'-H), 3.89 (s, 3H, 6'-OCH3), 3.83 (s, 
3H, 6-OCH3), 3.86 – 3.76 (m, 2H, OCH2-CH3), 3.60 (s, 3H, 7-OCH3), 3.36 (ddd, J = 13.1, 10.0, 
4.8 Hz, 1H, 3-H), 3.23 (dd, J = 14.0, 4.1 Hz, 2H, α-H, 3'-H), 2.97 – 2.83 (m, 3H, α-H, α'-H, 4-
H), 2.82 – 2.72 (m, 2H, α'-H, 4'-H), 2.57 (dt, J = 16.0, 4.5 Hz, 2H, 4'-H, 4-H), 1.15 (t, J = 7.1 
Hz, 3H, 'OCH2-CH3), 0.96 (s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 (C=O, 'C=O), 154.4 (C-12'), 152.6 (C-6), 
148.2 (C-6'), 145.7 (C-7'), 141.6 (C-9), 140.7 (C-7), 132.6 (C-10), 130.5 (C-10', C-14'), 130.3 
(C-9'), 129.4 (C-13), 129.2 (C-12), 129.2 (C-8a'), 128.4 (C-4a'), 128.3 (C-14), 123.4 (C-8a), 
122.1 (C-11), 115.3 (C-11', C-13'), 114.3 (C-8'), 113.3 (C-5'), 109.8 (C-5), 61.2 (OCH2-CH3, 
‘OCH2-CH3), 60.7 (7-OCH3), 56.6 (6'-OCH3, 6-OCH3), 56.1 (C-1'), 52.0 (C-1), 42.2 (C-α'), 40.2 
(C-α), 38.8 (C-3'), 37.8 (C-3), 28.3 (C-4'), 28.1 (C-4), 14.6 ('OCH2-CH3), 14.3 (OCH2-CH3). The 
resonances of C-8 and C-4a could not be identified.  
IR (ATR): ṽ [cm-1] = 2935, 1689, 1512, 1426, 1332, 1239, 1112, 1023, 769  
Purity (HPLC, method e) = 92% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C41H4579BrN2O9 + H]+ 789.2381, found: 789.2390 
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(±)-8-((1-(4-Hydroxybenzyl)-N-(ethoxycarbonyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinolin-7-yl)oxy)-N-ethoxycarbonyl-6,7-dimethoxy-1-(3’-bromo-4’-
trifluoromethoxy-benzyl)-1,2,3,4-tetrahydroisoquinoline (81; separable mixture of 
racemic diastereomers) 
 
 
 
 
C42H44BrF3N2O10 
MW = 872.21 g/mol 
Carbamate 66 (250 mg, 0.411 mmol) and enol ether 72 (146 mg, 0.493 mmol) were condensed 
following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) using TfOH as 
catalyst. The reaction was completed after 12 h. Purification by flash column chromatography 
(15% ethyl acetate in dichloromethane, Rf = 0.10 (1R,1’R)/(1S,1’S) isomers and 0.15 
(1R,1’S)/(1S,1’R) isomers) gave the title compounds as white solids.  
(1R,1’R)/(1S,1’S) isomers:  
yield: 134 mg, 0.153 mmol, 37%, white solid  
mp: 91.5 – 92.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.31 (d, J = 2.0 Hz, 1H, 10-H), 7.10 (dd, J = 8.4, 
1.6 Hz, 1H, 13-H), 6.99 (dd, J = 8.4, 2.1 Hz, 1H, 14-H), 6.81 – 6.76 (m, 2H, 10'-H, 14'-H), 6.70 
(s, 1H, 5'-H), 6.57 – 6.51 (m, 2H, 11'-H, 13'-H), 6.54 (s, 1H, 5-H), 6.19 (s, 1H, 8'-H), 5.29 (s, 
1H, 1-H), 5.02 (t, J = 6.5 Hz, 1H, 1'-H), 4.64 (s, 1H, OH), 4.15 – 4.03 (m, 1H, 3-H), 4.00 (q, J 
= 7.0 Hz, 2H, 'OCH2-CH3), 3.90 (s, 3H, 6'-OCH3), 3.85 (s, 3H, 6-OCH3), 3.97 – 3.71 (m, 3H, 
OCH2-CH3, 3'-H), 3.62 (s, 3H, 7-OCH3), 3.39 – 3.29 (m, 1H, 3-H), 3.24 – 3.13 (m, 1H, 3'-H), 
3.11 (dd, J = 13.9, 3.7 Hz, 1H, α-H), 2.91 – 2.72 (m, 5H, α-H, α'-H, 4'-H, 4-H), 2.62 (d, J = 15.4 
Hz, 1H, 4-H), 2.54 (dt, J = 16.0, 4.6 Hz, 1H, 4'-H), 1.14 (t, J = 6.9 Hz, 3H, 'OCH2-CH3), 0.88 (br 
s, 3H, OCH2-CH3) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.4 ('C=O), 155.2 (C=O), 154.2 (C-12'), 152.8 
(C-6), 148.1 (C-6'), 145.8 (C-7'), 145.0 (C-12), 140.9 (C-7), 139.9 (C-9), 134.8 (C-10), 130.5 
(C-10', C-14'), 130.4 (C-9'), 129.6 (C-14), 129.3 (C-8a'), 123.5 (C-8a), 121.5 (C-13), 115.6 (C-
11), 115.4 (C-11', C-13'), 114.1 (C-8'), 113.4 (C-5'), 110.2 (C-5), 61.2 ('OCH2-CH3), 61.1 
(OCH2-CH3), 60.7 (7-OCH3), 56.7, 56.6 (6'-OCH3, 6-OCH3), 55.9 (C-1'), 51.9 (C-1), 42.1 (C-
120 
 
α'), 39.6 (C-α), 38.8 (C-3'), 38.2 (C-3), 28.3 (C-4'), 27.9 (C-4), 14.6 ('OCH2-CH3), 14.1 (OCH2-
CH3).The resonances of C-8, C-4a, C-4a' and OCF3 could not be identified.  
IR (ATR): ṽ [cm-1] = 2931, 1668, 1612, 1514, 1426, 1332, 1247, 1168, 1119, 1023, 763  
Purity (HPLC, method b) = 85% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C42H4479BrF3N2O10 + H]+ 873.2204, found: 873.2217 
 
(1R,1’S)/(1S,1’R) isomers:  
yield: 91 mg, 0.104 mmol, 25%, white solid 
mp: 93.5 – 95.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.37 (d, J = 2.0 Hz, 1H, 10-H), 7.12 (dd, J = 8.4, 
1.6 Hz, 1H, 13-H), 7.03 (dd, J = 8.4, 2.1 Hz, 1H, 14-H), 6.81 – 6.72 (m, 2H, 10'-H, 14'-H), 6.70 
(s, 1H, 5'-H), 6.59 – 6.53 (m, 2H, 11'-H, 13'-H), 6.52 (s, 1H, 5-H), 6.09 (s, 1H, 8'-H), 5.29 (d, J 
= 5.6 Hz, 1H, 1-H), 4.98 (t, J = 6.4 Hz, 1H, 1'-H), 4.10 – 4.01 (m, 1H, 3-H), 4.02 (q, J = 7.2 Hz, 
2H, 'OCH2-CH3), 3.88 (s, 3H, 6'-OCH3), 3.96 – 3.76 (m, 3H, OCH2-CH3, 3'-H), 3.83 (s, 3H, 6-
OCH3), 3.58 (s, 3H, 7-OCH3), 3.37 (ddd, J = 13.3, 10.0, 4.8 Hz, 1H, 3-H), 3.23 (dd, J = 13.8, 
4.0 Hz, 2H, α-H, 3'-H), 2.95 – 2.81 (m, 3H, α-H, α'-H, 4-H), 2.81 – 2.72 (m, 2H, α'-H, 4'-H), 2.64 
– 2.54 (m, 2H, 4'-H, 4-H), 1.16 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.96 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 (C=O, 'C=O), 154.3 (C-12'), 154.2 (C-6), 
148.2 (C-6'), 145.6 (C-7'), 145.2 (C-12), 143.1 (C-7), 139.9 (C-9), 135.0 (C-10), 130.6 (C-10', 
C-14'), 130.4 (C-9'), 130.0 (C-8a'), 129.7 (C-14), 123.0 (C-8a), 121.9 (C-13), 115.3 (C-11), 
115.3 (C-11', C-13'), 114.4 (C-8'), 113.3 (C-5'), 109.8 (C-5), 61.3 ('OCH2-CH3), 61.2 (OCH2-
CH3), 60.7 (7-OCH3), 56.6, 56.5 (6'-OCH3, 6-OCH3), 56.5 (C-1'), 52.0 (C-1), 42.2 (C-α'), 39.7 
(C-α), 38.9 (C-3'), 38.0 (C-3), 28.3 (C-4'), 28.1 (C-4), 14.6 ('OCH2-CH3), 14.3 (OCH2-CH3). The 
resonances of C-8, C-4a, C-4a' and OCF3 could not be identified.  
IR (ATR): ṽ [cm-1] = 2922, 1668, 1613, 1514, 1455, 1333, 1253, 1170, 1120, 1024, 764 
Purity (HPLC, method b) = 90% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C42H4479BrF3N2O10 + H]+ 873.2204, found: 873.2217 
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(±)-8-((1-(4-Hydroxybenzyl)-N-(ethoxycarbonyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinolin-7-yl)oxy)-N-ethoxycarbonyl-6,7-dimethoxy-1-((4’-
bromothiophen-2’-yl)methyl)-1,2,3,4-tetrahydroisoquinoline (83; separable mixture of 
racemic diastereomers) 
 
 
 
 
C39H43BrN2O9S 
MW = 794.19 g/mol 
Carbamate 66 (300 mg, 0.493 mmol) and enol ether 77 (130 mg, 0.591 mmol) were condensed 
following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) using TfOH as 
catalyst. The reaction was completed after 12 h. Purification by flash column chromatography 
(15% ethyl acetate in dichloromethane, Rf = 0.10 (1R,1’R)/(1S,1’S) isomers and 0.15 
(1R,1’S)/(1S,1’R) isomers) gave the title compounds as white solids.  
(1R,1’R)/(1S,1’S) isomers:  
yield: 137 mg, 0.172 mmol, 35%, white solid  
mp: 108.5 – 114.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.96 (d, J = 1.4 Hz, 1H, 12-H), 6.81 – 6.77 (m, 2H, 
14'-H and 10'-H), 6.68 (s, 1H, 5'-H), 6.58 (s, 1H, 10-H), 6.57 – 6.54 (m, 2H, 13'-H and 11'-H), 
6.52 (s, 1H, 5-H), 6.22 (s, 1H, 8'-H), 5.33 (d, J = 9.5 Hz, 1H, 1-H), 5.02 (t, J = 6.4 Hz, 1H, 1'-
H), 4.58 (s, 1H, OH), 4.11 – 4.05 (m, 1H, 3-H), 4.01 (q, J = 7.0 Hz, 2H, 'OCH2-CH3), 3.94 – 
3.81 (m, 3H, 3'-H, OCH2-CH3), 3.87 (s, 3H, 6'-OCH3), 3.85 (s, 3H, 6-OCH3), 3.61 (s, 3H, 7-
OCH3), 3.31 (dd, J = 15.2, 3.7 Hz, 1H, α-H), 3.29 – 3.12 (m, 2H, 3-H, 3'-H), 3.01 (dd, J = 15.1, 
9.3 Hz, 1H, α-H), 2.84 (dd, J = 9.1, 6.5 Hz, 1H, α'-H), 2.91 – 2.72 (m, 3H, 4-H, 4'-H, α'-H), 2.56 
(ddd, J = 20.0, 11.4, 3.9 Hz, 2H, 4-H, 4'-H), 1.14 (t, J = 7.0 Hz, 3H, 'OCH2-CH3), 1.01 (br s, 3H, 
OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 (C=O or C=O'), 155.4 (C=O or C=O'), 154.2 
(C-12'), 152.8 (C-6), 148.4 (C-6'), 146.0 (C-7'), 142.6 (C-9), 140.8 (C-7), 130.6 (C-14' and C-
10'), 130.4 (C-9'), 129.3 (C-8a'), 128.6 (C-10), 123.1 (C-8a), 121.3 (C-12), 115.4 (C-13' and C-
11'), 114.4 (C-8'), 113.5 (C-5'), 110.0 (C-5), 108.9 (C-11), 61.3 (OCH2-CH3), 61.2 ('OCH2-CH3), 
60.7 (7-OCH3), 56.6 (6-OCH3 or 6'-OCH3), 56.5 (6-OCH3 or 6'-OCH3), 55.9 (C-1'), 51.9 (C-1), 
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42.1 (C-α'), 38.7 (C-3'), 37.6 (C-3), 34.6 (C-α), 28.3 (C-4'), 27.9 (C-4), 14.6 ('OCH2-CH3), 14.3 
(OCH2-CH3). The resonances of C-8, C-4a and C-4a' could not be identified.  
IR (ATR): ṽ [cm-1] = 2927, 2843, 1667, 1513, 1422, 1331, 1222, 1109, 1023, 821, 764 
Purity (HPLC, method c) = 93% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C39H4379BrN2O9S - H]- 793.1800, found: 793.1829 
 
(1R,1’S)/(1S,1’R) isomers:  
yield: 130 mg, 0.163 mmol, 33%, white solid 
mp: 110.0 – 119.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.98 (d, J = 1.4 Hz, 1H, 12-H), 6.80 – 6.76 (m, 2H, 
14'-H, 10'-H), 6.68 (s, 1H, 5'-H), 6.62 (s, 1H, 10-H), 6.59 – 6.54 (m, 2H, 13'-H and 11'-H), 6.50 
(s, 1H, 5-H), 6.11 (s, 1H, 8'-H), 5.29 (d, J = 7.0 Hz, 1H, 1-H), 4.99 (t, J = 6.6 Hz, 1H, 1'-H), 4.02 
(q, J = 7.2 Hz, 3H, 3'-H, 'OCH2-CH3), 4.00 – 3.88 (m, 3H, 3-H, OCH2-CH3), 3.86 (s, 3H, 6'-
OCH3), 3.83 (s, 3H, 6-OCH3), 3.58 (s, 3H, 7-OCH3), 3.45 (dd, J = 15.2, 3.9 Hz, 1H, α-H), 3.35 
– 3.20 (m, 2H, 3-H, 3'-H), 3.08 (dd, J = 15.1, 8.9 Hz, 1H, α-H), 2.93 – 2.81 (m, 2H, 4'-H, α'-H), 
2.77 (dd, J = 13.9, 7.0 Hz, 2H, 4-H, α'-H), 2.63 – 2.51 (m, 2H, 4-H, 4'-H), 1.16 (t, J = 7.1 Hz, 
3H, 'OCH2-CH3), 1.07 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.7 (C=O or C=O'), 155.5 (C=O or C=O'), 154.3 
(C-12'), 152.8 (C-6), 148.3 (C-6'), 145.7 (C-7'), 142.6 (C-9), 140.7 (C-7), 130.6 (C-14' and C-
10'), 130.4 (C-9'), 129.2 (C-8a'), 128.7 (C-10), 122.6 (C-8a), 121.3 (C-12), 115.3 (C-13' and C-
11'), 114.6 (C-8'), 113.4 (C-5'), 109.7 (C-5), 108.9 (C-11), 61.4 (OCH2-CH3), 61.2 ('OCH2-CH3), 
60.7 (7-OCH3), 56.5 (6-OCH3 and 6'-OCH3), 56.1 (C-1'), 52.0 (C-1), 42.2 (C-α'), 38.9 (C-3), 
38.0 (C-3'), 34.6 (C-α), 28.3 (C-4'), 28.0 (C-4), 14.6 ('OCH2-CH3), 14.5 (OCH2-CH3). The 
resonances of C-8, C-4a and C-4a' could not be identified.  
IR (ATR): ṽ [cm-1] = 2936, 1690, 1511, 1421, 1221, 1099, 1022, 819,764 
Purity (HPLC, method c) = 95% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C39H4379BrN2O9S - H]- 793.1800, found: 793.1829 
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(±)-8-((1-(4-Hydroxybenzyl)-N-(ethoxycarbonyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinolin-7-yl)oxy)-N-ethoxycarbonyl-6,7-dimethoxy-1-(3’-bromo-4’-
chlorobenzyl)-1,2,3,4-tetrahydroisoquinoline (84; separable mixture of racemic 
diastereomers) 
 
 
 
 
C41H44BrClN2O9 
MW = 822.19 g/mol 
Carbamate 66 (350 mg, 0.575 mmol) and enol ether 73 (171 mg, 0.695 mmol) were condensed 
following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) using TfOH as 
catalyst. The reaction was completed after 12 h. Purification by flash column chromatography 
(15% ethyl acetate in dichloromethane, Rf = 0.09 (1R,1’R)/(1S,1’S) isomers and 0.13 
(1R,1’S)/(1S,1’R) isomers) gave the title compounds as a white solids.  
(1R,1’R)/(1S,1’S) isomers:  
yield: 128 mg, 0.155 mmol, 27%, white solid  
mp: 84.0 – 88.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.28 (d, J = 2.0 Hz, 1H, 10-H), 7.24 (d, J = 8.2 Hz, 
1H, 13-H), 6.91 (dd, J = 8.1, 2.0 Hz, 1H, 14-H), 6.81 – 6.76 (m, 2H, 14'-H and 10'-H), 6.70 (s, 
1H, 5'-H), 6.57 – 6.52 (m, 2H, 13'-H and 11'-H), 6.54 (s, 1H, 5-H), 6.19 (s, 1H, 8'-H), 5.34 – 
5.27 (m, 1H, 1-H), 5.02 (t, J = 6.3 Hz, 1H, 1'-H), 4.66 (s, 1H, OH), 4.15 – 4.04 (m, 1H, 3-H), 
4.00 (q, J = 6.9 Hz, 2H, 'OCH2-CH3), 3.89 (s, 3H, 6'-OCH3), 3.85 (s, 3H, 6-OCH3), 3.93 – 3.74 
(m, 3H, OCH2-CH3, 3'-H), 3.62 (s, 3H, 7-OCH3), 3.37 – 3.26 (m, 1H, 3-H), 3.24 – 3.13 (m, 2H, 
3'-H), 3.07 (dd, J = 14.0, 3.8 Hz, 1H, α-H), 2.92 – 2.73 (m, 5H, 4-H, α-H, 4'-H, α'-H), 2.61 (d, J 
= 14.5 Hz, 1H, 4-H), 2.54 (dt, J = 16.1, 4.5 Hz, 1H, 4'-H), 1.14 (t, J = 7.0 Hz, 3H, 'OCH2-CH3), 
0.90 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.4 (C=O or C=O'), 155.3 (C=O or C=O'), 154.2 
(C-12'), 152.7 (C-6), 148.2 (C-6'), 145.8 (C-7'), 140.9 (C-7), 139.7 (C-9), 134.6 (C-10), 132.1 
(C-12), 130.5 (C-14' and C-10'), 130.5 (C-9'), 129.7 (C-13 or C-14), 129.6 (C-13 or C-14), 129.2 
(C-8a'), 128.6 (C-4a'), 123.5 (C-8a), 121.8 (C-11), 115.4 (C-13' and C-11'), 114.1 (C-8'), 113.4 
(C-5'), 110.1 (C-5), 61.2 (OCH2-CH3 and 'OCH2-CH3), 60.7 (7-OCH3), 56.7 (6-OCH3), 56.6 (6'-
OCH3), 55.9 (C-1'), 51.9 (C-1), 42.1 (C-α'), 39.6 (C-α), 38.8 (C-3'), 37.5 (C-3), 28.3 (C-4'), 27.9 
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(C-4), 14.6 ('OCH2-CH3), 14.2 (OCH2-CH3). The resonances of C-8 and C-4a could not be 
identified.  
IR (ATR): ṽ [cm-1] = 3174, 1689, 1509, 1419, 1201, 1097, 1021, 762  
Purity (HPLC, method c) = 89% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C41H4479Br35ClN2O9 - H]- 821.1846, found: 821.1851 
 
(1R,1’S)/(1S,1’R) isomers:  
yield:  122 mg, 0.150 mmol, 26%, white solid  
mp: 106.5 – 108.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.34 (d, J = 2.0 Hz, 1H, 10-H), 7.25 (d, J = 8.1 Hz, 
1H, 13-H), 6.95 (dd, J = 8.2, 2.0 Hz, 1H, 14-H), 6.80 – 6.75 (m, 2H, 14'-H and 10'-H), 6.69 (s, 
1H, 5'-H), 6.58 – 6.53 (m, 2H, 13'-H and 11'-H), 6.51 (s, 1H, 5-H), 6.08 (s, 1H, 8'-H), 5.28 (d, J 
= 8.5 Hz, 1H, 1-H), 4.98 (t, J = 6.7 Hz, 1H, 1'-H), 4.02 (q, J = 6.9 Hz, 3H, 3'-H, 'OCH2-CH3), 
3.88 (s, 3H, 6'-OCH3), 3.87 (ddd, J = 25.0, 16.3, 5.2 Hz, 3H, 3-H, OCH2-CH3), 3.83 (s, 3H, 6-
OCH3), 3.58 (s, 3H, 7-OCH3), 3.36 (ddd, J = 13.2, 9.9, 4.7 Hz, 1H, 3'-H), 3.28 – 3.22 (m, 1H, 
3-H), 3.20 (dd, J = 13.8, 4.1 Hz, 1H, α-H), 2.93 – 2.83 (m, 3H, α-H, 4'-H, α'-H), 2.82 – 2.73 (m, 
2H, 4-H, α'-H), 2.63 – 2.54 (m, 2H, 4-H, 4'-H), 1.15 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.99 (br s, 
3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.5 (C=O), 155.5 (C=O'), 154.4 (C-12'), 152.7 
(C-6), 148.2 (C-6'), 145.6 (C-7'), 140.7 (C-7), 139.7 (C-9), 134.7 (C-10), 132.1 (C-12), 130.6 
(C-14' and C-10'), 130.4 (C-9'), 129.7 (C-14), 129.7 (C-13), 129.2 (C-8a'), 128.5 (C-4a'), 123.1 
(C-8a), 121.8 (C-11), 115.3 (C-13' and C-11'), 114.4 (C-8'), 113.3 (C-5'), 109.8 (C-5), 61.3 
(OCH2-CH3), 61.2 ('OCH2-CH3), 60.7 (7-OCH3), 56.6 (6-OCH3 and 6'-OCH3), 56.1 (C-1'), 52.0 
(C-1), 42.2 (C-α'), 39.8 (C-α), 38.8 (C-3), 38.0 (C-3'), 28.3 (C-4'), 28.1 (C-4), 14.6 ('OCH2-CH3), 
14.3 (OCH2-CH3). The resonances of C-8 and C-4a could not be identified.  
IR (ATR): ṽ [cm-1] = 3355, 2841, 1689, 1668, 1514, 1424, 1331, 1203, 1110, 1023, 765  
Purity (HPLC, method c) = 95% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C41H4479Br35ClN2O9  - H]- 821.1846, found: 821.1852 
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(±)-8-((1-(4-Hydroxybenzyl)-N-(ethoxycarbonyl)-6-methoxy-1,2,3,4-
tetrahydroisoquinolin-7-yl)oxy)-N-ethoxycarbonyl-6,7-dimethoxy-1-(4-bromobutyl)-
1,2,3,4-tetrahydroisoquinoline (85; separable mixture of racemic diastereomers) 
 
 
 
 
 
C38H47BrN2O9 
MW = 754.25 g/mol 
Carbamate 66 (300 mg, 0.493 mmol) and aldehyde 79 (98 mg, 0.591 mmol) were condensed 
following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) using TfOH as 
catalyst. The reaction was completed after 12 h. Purification by flash column chromatography 
(15% ethyl acetate in dichloromethane, Rf = 0.10 (precursor of RMS10) and 0.16 (precursor of 
RMS9) gave the title compounds as a white solids.  
Precursor of RMS10:  
yield: 133 mg, 0.178 mmol, 36%, white solid  
mp: 77.5 – 78.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.80 – 6.75 (m, 2H, 14'-H and 10'-H), 6.65 (s, 1H, 
5'-H), 6.62 – 6.58 (m, 2H, 13'-H and 11'-H), 6.52 (s, 1H, 5-H), 6.19 (s, 1H, 8'-H), 5.12 (s, 1H, 
1-H), 5.02 (t, J = 6.5 Hz, 1H, 1'-H), 4.14 – 3.94 (m, 6H, 3-H, 3'-H, 'OCH2-CH3, OCH2-CH3), 3.86 
(s, 3H, 6'-OCH3), 3.82 (s, 3H, 6-OCH3), 3.58 (s, 3H, 7-OCH3), 3.27 (t, J = 6.9 Hz, 2H, 4''-H), 
3.26 – 3.20 (m, 1H, 3-H), 3.16 (ddd, J = 13.5, 9.7, 4.4 Hz, 1H, 3'-H), 2.93 – 2.84 (m, 1H, 4-H), 
2.82 (t, J = 5.5 Hz, 1H, α'-H), 2.78 – 2.72 (m, 1H, 4'-H), 2.68 (dt, J = 16.5, 4.5 Hz, 1H, 4-H), 
2.51 (dt, J = 16.0, 4.6 Hz, 1H, 4'-H), 1.86 – 1.68 (m, 3H, 1''-H, 3''-H), 1.68 – 1.56 (m, 1H, 1''-
H), 1.47 – 1.38 (m, 2H, 2''-H), 1.13 (t, J = 7.0 Hz, 6H, 'OCH2-CH3 and OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.7 ('C=O), 155.4 (C=O), 154.5 (C-12'), 152.4 
(C-6), 148.2 (C-6'), 146.3 (C-7'), 145.1 (C-8), 140.6 (C-7), 130.4 (C-14' and C-10'), 130.1 (C-
9'), 129.6 (C-8a'), 129.3 (C-4a), 128.3 (C-4a'), 125.1 (C-8a), 115.4 (C-13' and C-11'), 114.2 (C-
8'), 113.6 (C-5'), 110.2 (C-5), 61.2 ('OCH2-CH3 or OCH2-CH3), 61.1 ('OCH2-CH3 or OCH2-CH3), 
60.6 (7-OCH3), 56.7 (6-OCH3 or 6'-OCH3), 56.6 (6-OCH3 or 6'-OCH3), 55.8 (C-1'), 50.1 (C-1), 
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42.1 (C-α'), 38.6 (C-3'), 37.4 (C-3), 33.7 (C-1''), 33.6 (C-4''), 32.3 (C-3''), 28.2 (C-4'), 27.8 (C-
4), 24.9 (C-2''), 14.6 ('OCH2-CH3), 14.5 (OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 2928, 2854, 2605, 2498, 1692, 1513, 1426, 1331, 1234, 1100, 1026, 767  
Purity (HPLC, method c) = 95% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C38H4779BrN2O9 + H]+ 755.2538, found: 755.2548 
 
Precursor of RMS9: 
yield: 85.5 mg, 0.113 mmol, 23%, white solid  
mp: 200.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.81 – 6.75 (m, 2H, 14'-H and 10'-H), 6.66 (s, 1H, 
5'-H), 6.60 – 6.55 (m, 2H, 13'-H and 11'-H), 6.49 (s, 1H, 5-H), 6.10 (s, 1H, 8'-H), 5.15 – 5.07 
(m, 1H, 1-H), 4.97 (t, J = 6.6 Hz, 1H, 1'-H), 4.16 – 3.97 (m, 6H, 3-H, 3'-H, 'OCH2-CH3, OCH2-
CH3), 3.85 (s, 3H, 6'-OCH3), 3.81 (s, 3H, 6-OCH3), 3.56 (s, 3H, 7-OCH3), 3.33 (t, J = 6.9 Hz, 
2H, 4''-H), 3.30 – 3.20 (m, 2H, 3-H, 3'-H), 2.96 – 2.85 (m, 2H, 4-H, α'-H), 2.84 – 2.74 (m, 2H, 
4'-H, α'-H), 2.69 (dt, J = 16.2, 4.4 Hz, 1H, 4-H), 2.57 (dt, J = 15.5, 4.4 Hz, 1H, 4'-H), 1.91 – 
1.78 (m, 3H, 1''-H, 3''-H), 1.73 – 1.61 (m, 1H, 1''-H), 1.51 – 1.40 (m, 2H, 2''-H), 1.21 – 1.12 (m, 
6H, 'OCH2-CH3 and OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.9 (C=O or C=O'), 155.5 (C=O or C=O'), 154.4 
(C-12'), 152.4 (C-6), 148.4 (C-6'), 146.1 (C-7'), 145.3 (C-8), 140.5 (C-7), 130.6 (C-14' and C-
10'), 130.4 (C-9'), 129.6 (C-8a'), 124.7 (C-8a), 115.3 (C-13' and C-11'), 114.7 (C-8'), 113.5 (C-
5'), 109.8 (C-5), 61.3 ('OCH2-CH3 or OCH2-CH3), 61.2 ('OCH2-CH3 or OCH2-CH3), 60.6 (7-
OCH3), 56.7 (6-OCH3 or 6'-OCH3), 56.5 (6-OCH3 or 6'-OCH3), 56.1 (C-1'), 50.3 (C-1), 42.2 (C-
α'), 38.9 (C-3'), 37.8 (C-3), 33.9 (C-1''), 33.6 (C-4''), 32.5 (C-3''), 28.3 (C-4'), 28.1 (C-4), 25.0 
(C-2''), 14.6 ('OCH2-CH3 and OCH2-CH3). The resonances of C-4a and C-4a' could not be 
identified.  
IR (ATR): ṽ [cm-1] = 2927, 2851, 1690, 1611, 1513, 1427, 1332, 1233, 1100, 1023, 806, 761  
Purity (HPLC, method c) = 93% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C38H4779BrN2O9 + H]+ 755.2538, found: 755.2558 
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(±)-N,N'-Bis-(ethoxycarbonyl)-12-desmethoxy-bisnortetrandrine and –isotetrandrine 
(86)  
 
 
 
 
 
C41H44N2O9 
MW = 708.31 g/mol 
Previously separated diastereomers of bisbenzylisoquinoline 80 (50.0 mg, 0.0633 mmol of 
each diastereomer) were reacted following General Procedure 3 (intramolecular Ullmann 
coupling). The reactions were completed after 42 h. Purification was accomplished by flash 
column chromatography (30% acetone in hexanes, Rf = 0.18) and the products obtained as 
beige solids. 
(1R,1’R)/(1S,1’S) isomers:  
yield: 34.6 mg, 0.0488 mmol, 77%, beige solid  
mp: 83.0 – 83.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.39 (d, J = 8.4 Hz, 1H, 10'-H or 14'-H), 7.14 (t, J = 
7.8 Hz, 1H, 13-H), 7.10 (dd, J = 8.1, 2.5 Hz, 1H, 11'-H or 13'-H), 6.97 (dd, J = 8.1, 2.5 Hz, 1H, 
12-H), 6.64 (s, 1H, 5'-H), 6.70 – 6.60 (m, 2H, 11'-H or 13'-H, 14-H), 6.48 (t, J = 1.9 Hz, 1H, 10-
H), 6.33 (s, 1H, 5-H), 6.22 – 6.16 (m, 1H, 10'-H or 14'-H), 6.18 (s, 1H, 8'-H), 5.31 (dd, J = 8.1, 
3.6 Hz, 1H, 1-H), 5.05 (d, J = 10.4 Hz, 1H, 1'-H), 4.36 – 4.21 (m, 3H, 'OCH2-CH3, 3-H), 3.99 
(ddd, J = 12.2, 5.7, 3.5 Hz, 1H, 3'-H), 3.86 – 3.76 (m, 2H, OCH2-CH3), 3.74 (s, 3H, 6-OCH3), 
3.49 (dd, J = 13.5, 5.0 Hz, 1H, α'-H), 3.41 (td, J = 11.7, 4.8 Hz, 2H, 3'-H, 3-H), 3.34 (s, 3H, 6'-
OCH3), 3.26 (s, 3H, 7-OCH3), 3.19 – 3.08 (m, 1H, 4'-H), 2.95 – 2.80 (m, 2H, 4'-H, 4-H), 2.80 – 
2.72 (m, 2H, α-H), 2.71 – 2.59 (m, 2H, α'-H, 4-H), 1.36 (t, J = 6.8 Hz, 3H, 'OCH2-CH3), 0.89 (br 
s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 160.3 (C-11), 155.9 (C=O or 'C=O), 155.6 (C=O 
or 'C=O), 154.2 (C-12'), 152.1 (C-6), 149.1 (C-6'), 147.0 (C-8), 144.9 (C-7'), 142.0 (C-9), 138.9 
(C-7), 134.6 (C-9'), 132.2 (C-10' or C-14'), 130.1 (C-10' or C-14'), 129.1 (C-13), 128.8 (C-8a'), 
128.2 (C-4a'), 122.9 (C-8a), 122.2 (C-14), 122.0 (C-11' or C-13'), 121.6 (C-11' or C-13'), 119.7 
(C-8'), 115.4 (C-10, C-12), 114.0 (C-5'), 107.3 (C-5), 61.4 ('OCH2-CH3), 60.7 (OCH2-CH3), 60.3 
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(7-OCH3), 57.7 (C-1'), 57.0 (6'-OCH3), 56.3 (6-OCH3), 53.5 (C-1), 42.0 (C-α'), 3', 41.6 (C-α), 
36.6 (C-3), 28.0 (C-4), 27.9 (C-4'), 14.8 (OCH2-CH3, 'OCH2-CH3). The resonance of C-4a could 
not be identified.  
IR (ATR): ṽ [cm-1] = 2925, 2854, 1691, 1586, 1506, 1417, 1332, 1278, 1211, 1107, 1025, 839, 
765  
Purity (HPLC, method e) = > 99% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C41H44N2O9 + H]+ 709.3120, found: 709.3125 
 
(1R,1’S)/(1S,1’R) isomers:  
yield: 18 mg, 0.0254 mmol, 40%, beige solid  
mp: 92.0 – 93.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.36 (d, J = 8.2 Hz, 1H, 10'-H or 14'-H), 7.11 (t, J = 
7.8 Hz, 1H, 13-H), 7.05 (d, J = 7.2 Hz, 1H, 11'-H or 13'-H), 6.94 (dd, J = 8.2, 2.5 Hz, 1H, 12-
H), 6.64 (s, 1H, 5'-H), 6.66 – 6.60 (m, 2H, 11'-H or 13'-H, 14-H), 6.40 – 6.32 (m, 2H, 10-H, 10'-
H or 14'-H), 6.28 (s, 1H, 5-H), 6.20 (s, 1H, 8'-H), 5.29 (d, J = 9.4 Hz, 1H, 1-H), 5.11 (dd, J = 
9.8, 6.5 Hz, 1H, 1'-H), 4.29 – 4.15 (m, 3H, 'OCH2-CH3, 3-H), 3.97 – 3.89 (m, 1H, 3'-H), 3.88 – 
3.76 (m, 2H, OCH2-CH3), 3.73 (s, 3H, 6-OCH3), 3.60 (s, 3H, 6'-OCH3), 3.57 – 3.51 (m, 1H, α'-
H), 3.49 – 3.41 (m, 1H, 3'-H), 3.37 – 3.27 (m, 1H, 3-H), 3.21 – 3.14 (m, 2H, α-H, 4'-H), 3.16 (s, 
3H, 7-OCH3), 2.88 – 2.76 (m, 2H, 4'-H, 4-H), 2.71 (dd, J = 12.8, 10.5 Hz, 1H, α'-H), 2.62 (dd, 
J = 13.7, 9.6 Hz, 1H, α-H), 2.53 – 2.42 (m, 1H, 4-H), 1.33 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.96 
(br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 160.4 (C-11), 155.8, 155.4 ('C=O, C=O), 154.3 
(C-12'), 152.5 (C-6), 150.1 (C-6'), 144.4 (C-7'), 142.4 (C-9), 137.9 (C-7), 134.7 (C-9'), 131.5 
(C-10' or C-14'), 130.5 (C-4a'), 130.0 (C-10' or C-14'), 128.9 (C-13), 128.3 (C-8a'), 122.4 (C-
14), 122.0 (C-11', C-13'), 120.6 (C-8a), 119.6 (C-8'), 115.8 (C-10), 115.4 (C-12), 111.8 (C-5'), 
106.8 (C-5), 61.3 ('OCH2-CH3), 60.9 (OCH2-CH3), 60.5 (7-OCH3), 57.0 (C-1'), 56.3 (6-OCH3), 
56.1 (6'-OCH3), 54.2 (C-1), 41.8 (C-α'), 41.5 (C-3'), 39.6 (C-α), 36.8 (C-3), 28.2 (C-4), 28.1 (C-
4'), 14.8 ('OCH2-CH3), 14.2 (OCH2-CH3). The resonances of C-4a and C-8 could not be 
identified.  
IR (ATR): ṽ [cm-1] = 2924, 1693, 1584, 1507, 1418, 1330, 1276, 1208, 1099, 1022, 837, 769  
Purity (HPLC, method e) = 88% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C41H44N2O9 + H]+ 709.3120, found: 709.3121 
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(±)-N,N'-Bis-(ethoxycarbonyl)-12-desmethoxy-12-trifluoromethoxy-bisnortetrandrine 
and –isotetrandrine (87) 
 
 
 
 
C42H43F3N2O10 
MW = 792.29 g/mol 
Previously separated diastereomers of bisbenzylisoquinoline 81 (60.0 mg, 0.0687 mmol of 
each diastereomer) were reacted following General Procedure 3 (intramolecular Ullmann 
coupling). The reactions were completed after 30 h. Purification was accomplished by flash 
column chromatography (25% acetone in hexanes, Rf = 0.23) and the products obtained as 
beige solids. 
(1R,1’R)/(1S,1’S) isomers:  
yield: 35.0 mg, 0.0441 mmol, 64%, beige solid  
mp: 77.5 – 78.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.41 (d, J = 8.4 Hz, 1H, 10'-H or 14'-H), 7.15 – 7.07 
(m, 2H, 13-H and 11'-H or 13'-H), 6.68 – 6.64 (m, 1H, 11'-H or 13'-H), 6.65 (s, 1H, 5'-H), 6.62 
(dd, J = 8.1, 2.0 Hz, 1H, 14-H), 6.59 (d, J = 1.9 Hz, 1H, 10-H), 6.33 (s, 1H, 5-H), 6.22 (dd, J = 
8.3, 2.2 Hz, 1H, 10'-H or 14'-H), 6.17 (s, 1H, 8'-H), 5.29 (dd, J = 7.9, 2.8 Hz, 1H, 1-H), 5.05 (s, 
1H, 1'-H), 4.37 – 4.27 (m, 1H, 3-H), 4.26 (q, J = 7.2 Hz, 2H, 'OCH2-CH3), 4.00 (ddd, J = 12.2, 
5.7, 3.5 Hz, 1H, 3'-H), 3.87 – 3.76 (m, 2H, OCH2-CH3), 3.74 (s, 3H, 6-OCH3), 3.51 (d, J = 8.5 
Hz, 1H, α'-H), 3.41 (td, J = 11.8, 4.9 Hz, 2H, 3'-H, 3-H), 3.34 (s, 3H, 6'-OCH3), 3.26 (s, 3H, 7-
OCH3), 3.15 (td, J = 11.3, 10.8, 5.6 Hz, 1H, 4'-H), 2.94 – 2.84 (m, 1H, 4-H), 2.84 – 2.72 (m, 
3H, α-H, 4'-H), 2.73 – 2.61 (m, 2H, α'-H, 4-H), 1.36 (t, J = 6.2 Hz, 3H, 'OCH2-CH3), 0.87 (br s, 
3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.9 ('C=O), 155.5 (C=O), 153.5 (C-12'), 152.3 
(C-6), 152.2 (C-11), 149.1 (C-6'), 147.0 (C-8), 144.8 (C-7'), 140.8 (C-9), 138.9 (C-7), 136.6 (q, 
J = 1.8 Hz, C-12), 135.3 (C-9'), 132.3, 130.3 (C-10', C-14'), 130.2 (C-4a'), 128.7 (C-8a'), 122.5 
(C-13), 122.5 (C-8a), 122.0 (C-14), 121.9, 121.3 (C-11', C-13'), 119.6 (C-8'), 117.4 (C-10), 
113.9 (C-5'), 107.4 (C-5), 61.4 ('OCH2-CH3), 60.8 (OCH2-CH3), 60.3 (7-OCH3), 57.6 (C-1'), 56.9 
(6'-OCH3), 56.3 (6-OCH3), 53.4 (C-1), 42.0 (C-α', C-3'), 41.1 (C-α), 36.6 (C-3), 27.9 (C-4), 27.8 
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(C-4'), 14.8 ('OCH2-CH3), 14.0 (OCH2-CH3). The resonances of C-4a and OCF3 could not be 
identified.  
IR (ATR): ṽ [cm-1] = 1693, 1505, 1423, 1281, 1248, 1201, 1110, 1024, 842, 767  
Purity (HPLC, method b) = 96% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H43F3N2O10 + H]+ 793.2943, found: 793.2955 
 
(1R,1’S)/(1S,1’R) isomers:  
yield: 15.0 mg, 0.0189 mmol, 28%, beige solid 
mp: 73.5 – 74.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.38 (d, J = 8.0 Hz, 1H, 10'-H or 14'-H), 7.11 – 7.05 
(m, 2H, 11'-H or 13'-H, 13-H), 6.64 (s, 1H, 5'-H), 6.62 (dt, J = 8.3, 2.6 Hz, 2H, 11'-H or 13'-H, 
14-H), 6.47 (s, 1H, 10-H), 6.39 (d, J = 8.4 Hz, 1H, 10'-H or 14'-H), 6.29 (s, 1H, 5-H), 6.19 (s, 
1H, 8'-H), 5.26 (d, J = 9.4 Hz, 1H, 1-H), 5.12 (q, J = 7.5 Hz, 1H, 1'-H), 4.29 – 4.15 (m, 3H, 
'OCH2-CH3, 3-H), 3.99 – 3.88 (m, 1H, 3'-H), 3.88 – 3.76 (m, 2H, OCH2-CH3), 3.73 (s, 3H, 6-
OCH3), 3.60 (s, 3H, 6'-OCH3), 3.58 – 3.52 (m, 1H, α'-H), 3.45 (td, J = 11.5, 4.9 Hz, 1H, 3'-H), 
3.35 – 3.25 (m, 1H, 3-H), 3.22 – 3.10 (m, 2H, α-H, 4'-H), 3.16 (s, 3H, 7-OCH3), 2.86 – 2.73 (m, 
2H, 4'-H, 4-H), 2.72 (dd, J = 12.8, 10.6 Hz, 1H, α'-H), 2.61 (dd, J = 13.8, 9.7 Hz, 1H, α-H), 2.50 
(d, J = 16.3 Hz, 1H, 4-H), 1.34 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.98 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.8, 155.3 ('C=O, C=O), 153.8 (C-12'), 152.6 
(C-6), 152.3 (C-11), 150.1 (C-6'), 144.3 (C-7'), 141.1 (C-9), 138.0 (C-7), 136.7 (C-12), 135.4 
(C-9'), 131.7, 130.7 (C-10', C-14'), 128.2 (C-8a'), 122.2 (C-11' or C-13' or C-13, C-14), 121.7 
(C-11' or C-13' or C-13), 120.5 (C-8a), 119.6 (C-8'), 117.9 (C-10), 111.8 (C-5'), 106.9 (C-5), 
61.4 ('OCH2-CH3), 61.0 (OCH2-CH3), 60.5 (7-OCH3), 56.9 (C-1'), 56.3 (6-OCH3), 56.0 (6'-
OCH3), 54.1 (C-1), 41.8 (C-α', C-3'), 39.3 (C-α), 36.9 (C-3), 28.2 (C-4), 28.1 (C-4'), 14.8 ('OCH2-
CH3), 14.2 (OCH2-CH3)  
IR (ATR): ṽ [cm-1] = 1694, 1506, 1420, 1273, 1248, 1200, 1099, 1021, 841, 770  
Purity (HPLC, method e) = 95% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C42H43F3N2O10 + H]+ 793.2943, found: 793.2955 
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(±)-N,N'-Bis-(ethoxycarbonyl) ring C-thiophene analogues of bisnortetrandrine and –
isotetrandrine (89) 
 
 
 
 
C39H42N2O9S 
MW = 714.26 g/mol 
Previously separated diastereomers of bisbenzylisoquinoline 83 (100 mg, 0.126 mmol of each 
diastereomer) were reacted following General Procedure 3 (intramolecular Ullmann coupling). 
The reactions were completed after 70 h. Purification was accomplished by flash column 
chromatography (25% acetone in hexanes, Rf = 0.17) and the products obtained as white 
solids. 
(1R,1’R)/(1S,1’S) isomers:  
yield: 51.3 mg, 0.0718 mmol, 57%, white solid  
mp: 74.5 – 76.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.35 (d, J = 8.2 Hz, 1H, 14'-H or 10'-H), 7.13 (dd, J 
= 8.2, 2.5 Hz, 1H, 13'-H or 11'-H), 6.70 (d, J = 5.8 Hz, 1H, 13'-H or 11'-H), 6.60 (s, 1H, 5'-H), 
6.41 (d, J = 1.7 Hz, 1H, 12-H), 6.34 (s, 1H, 5-H), 6.28 (s, 1H, 10-H), 6.19 (dd, J = 8.3, 2.2 Hz, 
1H, 14'-H or 10'-H), 6.01 (s, 1H, 8'-H), 5.45 (d, J = 6.8 Hz, 1H, 1-H), 5.00 (s, 1H, 1'-H), 4.30 – 
4.19 (m, 2H, 'OCH2-CH3), 4.11 – 4.02 (m, 1H, 3-H), 4.01 – 3.88 (m, 3H, 3'-H, OCH2-CH3), 3.73 
(s, 3H, 6-OCH3), 3.50 – 3.37 (m, 3H, 3-H, 3'-H, α'-H), 3.32 (s, 3H, 6'-OCH3), 3.22 (s, 3H, 7-
OCH3), 3.15 – 3.04 (m, 1H, 4'-H), 3.00 (dd, J = 15.2, 2.6 Hz, 1H, α-H), 2.91 – 2.75 (m, 3H, 4-
H, α-H, 4'-H), 2.69 (dt, J = 16.1, 4.9 Hz, 1H, 4-H), 2.63 (d, J = 11.8 Hz, 1H, α'-H), 1.35 (t, J = 
7.1 Hz, 3H, 'OCH2-CH3), 1.06 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 157.0 (C-12'), 152.3 (C-6), 149.3 (C-6'), 144.9 (C-
7'), 141.5 (C-9), 139.2 (C-7), 134.4 (C-9'), 132.1 (C-14' or C-10'), 130.3 (C-4a'), 129.8 (C-14' 
or C-10'), 128.6 (C-8a'), 123.5 (C-8a), 121.0 (C-13' and C-11'), 120.2 (C-8'), 118.2 (C-10), 
113.7 (C-5'), 107.3 (C-5), 101.1 (C-12), 61.4 ('OCH2-CH3), 61.1 (OCH2-CH3), 60.2 (7-OCH3), 
57.7 (C-1'), 56.6 (6'-OCH3), 56.3 (6-OCH3), 54.2 (C-1), 41.6 (C-3' and C-α'), 38.5 (C-α), 38.2 
(C-3), 28.0 (C-4), 27.9 (C-4'), 14.8 ('OCH2-CH3), 14.4 (OCH2-CH3). The resonances of 'C=O, 
C=O, C-8, C-4a and C-11 could not be identified.  
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IR (ATR): ṽ [cm-1] = 2929, 1693, 1558, 1505, 1416, 1277, 1219, 1101, 1020, 875, 770  
Purity (HPLC, method c) = 95% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C39H42N2O9S + H]+ 715.2684, found: 715.2686 
 
(1R,1’S)/(1S,1’R) isomers:  
yield: 15.3 mg, 0.0214 mmol, 17%, white solid  
mp: 116.0 – 119.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.31 (dd, J = 8.2, 2.2 Hz, 1H, 14'-H or 10'-H), 7.08 
(dd, J = 7.9, 2.2 Hz, 1H, 13'-H or 11'-H), 6.66 (dd, J = 8.3, 2.6 Hz, 1H, 13'-H or 11'-H), 6.62 (s, 
1H, 5'-H), 6.40 (dd, J = 8.2, 2.2 Hz, 1H, 14'-H or 10'-H), 6.31 (d, J = 1.7 Hz, 1H, 10-H), 6.27 (s, 
1H, 5-H), 6.17 (s, 1H, 8'-H), 5.97 (d, J = 1.7 Hz, 1H, 12-H), 5.32 (d, J = 8.0 Hz, 1H, 1-H), 5.11 
(t, J = 8.7 Hz, 1H, 1'-H), 4.29 – 4.19 (m, 3H, 3-H, 'OCH2-CH3), 4.00 – 3.88 (m, 3H, 3'-H, OCH2-
CH3), 3.72 (s, 3H, 6-OCH3), 3.58 (d, J = 6.6 Hz, 1H, α'-H), 3.55 (s, 3H, 6'-OCH3), 3.40 (td, J = 
11.4, 4.9 Hz, 1H, 3'-H), 3.32 (d, J = 15.0 Hz, 1H, α-H), 3.27 – 3.13 (m, 2H, 3-H, 4'-H), 3.12 (s, 
3H, 7-OCH3), 2.86 – 2.70 (m, 3H, 4-H, 4'-H, α'-H), 2.68 – 2.54 (m, 2H, 4-H, α-H), 1.33 (t, J = 
7.0 Hz, 3H, 'OCH2-CH3), 1.09 (br s, 3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 156.8 (C-12'), 155.8 (C=O), 152.6 (C-6), 150.1 (C-
6'), 144.0 (C-7'), 141.8 (C-9), 137.8 (C-7), 134.8 (C-9'), 131.6 (C-14' or C-10'), 129.6 (C-14' or 
C-10'), 128.3 (C-8a'), 122.1 (C-13' or C-11'), 121.3 (C-13' or C-11'), 120.3 (C-8a), 119.8 (C-8'), 
118.0 (C-12), 111.8 (C-5'), 106.7 (C-5), 99.6 (C-10), 61.3 ('OCH2-CH3), 61.2 (OCH2-CH3), 60.5 
(7-OCH3), 57.1 (C-1'), 56.3 (6-OCH3), 56.0 (6'-OCH3), 55.7 (C-1), 41.9 (C-3'), 41.2 (C-α'), 37.2 
(C-3), 35.6 (C-α), 28.1 (C-4), 28.0 (C-4'), 14.8 ('OCH2-CH3), 14.6 (OCH2-CH3). The resonances 
of 'C=O, C-4a', C-4a, C-8, and C-11 could not be identified.  
IR (ATR): ṽ [cm-1] = 2927, 2854, 1694, 1557, 1505, 1417, 1219, 1098, 1022, 842, 770  
Purity (HPLC, method c) = 90% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C39H42N2O9S + H]+ 715.2684, found: 715.2688 
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(±)-N,N'-Bis-(ethoxycarbonyl)-12-desmethoxy-12-chloro-bisnortetrandrine and –
isotetrandrine (90) 
 
 
 
 
C41H43ClN2O9 
MW = 742.27 g/mol 
Previously separated diastereomers of bisbenzylisoquinoline 84 (110 mg, 0.133 mmol of each 
diastereomer) were reacted following General Procedure 3 (intramolecular Ullmann coupling). 
The reactions were completed after 60 h. Purification was accomplished by flash column 
chromatography (25% acetone in hexanes, Rf = 0.15) and the products obtained as a white 
solid. 
(1R,1’R)/(1S,1’S) isomers:  
yield: 48.4 mg, 0.0652 mmol, 49%, white solid 
mp: 50.0 – 56.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.41 (d, J = 8.2 Hz, 1H, 14'-H or 10'-H), 7.21 (d, J 
= 7.9 Hz, 1H, 13-H), 7.13 (dd, J = 8.2, 2.6 Hz, 1H, 13'-H or 11'-H), 6.70 – 6.64 (m, 1H, 13'-H 
or 11'-H), 6.64 (s, 1H, 5'-H), 6.58 (dd, J = 8.0, 1.9 Hz, 1H, 14-H), 6.54 (d, J = 1.8 Hz, 1H, 10-
H), 6.32 (s, 1H, 5-H), 6.21 (dd, J = 8.3, 2.2 Hz, 1H, 14'-H or 10'-H), 6.16 (s, 1H, 8'-H), 5.28 (d, 
J = 6.1 Hz, 1H, 1-H), 5.05 (s, 1H, 1'-H), 4.35 – 4.22 (m, 3H, 3-H, 'OCH2-CH3), 3.99 (ddd, J = 
12.7, 5.7, 3.6 Hz, 1H, 3'-H), 3.87 – 3.76 (m, 2H, OCH2-CH3), 3.73 (s, 3H, 6-OCH3), 3.50 (dd, J 
= 11.9, 5.2 Hz, 1H, α'-H), 3.45 – 3.36 (m, 2H, 3-H, 3'-H), 3.35 (s, 3H, 6'-OCH3), 3.25 (s, 3H, 7-
OCH3), 3.14 (ddd, J = 16.5, 11.2, 5.8 Hz, 1H, 4'-H), 2.93 – 2.77 (m, 2H, 4-H, 4'-H), 2.76 – 2.72 
(m, 2H, α-H), 2.69 – 2.61 (m, 2H, 4-H, α'-H), 1.36 (t, J = 7.0 Hz, 3H, 'OCH2-CH3), 0.88 (br s, 
3H, OCH2-CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.9 (C=O or C=O'), 155.7 (C-11), 155.5 (C=O 
or C=O'), 153.8 (C-12'), 152.1 (C-6), 149.1 (C-6'), 147.0 (C-8), 144.8 (C-7'), 140.6 (C-9), 138.9 
(C-7), 135.2 (C-9'), 132.3 (C-14' or C-10'), 130.2 (C-14' or C-10'), 130.2 (C-4a'), 129.7 (C-13), 
128.7 (C-8a'), 128.2 (C-4a), 122.7 (C-14), 122.5 (C-8a), 121.9 (C-13' or C-11'), 121.4 (C-13' 
or C-11'), 120.3 (C-12), 119.6 (C-8'), 117.0 (C-10), 113.9 (C-5'), 107.4 (C-5), 61.4 ('OCH2-
CH3), 60.8 (OCH2-CH3), 60.3 (7-OCH3), 57.6 (C-1'), 56.9 (6'-OCH3), 56.3 (6-OCH3), 53.4 (C-
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1), 41.9 (C-3' and C-α'), 41.1 (C-α), 36.7 (C-3), 27.9 (C-4 and C-4'), 14.8 ('OCH2-CH3), 14.1 
(OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 2927, 2853, 1692, 1505, 1417, 1277, 1205, 1105, 1023, 840, 765  
Purity (HPLC, method c) = 95% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C41H4335ClN2O9 + H]+ 743.2730, found: 743.2735 
 
(1R,1’S)/(1S,1’R) isomers:  
yield: 54.3 mg, 0.0732 mmol, 55%, white solid  
mp: 113.5 – 118.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.39 (d, J = 8.2 Hz, 1H, 14'-H or 10'-H), 7.18 (d, J 
= 7.9 Hz, 1H, 13-H), 7.09 (dd, J = 8.2, 2.5 Hz, 1H, 13'-H or 11'-H), 6.65 (s, 1H, 5'-H), 6.62 (dd, 
J = 8.4, 2.2 Hz, 2H, 13'-H or 11'-H), 6.58 (dd, J = 8.0, 1.8 Hz, 1H, 14-H), 6.43 – 6.37 (m, 2H, 
10-H, 14'-H or 10'-H), 6.28 (s, 1H, 5-H), 6.18 (s, 1H, 8'-H), 5.25 (d, J = 8.2 Hz, 1H, 1-H), 5.11 
(dd, J = 10.4, 6.2 Hz, 1H, 1'-H), 4.31 – 4.11 (m, 3H, 3, 'OCH2-CH3), 3.99 – 3.88 (m, 1H, 3'-H), 
3.87 – 3.77 (m, 2H, OCH2-CH3), 3.73 (s, 3H, 6-OCH3), 3.60 (s, 3H, 6'-OCH3), 3.55 (dd, J = 
11.8, 5.7 Hz, 1H, α'-H), 3.46 (td, J = 11.5, 4.9 Hz, 1H, 3'-H), 3.30 (td, J = 13.8, 12.9, 4.5 Hz, 
1H, 3-H), 3.16 (s, 3H, 7-OCH3), 3.19 – 3.08 (m, 2H, α-H, 4'-H), 2.82 (dt, J = 15.7, 4.6 Hz, 1H, 
4'-H), 2.80 – 2.74 (m, 1H, 4-H), 2.72 (dd, J = 12.8, 10.6 Hz, 1H, α'-H), 2.63 – 2.54 (m, 1H, α-
H), 2.47 (d, J = 16.8 Hz, 1H, 4-H), 1.33 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.98 (br s, 3H, OCH2-
CH3)  
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.8 (C-11), 155.4 (C=O and C=O'), 153.8 (C-
12'), 152.6 (C-6), 150.1 (C-6'), 144.0 (C-7'), 140.8 (C-9), 137.9 (C-7), 135.3 (C-9'), 131.6 (C-
14' or C-10'), 130.6 (C-4a'), 130.2 (C-14' or C-10'), 129.6 (C-4a), 129.4 (C-13), 128.3 (C-8a'), 
123.0 (C-14), 121.9 (C-13' and C-11'), 120.2 (C-8a and C-12), 119.6 (C-8'), 117.3 (C-10), 111.9 
(C-5'), 106.9 (C-5), 61.4 ('OCH2-CH3), 61.0 (OCH2-CH3), 60.5 (7-OCH3), 57.0 (C-1'), 56.2 (6-
OCH3), 56.1 (6'-OCH3), 54.1 (C-1), 41.7 (C-3'), 41.5 (C-α'), 39.2 (C-α), 37.3 (C-3), 28.2 (C-4), 
28.1 (C-4'), 14.8 ('OCH2-CH3), 14.2 (OCH2-CH3). The resonance of C-8 could not be identified.  
IR (ATR): ṽ [cm-1] = 2936, 2828, 1692, 1506, 1416, 1276, 1204, 1099, 1022, 840, 768 
Purity (HPLC, method c) = 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C41H4335ClN2O9 + Na]+ 765.2549, found: 765.2550 
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(±)-N,N'-Bis-(ethoxycarbonyl) ring C-propylidene analogues of bisnortetrandrine and –
isotetrandrine (91) 
 
 
 
 
C38H46N2O9 
MW = 674.32 g/mol 
Previously separated diastereomers of bisbenzylisoquinoline 85 (85 mg, 0.112 mmol of each 
diastereomer), potassium iodide (3.70 mg, 0.0225 mmol, 0.2 eq.) and potassium carbonate 
(37.2 mg, 0.225 mmol, 2.0 eq.) were dissolved in 6.0 mL of anhydrous DMF. The mixture was 
stirred for 48 h at 105 °C. Purification was accomplished by flash column chromatography 
(25% acetone in hexanes, Rf = 0.25) and the products obtained as white solids. 
Precursor of RMS10:  
yield: 45.3 mg, 0.0672 mmol, 60%, white solid  
mp: 103.5 – 104.5 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.24 (br s, 1H, 14'-H or 10'-H), 6.86 (br s, 1H, 13'-
H or 11'-H), 6.65 (br s, 1H, 13'-H or 11'-H), 6.60 (s, 1H, 5'-H), 6.28 (s, 1H, 5-H), 6.20 (br s, 1H, 
14'-H or 10'-H), 5.66 (s, 1H, 8'-H), 5.26 (d, J = 4.5 Hz, 1H, 1-H), 4.93 (dd, J = 10.0, 4.1 Hz, 1H, 
1'-H), 4.28 – 4.18 (m, 3H, 4''-H, OCH2-CH3), 4.18 – 4.08 (m, 2H, 'OCH2-CH3), 4.04 – 3.96 (m, 
2H, 3-H, 4''-H), 3.81 (dt, J = 12.4, 5.5 Hz, 1H, 3'-H), 3.70 (s, 3H, 6-OCH3), 3.62 – 3.56 (m, 1H, 
3'-H), 3.55 (s, 3H, 6'-OCH3), 3.37 (dd, J = 12.2, 5.2 Hz, 1H, α'-H), 3.33 – 3.24 (m, 1H, 3-H), 
3.13 (s, 3H, 7-OCH3), 2.98 (ddd, J = 14.9, 9.0, 5.4 Hz, 1H, 4'-H), 2.88 – 2.75 (m, 2H, 4-H, 4'-
H), 2.64 (dt, J = 16.2, 4.6 Hz, 1H, 4-H), 2.54 (t, J = 11.6 Hz, 1H, α'-H), 1.91 – 1.80 (m, 1H, 3''-
H), 1.65 – 1.52 (m, 4H, 1''-H, 2''-H, 3''-H), 1.49 – 1.39 (m, 1H, 2''-H), 1.32 (t, J = 7.1 Hz, 3H, 
OCH2-CH3), 1.25 (t, J = 7.1 Hz, 3H, 'OCH2-CH3) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 158.0 (C-12'), 155.8 ('C=O), 155.7 (C=O), 152.3 
(C-6), 149.6 (C-6'), 145.0 (C-7'), 138.2 (C-7), 131.7 (C-14' or C-10'), 129.6 (C-4a'), 129.5 (C-
14' or C-10'), 128.1 (C-8a'), 123.3 (C-8a), 120.1 (C-8'), 116.9 (C-13' and C-11'), 113.2 (C-5'), 
107.2 (C-5), 68.9 (C-4''), 61.3 (OCH2-CH3), 61.0 ('OCH2-CH3), 60.1 (7-OCH3), 57.4 (C-1'), 56.8 
(6'-OCH3), 56.2 (6-OCH3), 50.6 (C-1), 41.6 (C-α'), 40.9 (C-3'), 37.7 (C-3), 34.1 (C-1''), 28.6 (C-
3''), 28.0 (C-4 and C-4'), 22.0 (C-2''), 14.8 (OCH2-CH3), 14.7 ('OCH2-CH3). The resonances of 
C-9', C-4a and C-8 could not be identified.  
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IR (ATR): ṽ [cm-1] = 2924, 2840, 1689, 1509, 1415, 1273, 1207, 1099, 1023, 879, 769 
Purity (HPLC, method c) = 99% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C38H46N2O9 + H]+ 675.3276, found: 675.3288 
 
Precursor of RMS9: 
yield: 21.9 mg, 0.0325 mmol, 29%, white solid  
mp: 178.0 °C  
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.20 (d, J = 6.5 Hz, 1H, 14'-H or 10'-H), 6.96 (d, J 
= 6.7 Hz, 1H, 13'-H or 11'-H), 6.60 (s, 1H, 5'-H), 6.43 (d, J = 5.8 Hz, 1H, 13'-H or 11'-H), 6.28 
(s, 1H, 5-H), 6.23 (d, J = 7.4 Hz, 1H, 14'-H or 10'-H), 5.90 (s, 1H, 8'-H), 5.16 (dd, J = 9.5, 2.0 
Hz, 1H, 1-H), 4.98 (dd, J = 10.3, 5.6 Hz, 1H, 1'-H), 4.27 – 4.11 (m, 4H, 'OCH2-CH3, OCH2-
CH3), 4.11 – 4.00 (m, 3H, 3-H, 4''-H), 3.87 – 3.78 (m, 1H, 3'-H), 3.72 (s, 3H, 6-OCH3), 3.58 (s, 
3H, 6'-OCH3), 3.55 – 3.46 (m, 1H, 3'-H), 3.43 (dd, J = 12.7, 6.0 Hz, 1H, α'-H), 3.30 – 3.20 (m, 
1H, 3-H), 3.15 (s, 3H, 7-OCH3), 3.06 (ddd, J = 15.5, 9.8, 5.5 Hz, 1H, 4'-H), 2.88 – 2.74 (m, 2H, 
4-H, 4'-H), 2.67 – 2.55 (m, 2H, 4-H, α'-H), 1.81 – 1.70 (m, 2H, 1''-H, 3''-H), 1.69 – 1.59 (m, 1H, 
1''-H), 1.58 – 1.49 (m, 1H, 3''-H), 1.48 – 1.38 (m, 1H, 2''-H), 1.36 – 1.24 (m, 7H, 2''-H, 'OCH2-
CH3, OCH2-CH3) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 156.4 (C-12'), 155.9 (C=O or C=O'), 155.7 (C=O 
or C=O'), 152.2 (C-6), 149.9 (C-6'), 144.7 (C-7'), 138.2 (C-7), 130.9 (C-14' or C-10'), 130.1 (C-
4a'), 129.4 (C-14' or C-10'), 128.6 (C-8a'), 121.8 (C-8a), 119.7 (C-8'), 112.3 (C-5'), 107.1 (C-
5), 68.7 (C-4''), 61.3 ('OCH2-CH3 or OCH2-CH3), 61.2 ('OCH2-CH3 or OCH2-CH3) , 60.4 (7-
OCH3), 57.1 (C-1'), 56.4 (6'-OCH3), 56.3 (6-OCH3), 50.3 (C-1), 41.4 (C-α'), 41.3 (C-3'), 37.7 
(C-3), 33.5 (C-1''), 28.3 (C-4), 28.1 (C-4'), 27.4 (C-3''), 21.4 (C-2''), 14.8 (OCH2-CH3), 14.8 
('OCH2-CH3). The resonances of C-9', C-4a and C-8 could not be identified.  
IR (ATR): ṽ [cm-1] = 2927, 2860, 1690, 1508, 1414, 1275, 1203, 1098, 1023, 768  
Purity (HPLC, method c) = 83% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C38H46N2O9 + H]+ 675.3276, found: 675.3274 
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(±)-12-Desmethoxytetrandrine and –isotetrandrine - RMS1-2  
 
 
 
 
 
C37H40N2O5 
MW = 592.29 g/mol 
RMS1: (1R,1’S)/(1S,1’R) isomers of carbamate 86 (17.0 mg, 0.024 mmol) were reduced 
following General Procedure 4. The reaction was completed after 12 h. Purification by flash 
column chromatography (ethyl acetate → 1.0% triethylamine and 7.5% methanol in ethyl 
acetate, Rf  = 0.14) affording the product as a beige solid.  
yield: 13 mg, 0.0219 mmol, 91%, beige solid 
mp: 196.5 – 198.0 °C  
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.28 (dd, J = 8.3, 2.1 Hz, 1H, 10'-H or 14'-H), 7.18 (t, J = 
7.8 Hz, 1H, 13-H), 7.07 (dd, J = 8.1, 2.5 Hz, 1H, 11'-H or H-13'), 6.96 (dd, J = 8.1, 2.5 Hz, 1H, 
12-H), 6.85 (d, J = 7.4 Hz, 1H, 14-H), 6.62 (dd, J = 8.2, 1.7 Hz, 1H, 11'-H or 13'-H), 6.53 (s, 
1H, 5'-H), 6.45 – 6.37 (m, 2H, 10-H, 10'-H or 14'-H), 6.28 (s, 1H, 5-H), 5.99 (s, 1H, 8'-H), 3.92 
– 3.82 (m, 2H, 1-H, 1'-H), 3.75 (s, 3H, 6-OCH3), 3.60 (s, 3H, 6'-OCH3), 3.45 – 3.36 (m, 1H, 3'-
H), 3.33 – 3.21 (m, 2H, α'-H, 3-H), 3.12 (s, 3H, 7-OCH3), 3.07 (d, J = 13.9 Hz, 1H, α-H), 2.96 
– 2.88 (m, 2H, α'-H, 4'-H), 2.86 – 2.75 (m, 4H, 3-H, 3'-H, 4-H, 4'-H), 2.68 – 2.61 (m, 1H, α-H), 
2.58 (s, 3H, 2'-NCH3), 2.43 – 2.34 (m, 1H, 4-H), 2.25 (s, 3H, 2-NCH3)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 160.4 (C-11), 154.3 (C-12'), 152.0 (C-6), 150.0 (C-6'), 
144.5 (C-9), 143.7 (C-7'), 137.2 (C-7), 135.4 (C-9'), 132.3 (C-10' or 14'), 130.3 (C-10' or 14'), 
129.1 (C-13), 127.9 (C-8a'), 123.4 (C-14), 122.0 (C-11' or 13'), 121.5 (C-11' or 13'), 121.0 (C-
8a), 120.0 (C-8'), 115.3 (C-10), 115.1 (C-12), 111.3 (C-5'), 105.6 (C-5), 63.9 (C-1'), 62.1 (C-1), 
60.7 (7-OCH3), 55.9 (6-OCH3), 55.7 (6'-OCH3), 46.2 (C-3'), 45.4 (C-3), 43.0 (2'-NCH3), 42.9 (2-
NCH3), 39.4 (C-α), 37.9 (C-α'), 25.9 (C-4'), 23.7 (C-4). The resonances of C-8, C-4a and C-4a' 
could not be identified.  
IR (ATR): ṽ [cm-1] = 2923, 2853, 1740, 1606, 1506, 1462, 1255, 1114, 1018, 841, 698 
Purity (HPLC, method c) = 99%, d.r. > 99:1 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C37H40N2O5 + H]+ 593.3010, found: 593.3011 
138 
 
 
RMS2: (1R,1’R)/(1S,1’S) isomers of carbamate 86 (47.0 mg, 0.0663 mmol) were reduced 
following General Procedure 4. The reaction was completed after 12 h. Purification by flash 
column chromatography (ethyl acetate → 1.0% triethylamine and 7.5% methanol in ethyl 
acetate, Rf  = 0.14) affording the product as a white solid.  
yield: 37 mg, 0.0624 mmol, 94%, white solid 
mp: 206.0 – 206.5 °C  
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.35 (dd, J = 8.2, 2.2 Hz, 1H, 10'-H or 14'-H), 7.23 (t, J = 
7.8 Hz, 1H, 13-H), 7.11 (dd, J = 8.1, 2.6 Hz, 1H, 11'-H or 13'-H), 6.99 (dd, J = 7.8, 2.3 Hz, 1H, 
12-H), 6.97 (s, 1H, 14-H), 6.77 (dd, J = 8.3, 2.6 Hz, 1H, 11'H or 13'-H), 6.55 (t, J = 1.9 Hz, 1H, 
10-H), 6.51 (s, 1H, 5'-H), 6.31 (s, 1H, 5-H), 6.30 – 6.28 (m, 1H, 10'-H or 14'-H), 5.99 (s, 1H, 8'-
H), 3.92 – 3.86 (m, 1H, 1'-H), 3.78 (d, J = 8.7 Hz, 1H, 1-H), 3.75 (s, 3H, 6-OCH3), 3.56 – 3.48 
(m, 1H, 3-H), 3.49 – 3.42 (m, 1H, 3'-H), 3.37 (s, 3H, 6'-OCH3), 3.32 – 3.25 (m, 1H, α'-H), 3.18 
(s, 3H, 7-OCH3), 2.99 – 2.87 (m, 4H, 3-H, 3'-H, 4-H, 4'-H), 2.80 (t, J = 11.7 Hz, 1H, α'-H), 2.77 
– 2.72 (m, 2H, α-H, 4'-H), 2.63 (s, 3H, 2'-NCH3), 2.59 – 2.52 (m, 1H, α-H), 2.49 – 2.38 (m, 1H, 
4-H), 2.34 (s, 3H, 2-NCH3)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 160.2 (C-11), 154.1 (C-12'), 151.6 (C-6), 148.8 (C-6'), 
144.0 (C-7'), 143.9 (C-9), 138.0 (C-7), 135.1 (C-9'), 132.8 (C-10' or C-14'), 130.3 (C-10' or 14'), 
129.2 (C-13), 128.0 (C-8a'), 123.3 (C-14), 123.1 (C-8a), 122.0 (C-11' or C-13'), 121.8 (C-11' 
or C-13'), 120.4 (C-8'), 115.6 (C-10), 115.2 (C-12), 112.8 (C-5'), 105.9 (C-5), 64.1 (C-1'), 61.5 
(C-1), 60.4 (7-OCH3), 56.0 (6'-OCH3 or 6-OCH3), 55.9 (6'-OCH3 or 6-OCH3), 45.4 (C-3'), 44.2 
(C-3), 42.8 (C-α), 42.7 (2'-NCH3), 42.4 (2-NCH3), 38.5 (C-α'), 25.2 (C-4'), 22.2 (C-4). The 
resonances of C-8, C-4a and C-4a' could not be identified.  
IR (ATR): ṽ [cm-1] = 2926, 2841, 1586, 1505, 1268, 1211, 1111, 1023, 841, 785  
Purity (HPLC, method c) = 99%, d.r. 95:5 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C37H40N2O5 + H]+ 593.3010, found: 593.3011 
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(±)-12-Desmethoxy-12-trifluoromethoxytetrandrine and –isotetrandrine - RMS3-4  
 
 
 
 
 
C38H39F3N2O6 
MW = 676.28 g/mol 
RMS3: (1R,1’S)/(1S,1’R) isomers of carbamate 87 (13.0 mg, 0.0164 mmol) were reduced 
following General Procedure 4. The reaction was completed after 12 h. Purification by flash 
column chromatography (ethyl acetate → 1.5% triethylamine and 7.5% methanol in ethyl 
acetate, Rf  = 0.11) affording the product as a white solid.  
yield: 9.7 mg, 0.0143 mmol, 87%, white solid  
mp: 111.0 – 112.5 °C  
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.30 (dd, J = 8.2, 2.1 Hz, 1H, 10'-H or 14'-H), 7.12 (d, J 
= 8.3 Hz, 1H, 13-H), 7.08 (d, J = 8.5 Hz, 1H, 11'-H or 13'-H), 6.83 (dd, J = 8.2, 1.5 Hz, 1H, 14-
H), 6.64 – 6.57 (m, 2H, 10-H, 11'-H or 13'-H), 6.53 (s, 1H, 5'-H), 6.45 (br s, 1H, 10'-H or 14'-
H), 6.27 (s, 1H, 5-H), 5.97 (s, 1H, 8'-H), 3.90 – 3.84 (m, 1H, 1'-H), 3.82 (d, J = 9.6 Hz, 1H, 1-
H), 3.75 (s, 3H, 6-OCH3), 3.60 (s, 3H, 6'-OCH3), 3.45 – 3.35 (m, 1H, 3'-H), 3.25 (dd, J = 12.9, 
6.3 Hz, 2H, α'-H, 3-H), 3.13 (s, 3H, 7-OCH3), 3.05 (d, J = 13.8 Hz, 1H,α-H), 2.96 – 2.87 (m, 
1H, α'-H, 4'-H), 2.87 – 2.75 (m, 4H, 3'-H, 3-H, 4-H, 4'-H), 2.63 (dd, J = 10.2, 3.6 Hz, 1H, α-H), 
2.58 (s, 3H, 2'-NCH3), 2.42 – 2.31 (m, 1H, 4-H), 2.26 (s, 3H, 2-NCH3) 
13C NMR (126 MHz, CDCl3) δ [ppm] = 153.7 (C-12'), 152.3 (C-11), 152.1 (C-6), 149.9 (C-6'), 
143.6 (C-7'), 143.4 (C-9), 137.2 (C-7), 136.1 (C-12), 136.0 (C-9'), 132.4 (C-10' or C-14'), 130.5 
(C-10' or C-14'), 127.8 (C-8a'), 123.3 (C-14), 122.5 (C-13), 121.8 (C-11' or C-13'), 121.5 (C-
11' or C-13'), 120.4 (C-8a), 119.9 (C-8'), 117.2 (C-10), 111.3 (C-5'), 105.6 (C-5), 63.8 (C-1'), 
62.2 (C-1), 60.7 (7-OCH3), 55.9 (6-OCH3), 55.7 (6'-OCH3), 46.1 (C-3'), 45.3 (C-3), 42.9 (2'-
NCH3), 42.7 (2-NCH3), 39.2 (C-α), 37.7 (C-α'), 25.9 (C-4'), 22.8 (C-4). The resonances of C-8, 
C-4a, C-4a' and OCF3 could not be identified.  
IR (ATR): ṽ [cm-1] = 2933, 2843, 1593, 1505, 1416, 1198, 1164, 1112, 1008, 838, 729 
Purity (HPLC, method c) = 98%, d.r. 95:5 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C38H39F3N2O6 + H]+ 677.2833, found: 677.2838 
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RMS4: (1R,1’R)/(1S,1’S) isomers of carbamate 87 (32.0 mg, 0.0404 mmol) were reduced 
following General Procedure 4. The reaction was completed after 12 h. Purification by flash 
column chromatography (ethyl acetate → 1.5% triethylamine and 7.5% methanol in ethyl 
acetate, Rf  = 0.11) affording the product as a white solid. 
yield: 20.2 mg, 0.0298 mmol, 74%, white solid  
mp: 174.0 – 176.0 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.36 (dd, J = 8.2, 2.2 Hz, 1H, 10'-H or 14'-H), 7.17 (d, J 
= 8.1 Hz, 1H, 13-H), 7.12 (dd, J = 8.2, 2.6 Hz, 1H, 11'-H or 13'-H), 6.94 (d, J = 8.2 Hz, 1H, 14-
H), 6.76 (dd, J = 8.3, 2.6 Hz, 1H, 11'-H or 13'-H), 6.63 (d, J = 1.9 Hz, 1H, 10-H), 6.51 (s, 1H, 
5'-H), 6.31 (s, 1H, 5-H), 6.32 – 6.28 (m, 1H, 10'-H or 14'-H), 5.98 (s, 1H, 8'-H), 3.89 (dd, J = 
10.9, 5.7 Hz, 1H, 1'-H), 3.75 (s, 3H, 6-OCH3), 3.72 (s, 1H, 1-H), 3.55 – 3.43 (m, 2H, 3-H, 3'-H), 
3.38 (s, 3H, 6'-OCH3), 3.31 – 3.24 (m, 1H, α'-H), 3.18 (s, 3H, 7-OCH3), 3.00 – 2.85 (m, 4H, 3-
H, 3'-H, 4-H, 4'-H), 2.83 (d, J = 11.7 Hz, 1H, α'-H), 2.79 – 2.70 (m, 2H, α-H, 4'-H), 2.63 (s, 3H, 
2'-NCH3), 2.54 (d, J = 13.6 Hz, 1H, α-H), 2.41 (dd, J = 11.3, 5.2 Hz, 1H, 4-H), 2.34 (s, 3H, 2-
NCH3)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 153.6 (C-12'), 152.2 (C-11), 151.7 (C-6), 148.8 (C-6'), 
148.6 (C-8), 143.9 (C-7'), 142.6 (C-9), 138.0 (C-7), 136.2 (C-12), 135.7 (C-9'), 133.0 (C-10' or 
14'), 130.4 (C-10' or 14'), 128.3 (C-4a'), 128.2 (C-4a), 127.9 (C-8a'), 123.2 (C-14), 122.7 (C-
8a and 13), 121.8 (C-11' or C-13'), 121.7 (C-11' or C-13'), 121.0 (q, J = 257.2 Hz, OCF3), 120.3 
(C-8'), 117.7 (C-10), 112.7 (C-5'), 106.0 (C-5), 64.1 (C-1'), 61.3 (C-1), 60.4 (7-OCH3), 55.9 (6'-
OCH3 and 6-OCH3), 45.4 (C-3'), 44.1 (C-3), 42.7 (2'-NCH3), 42.3 (C-α), 42.3 (2-NCH3), 38.3 
(C-α'), 25.3 (C-4'), 21.9 (C-4)  
IR (ATR): ṽ [cm-1] = 2926, 2846, 1596, 1504, 1250, 1200, 1163, 1113, 1020, 840 
Purity (HPLC, method c) = 99%, d.r. 94:6 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C38H39F3N2O6 + H]+ 677.2833, found: 677.2839 
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(±)-Ring C thiophene analogues of  tetrandrine and –isotetrandrine - RMS5-6  
 
 
 
 
 
C35H38N2O5S 
MW = 598.25 g/mol 
RMS5: (1R,1’S)/(1S,1’R) isomers of carbamate 89 (10.0 mg, 0.014 mmol) were reduced 
following General Procedure 4. The reaction was completed after 4 h. Purification by flash 
column chromatography (ethyl acetate → 2.0% trimethylamine in ethyl acetate, Rf = 0.08) 
affording the product as a beige solid.  
yield: 5.2 mg, 0.0087 mmol, 62%, beige solid  
mp: 149.0 – 151.0 °C  
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.27 – 7.24 (m, 1H, 14'-H or 10'-H), 7.10 (dd, J = 8.1, 2.6 
Hz, 1H, 13'-H or 11'-H), 6.64 (dd, J = 8.3, 2.6 Hz, 1H, 13'-H or 11'-H), 6.48 (s, 1H, 5'-H), 6.48 
– 6.43 (m, 1H, 14'-H or 10'-H), 6.35 (d, J = 1.7 Hz, 1H, 12-H), 6.26 (s, 1H, 5-H), 6.02 (s, 2H, 
10-H, 8'-H), 3.94 (d, J = 7.6 Hz, 1H, 1-H), 3.91 – 3.85 (m, 1H, 1'-H), 3.74 (s, 3H, 6-OCH3), 3.52 
(s, 3H, 6'- OCH3), 3.50 – 3.43 (m, 1H, 3'-H), 3.28 (dd, J = 12.9, 7.0 Hz, 1H, α'-H), 3.17 – 3.11 
(m, 2H, 3-H, α-H), 3.09 (s, 3H, 7- OCH3), 2.96 (t, J = 11.0 Hz, 1H, α'-H), 2.93 – 2.73 (m, 6H, 3-
H, 4-H, α-H, 4'-H, 3'-H), 2.56 (s, 3H, 2'-NCH3), 2.49 (d, J = 19.4 Hz, 1H, 4-H), 2.37 (s, 3H, 2-
NCH3) 
13C NMR (126 MHz, CDCl3) δ [ppm] = 157.3 (C-11), 156.6 (C-12'), 152.0 (C-6), 149.8 (C-6'), 
144.5 (C-9), 143.2 (C-7'), 136.8 (C-7), 135.4 (C-9'), 132.1 (C-14' or C-10'), 130.1 (C-14' or C-
10'), 129.4 (C-4a), 129.1 (C-4a'), 127.5 (C-8a'), 121.9 (C-13' or C-11'), 121.0 (C-13' or C-11'), 
120.7 (C-8a), 120.0 (C-8'), 117.6 (C-10), 111.3 (C-5'), 105.2 (C-5), 99.7 (C-12), 64.1 (C-1'), 
63.2 (C-1), 60.7 (7-OCH3), 55.9 (6-OCH3), 55.6 (6'-OCH3), 46.2 (C-3'), 44.8 (C-3), 43.1 (2'-
NCH3), 43.0 (2-NCH3), 38.1 (C-α'), 33.8 (C-α), 25.5 (C-4'), 24.8 (C-4). The resonance of C-8 
could not be identified.  
IR (ATR): ṽ [cm-1] = 2924, 2853, 1736, 1556, 1507, 1451, 1261, 1106, 1017, 798  
Purity (HPLC, method c) = 98%, d.r. >99:1 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C35H38N2O5S + H]+ 599.2574, found: 599.2574 
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RMS6: (1R,1’R)/(1S,1’S) isomers of carbamate 89 (20.0 mg, 0.028 mmol) were reduced 
following General Procedure 4. The reaction was completed after 2 h. Purification by flash 
column chromatography (ethyl acetate → 2.0% trimethylamine in ethyl acetate, Rf = 0.08) 
affording the product as a beige solid.  
yield: 12.9 mg, 0.0215 mmol, 77%, beige solid 
mp: 251.5 – 252.5 °C  
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.31 (dd, J = 8.2, 2.2 Hz, 1H, 14'-H or 10'-H), 7.13 (dd, J 
= 8.1, 2.6 Hz, 1H, 13'-H or 11'-H), 6.78 (dd, J = 8.3, 2.6 Hz, 1H, 13'-H or 11'-H), 6.50 (s, 1H, 
5'-H), 6.44 (d, J = 1.7 Hz, 1H, 12-H), 6.29 (s, 1H, 5-H), 6.26 (dd, J = 8.3, 2.2 Hz, 1H, 14'-H or 
10'-H), 6.24 (d, J = 1.7 Hz, 1H, 10-H), 5.90 (s, 1H, 8'-H), 3.93 (d, J = 7.2 Hz, 1H, 1-H), 3.79 
(dd, J = 11.2, 5.5 Hz, 1H, 1'-H), 3.74 (s, 3H, 6-OCH3), 3.52 – 3.43 (m, 1H, 3'-H), 3.36 (s, 3H, 
6'-OCH3), 3.31 – 3.21 (m, 2H, 3-H, α'-H), 3.13 (s, 3H, 7-OCH3), 3.00 – 2.82 (m, 5H, 3-H, 4-H, 
α-H, 4'-H, 3'-H), 2.83 – 2.72 (m, 2H, α-H, α '-H), 2.76 – 2.67 (m, 1H, 4'-H), 2.58 (s, 3H, 2'-
NCH3), 2.46 (s, 3H, 2-NCH3), 2.46 – 2.35 (m, 1H, 4-H) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 156.9 (C-12'), 156.8 (C-11), 151.8 (C-6), 148.9 (C-6'), 
148.9 (C-8), 144.3 (C-7'), 143.7 (C-9), 138.2 (C-7), 135.1 (C-9'), 132.7 (C-14' or C-10'), 129.9 
(C-14' or C-10'), 128.5 (C-4a'), 128.0 (C-8a'), 123.7 (C-8a), 121.6 (C-13' or  C-11'), 121.0 (C-
13' or  C-11'), 120.7 (C-8'), 118.5 (C-10), 112.9 (C-5'), 106.0 (C-5), 100.9 (C-12), 64.5 (C-1'), 
61.8 (C-1), 60.3 (7-OCH3), 55.9 (6-OCH3), 55.9 (6'-OCH3), 45.4 (C-3'), 44.5 (C-3), 42.8 (2'-
NCH3), 42.5 (2-NCH3), 39.0 (C-α'), 37.5 (C-α), 24.9 (C-4'), 23.2 (C-4). The resonance of C-4a 
could not be identified.  
IR (ATR): ṽ [cm-1] = 2925, 2853, 1561, 1505, 1357, 1262, 1205, 1102, 1015, 809, 717  
Purity (HPLC, method c) = 97%, d.r. 96:4 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C35H38N2O5S + H]+ 599.2574, found: 599.2580 
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(±)-12-Desmethoxy-12-chlorotetrandrine and –isotetrandrine - RMS7-8  
 
 
 
 
C37H39ClN2O5 
MW = 626.26 g/mol 
RMS7: A solution of the (1R,1’S)/(1S,1’R) isomers of carbamate 90 (40.0 mg, 0.0538 mmol) 
in 1.0 mL anhydrous THF was cooled to 0 °C and methyllithium (1.6 M solution in diethyl ether; 
0.510 mL, 0.807 mmol, 15 eq.) was added slowly. The mixture was stirred at 0 °C for 4 h and 
was then quenched with 1.0 mL deionized water. After alkalizing to pH 12–14 with 2.0 M NaOH 
solution, the mixture was extracted with ethyl acetate (3 x 20 mL). The combined organic 
phases were dried over anhydrous Na2SO4 and concentrated in vacuo to afford the secondary 
amine as a yellow oil. The crude amine was dissolved in 1.0 mL methanol, a solution of 
formaldehyde (37% in water; 20.0 µL, 0.269 mmol, 5 eq.), one drop of acetic acid and sodium 
cyanoborohydride (10.7 mg, 0.161 mmol, 3 eq.) was added. The mixture was stirred at ambient 
temperature for 12 h and the volatiles removed in vacuo. Purification by flash column 
chromatography (ethyl acetate → 3.0% trimethylamine in ethyl acetate, Rf = 0.16) afforded the 
product as a white solid. 
yield: 9.9 mg, 0.0159 mmol, 30%, white solid  
mp: 227.5 – 230.0 °C 
1H NMR (800 MHz, CDCl3) δ [ppm] = 7.30 (d, J = 6.3 Hz, 1H, 14'-H or 10'-H), 7.25 – 7.22 (m, 
1H, 13-H), 7.09 (d, J = 7.0 Hz, 1H, 13'-H or 11'-H), 6.79 (d, J = 8.2 Hz, 1H, 14-H), 6.62 (s, 1H, 
13'-H or 11'-H), 6.54 (s, 2H, 10-H, 5'-H), 6.44 (s, 1H, 14'-H or 10'-H), 6.27 (s, 1H, 5-H), 5.97 (s, 
1H, 8'-H), 3.87 (s, 1H, 1'-H), 3.80 (s, 1H, 1-H), 3.75 (s, 3H, 6-OCH3), 3.61 (s, 3H, 6'-OCH3), 
3.40 (s, 1H, 3'-H), 3.26 (s, 2H, 3-H, α'-H), 3.13 (s, 3H, 7-OCH3), 3.03 (d, J = 13.9 Hz, 1H, α-H), 
2.92 (dt, J = 16.2, 6.1 Hz, 3H, 4-H, 4'-H, α'-H), 2.88 – 2.78 (m, 3H, 3-H, 4'-H, 3'-H), 2.66 – 2.54 
(m, 2H, α-H), 2.58 (s, 3H, 2'-NCH3), 2.44 – 2.30 (m, 1H, 4-H), 2.24 (s, 3H, 2-NCH3) 
13C NMR (201 MHz, CDCl3) δ [ppm] = 155.7 (C-11), 153.8 (C-12'), 152.1 (C-6), 150.0 (C-6'), 
143.7 (C-7'), 137.1 (C-7), 132.4 (C-14' or C-10'), 130.5 (C-14' or C-10'), 129.5 (C-13), 129.0 
(C-4a'), 127.6 (C-8a'), 124.1 (C-14), 122.1 (C-13' and C-11'), 120.6 (C-8a), 119.9 (C-8'), 119.5 
(C-12), 116.5 (C-10), 111.4 (C-5'), 105.7 (C-5), 63.7 (C-1'), 62.1 (C-1), 60.6 (7-OCH3), 55.9 (6-
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OCH3), 55.7 (6'-OCH3), 46.1 (C-3'), 42.8 (2-NCH3 and 2'-NCH3), 39.1 (C-α), 37.9 (C-α'), 25.8 
(C-4').The resonances of C-4a, C-8, C-9 and C-9' could not be identified.  
IR (ATR): ṽ [cm-1] = 2925, 2799, 1579, 1505, 1412, 1262, 1205, 1113, 1021, 817 
Purity (HPLC, method c) = 96%, d.r. >99:1 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C37H3935ClN2O5 + H]+ 627.2620, found: 627.2621 
 
RMS8: The (1R,1’R)/(1S,1’S) isomers of carbamate 90 (40.0 mg, 0.0538 mmol) were reacted 
and purified as described above for RMS7 to afford the desired product as a white solid. 
yield: 10.8 mg, 0.0172 mmol, 32%, white solid  
mp: 148.0 – 150.0 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.36 (dd, J = 8.2, 2.2 Hz, 1H, 14'-H or 10'-H), 7.28 (d, J 
= 8.0 Hz, 1H, 13-H), 7.14 (dd, J = 8.2, 2.6 Hz, 1H, 13'-H or 11'-H), 6.90 (dd, J = 8.1, 1.9 Hz, 
1H, 14-H), 6.76 (dd, J = 8.3, 2.6 Hz, 1H, 13'-H or 11'-H), 6.59 (d, J = 1.8 Hz, 1H, 10-H), 6.51 
(s, 1H, 5'-H), 6.30 (s, 1H, 5-H), 6.30 (dd, J = 8.6, 2.1 Hz, 2H, 14'-H or 10'-H), 5.98 (s, 1H, 8'-
H), 3.88 (dd, J = 10.9, 5.6 Hz, 1H, 1'-H), 3.75 (s, 3H, 6-OCH3), 3.71 (d, J = 9.9 Hz, 1H, 1-H), 
3.51 – 3.42 (m, 2H, 3-H, 3'-H), 3.37 (s, 3H, 6'-OCH3), 3.27 (dd, J = 12.3, 5.7 Hz, 1H, α'-H), 3.18 
(s, 3H, 7-OCH3), 2.94 (qd, J = 19.6, 17.5, 7.8 Hz, 4H, 3-H, 4-H, 4'-H, 3'-H), 2.81 (t, J = 11.7 
Hz, 1H, α'-H), 2.77 – 2.68 (m, 2H, α-H, 4'-H), 2.62 (s, 3H, 2'-NCH3), 2.53 (d, J = 13.6 Hz, 1H, 
α-H), 2.44 – 2.37 (m, 1H, 4-H), 2.32 (s, 3H, 2-NCH3) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 155.4 (C-11), 153.5 (C-12'), 151.5 (C-6), 148.7 (C-6'), 
143.8 (C-7'), 142.3 (C-9), 137.9 (C-7), 135.6 (C-9'), 132.8 (C-14' or C-10'), 130.3 (C-14' or C-
10'), 129.5 (C-13), 128.2 (C-4a'), 127.9 (C-8a'), 123.9 (C-14), 122.6 (C-8a), 121.7 (C-13' and 
C-11'), 120.2 (C-8'), 119.6 (C-12), 117.1 (C-10), 112.7 (C-5'), 105.8 (C-5), 63.9 (C-1'), 61.3 (C-
1), 60.3 (7-OCH3), 55.8 (6-OCH3 and 6'-OCH3), 45.2 (C-3'), 44.0 (C-3), 42.6 (2'-NCH3), 42.2 
(2-NCH3), 42.1 (C-α), 38.2 (C-α'), 25.2 (C-4'), 21.8 (C-4). The resonances of C-8 and C-4a 
could not be identified.  
IR (ATR): ṽ [cm-1] = 2922, 1747, 1578, 1505, 1413, 1266, 1206, 1111, 1019, 836 
Purity (HPLC, method c) = 95%, d.r. > 99:1 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C37H3935ClN2O5 + H]+ 627.2620, found: 627.2622 
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(±)-Ring C propylidene analogues of tetrandrine and –isotetrandrine - RMS9-10  
 
 
 
C34H42N2O5 
MW = 558.31 g/mol 
RMS9: The first fraction of separated diastereomers of carbamate 91 (20.0 mg, 0.0297 mmol) 
was reduced following General Procedure 4. The reaction was completed after 5 h. Purification 
by flash column chromatography (ethyl acetate → 3.0% trimethylamine in ethyl acetate, Rf = 
0.15) afforded the product as a white solid. 
yield: 14.7 mg, 0.0264 mmol, 89%, white solid 
mp: 92.0 – 94.0 °C 
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.09 (dd, J = 8.3, 2.2 Hz, 1H, 14'-H or 10'-H), 6.96 (dd, J 
= 8.2, 2.6 Hz, 1H, 13'-H or 11'-H), 6.64 (s, 1H, 5'-H), 6.51 (dd, J = 8.4, 2.8 Hz, 1H, 13'-H or 11'-
H), 6.33 (s, 1H, 5-H), 6.12 (dd, J = 8.4, 2.2 Hz, 1H, 14'-H or 10'-H), 5.42 (s, 1H, 8'-H), 4.27 (dt, 
J = 11.9, 4.5 Hz, 1H, 4''-H), 4.03 (ddd, J = 12.3, 9.2, 3.7 Hz, 1H, 4''-H), 3.84 (s, 3H, 6'-OCH3), 
3.73 (s, 3H, 6-OCH3), 3.56 (dd, J = 10.6, 5.7 Hz, 1H, 1'-H), 3.41 – 3.33 (m, 1H, 3'-H), 3.30 – 
3.21 (m, 2H, 1-H, 3-H), 3.15 (s, 3H, 7-OCH3), 3.14 – 3.10 (m, 1H, α'-H), 2.92 – 2.83 (m, 2H, 4-
H, 4'-H), 2.83 – 2.77 (m, 3H, 3-H, 4'-H, 3'-H), 2.70 (dd, J = 12.7, 10.6 Hz, 1H, α'-H), 2.51 (s, 
3H, 2'-NCH3), 2.45 (s, 3H, 2-NCH3), 2.44 – 2.38 (m, 1H, 4-H), 1.78 – 1.68 (m, 2H, 3''-H, 2''-H), 
1.66 – 1.53 (m, 2H, 3''-H, 1''-H), 1.48 – 1.36 (m, 2H, 2''-H, 1''-H) 
13C NMR (126 MHz, CDCl3) δ [ppm] = 155.4 (C-12'), 152.0 (C-6), 150.5 (C-6'), 145.5 (C-7'), 
138.6 (C-7), 131.9 (C-14' or C-10'), 131.1 (C-9'), 129.7 (C-14' or C-10'), 129.2 (C-4a), 128.9 
(C-4a'), 128.3 (C-8a'), 123.2 (C-8a), 120.5 (C-8'), 119.0 (C-13' or C-11'), 115.6 (C-13' or C-
11'), 112.0 (C-5'), 107.4 (C-5), 68.1 (C-4''), 64.5 (C-1'), 60.3 (7-OCH3), 57.9 (C-1), 56.4 (6'-
OCH3), 55.9 (6-OCH3), 46.1 (C-3'), 44.1 (C-3), 42.8 (2'-NCH3), 41.9 (2-NCH3), 38.2 (C-α'), 33.9 
(C-1''), 26.8 (C-3''), 25.7 (C-4'), 22.7 (C-4), 21.4 (C-2''). The resonance of C-8 could not be 
identified.  
IR (ATR): ṽ [cm-1] = 2925, 2850, 1607, 1508, 1451, 1266, 1216, 1010, 832, 750  
Purity (HPLC, method c) = 96%, d.r. > 99:1 (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C34H42N2O5 + H]+ 559.3166, found: 559.3163 
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RMS10: The second fraction of separated diastereomers of carbamate 91 (18.0 mg, 0.0267 
mmol) was reduced following General Procedure 4. The reaction was completed after 5 h. 
Purification by flash column chromatography (ethyl acetate → 3.0% trimethylamine in ethyl 
acetate, Rf = 0.15) afforded the product as a white solid. 
yield: 10.4 mg, 0.0186 mmol, 70%, white solid  
mp: 153.5 °C  
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.22 (dd, J = 8.3, 2.3 Hz, 1H, 14'-H or 10'-H), 6.89 (dd, J 
= 8.3, 2.7 Hz, 1H, 13'-H or 11'-H), 6.72 (dd, J = 8.3, 2.7 Hz, 1H, 13'-H or 11'-H), 6.48 (s, 1H, 
5'-H), 6.29 (dd, J = 8.3, 2.2 Hz, 1H, 14'-H or 10'-H), 6.25 (s, 1H, 5-H), 5.53 (s, 1H, 8'-H), 4.29 
(dt, J = 9.9, 4.6 Hz, 1H, 4''-H), 4.06 (ddd, J = 11.7, 9.0, 3.2 Hz, 1H, 4''-H), 3.77 – 3.73 (m, 1H, 
1'-H), 3.72 (s, 3H, 6-OCH3), 3.66 (dd, J = 8.2, 3.6 Hz, 1H, 1-H), 3.51 (s, 3H, 6'-OCH3), 3.40 – 
3.25 (m, 2H, 3-H, 3'-H), 3.22 (dd, J = 12.6, 5.0 Hz, 1H, α'-H), 3.05 (s, 3H, 7-OCH3), 3.00 – 2.77 
(m, 4H, 3-H, 4-H, 4'-H, 3'-H), 2.71 – 2.61 (m, 2H, 4'-H, α'-H), 2.59 (s, 3H, 2'-NCH3), 2.44 (s, 
3H, 2-NCH3), 2.38 (dd, J = 16.3, 5.7 Hz, 1H, 4-H), 1.91 – 1.81 (m, 1H, 3''-H), 1.73 – 1.56 (m, 
3H, 3''-H, 2''-H), 1.55 – 1.45 (m, 2H, 1''-H)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 158.1 (C-12'), 151.7 (C-6), 149.1 (C-6'), 148.7 (C-8), 
143.6 (C-7'), 137.3 (C-7), 132.4 (C-14' or C-10'), 131.4 (C-9'), 129.7 (C-14' or C-10'), 128.4 (C-
4a'), 128.3 (C-4a), 127.9 (C-8a'), 122.6 (C-8a), 121.0 (C-8'), 117.2 (C-13' or C-11'), 116.0 (C-
13' or C-11'), 111.7 (C-5'), 105.8 (C-5), 68.6 (C-4''), 64.3 (C-1'), 60.2 (7-OCH3), 58.9 (C-1), 
55.9 (6-OCH3), 55.8 (6'-OCH3), 45.4 (C-3'), 43.9 (C-3), 42.6 (2'-NCH3), 41.9 (2-NCH3), 38.1 
(C-α'), 34.8 (C-1''), 29.4 (C-3''), 25.8 (C-4'), 23.5 (C-2''), 22.3 (C-4) 
IR (ATR): ṽ [cm-1] = 2926, 2854, 1656, 1578, 1507, 1352, 1262, 1203, 1114, 1012, 812 
Purity (HPLC, method c) = 98%, d.r. > 99:1 (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C34H42N2O5 + H]+ 559.3166, found: 559.3172  
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(±)-N-Methyl-6,7-dimethoxy-1-(3’-benzyloxy-4’-methoxybenzyl)-1,2,3,4-
tetrahydroisoquinoline (sc1)  
 
 
 
 
 
C27H31NO4 
MW = 433.23 g/mol 
Carbamate 55 (100 mg, 0.175 mmol) was reduced following General Procedure 4. The 
reaction was completed after 4 h. Purification by flash column chromatography (2% 
triethylamine and 3% methanol in ethyl acetate, Rf = 0.29) affording the product as a beige 
solid. 
yield: 49.3 mg, 0.114 mmol, 65%, beige solid 
mp: 85.0 – 85.5 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.43 – 7.39 (m, 2H, 2''-H, 6''-H), 7.37 – 7.31 (m, 2H, 3''-
H, 5''-H), 7.30 – 7.24 (m, 1H, 4''-H), 6.77 (d, J = 8.1 Hz, 1H, 5'-H), 6.66 (d, J = 2.0 Hz, 1H, 2'-
H), 6.60 (dd, J = 8.1, 2.0 Hz, 1H, 6'-H), 6.54 (s, 1H, 5-H), 6.00 (s, 1H, 8-H), 5.07 (s, 2H, OCH2-
Ar), 3.85 (s, 3H, 4'-OCH3), 3.83 (s, 3H, 6-OCH3), 3.59 (dd, J = 7.6, 5.0 Hz, 1H, 1-H), 3.56 (s, 
3H, 7-OCH3), 3.15 – 3.09 (m, 2H, 3-H), 3.06 (dd, J = 13.7, 5.0 Hz, 1H, α-H), 2.83 – 2.76 (m, 
1H, 4-H), 2.76 – 2.67 (m, 2H, α-H, 3-H), 2.54 (dt, J = 15.5, 4.7 Hz, 1H, 4-H), 2.48 (s, 3H, NCH3) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 148.2 (C-4'), 147.8 (C-3'), 147.3 (C-6), 146.4 (C-7), 
137.4 (C-1''), 132.6 (C-1'), 129.4 , 8a, 128.6 (C-3'', C-5''), 127.9 (C-4''), 127.4 (C-2'', C-6''), 
126.2 (C-4a), 122.7 (C-6'), 116.0 (C-2'), 111.7 (C-5'), 111.2 (C-5), 111.1 (C-8), 71.2 (OCH2-
Ar), 64.9 (C-1), 56.2 (4'-OCH3), 55.9 (6-OCH3), 55.7 (7-OCH3), 47.2 (C-3), 42.8 (NCH3), 40.9 
(C- α), 25.7 (C-4) 
IR (ATR): ṽ [cm-1] = 2938, 2826, 1606, 1510, 1374, 1223, 1135, 1013, 697 
Purity (HPLC, method c) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C27H31NO4 + H]+ 434.2326, found: 434.2322 
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(±)-8-(4-(2-((N-Methyl)amino)ethyl)-2-methoxyphenoxy)-N-methyl-6,7-dimethoxy-1-(3’-
benzyloxy-4’-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (sc2)  
 
 
 
 
 
 
C37H44N2O6 
MW = 612.32 g/mol 
Carbamate 58 (25.0 mg, 0.0343 mmol) was reduced following General Procedure 4. The 
reaction was completed after 4 h. Purification by flash column chromatography (ethyl acetate 
→ 2% triethylamine and 5% methanol in ethyl acetate, Rf = 0.15) affording the product as a 
beige solid. 
yield: 19.5 mg, 0.0318 mmol, 93%, pale orange solid 
mp: 86.0 °C 
1H NMR (500 MHz, CDCl3) δ [ppm] = 7.39 – 7.33 (m, 2H, 2'''-H, 6'''-H), 7.32 – 7.27 (m, 2H, 3'''-
H, 5'''-H), 7.25 – 7.22 (m, 1H, 4'''-H), 6.83 (d, J = 2.0 Hz, 1H, 2''-H), 6.76 (d, J = 1.8 Hz, 1H, 2'-
H), 6.72 (d, J = 8.1 Hz, 1H, 5'-H), 6.69 (dd, J = 8.2, 1.8 Hz, 1H, 6'-H), 6.59 (dd, J = 8.2, 2.0 Hz, 
1H, 6''-H), 6.51 (s, 1H, 5-H), 6.46 (d, J = 8.2 Hz, 1H, 5''-H), 4.98 (dd, J = 15.5, 12.1 Hz, 2H, 
OCH2-Ph), 3.90 (s, 3H, 3''-OCH3), 3.83 (s, 3H, 6-OCH3), 3.81 (s, 3H, 4'-OCH3), 3.75 (dd, J = 
9.6, 2.9 Hz, 1H, 1-H), 3.66 (s, 3H, 7-OCH3), 3.21 (ddd, J = 13.3, 10.8, 5.2 Hz, 1H, 3-H), 2.96 – 
2.87 (m, 5H, α-H, NCH2-CH2-Ar, NCH2-CH2-Ar), 2.86 – 2.82 (m, 1H, 4-H), 2.74 (dd, J = 14.3, 
9.6 Hz, 1H, α-H), 2.69 (ddd, J = 13.3, 6.2, 2.4 Hz, 1H, 3-H), 2.48 (s, 3H, NCH3), 2.39 (ddd, J = 
16.8, 5.2, 2.5 Hz, 1H, 4-H), 2.17 (s, 3H, 2-NCH3) 
13C NMR (126 MHz, CDCl3) δ [ppm] = 152.0 (C-6), 148.9 (C-3''), 147.8 (C-4'), 147.6 (C-3'), 
146.5 (C-4''), 145.8 (C-8), 140.1 (C-7), 137.5 (C-1'''), 133.8 (C-1'), 132.3 (C-1''), 130.4 (C-4a), 
128.6 (C-3''', C-5'''), 127.8 (C-4'''), 127.6 (C-2''', C-6'''), 124.6 (C-8a), 122.0 (C-6'), 120.8 (C-6''), 
115.4 (C-2'), 114.4 (C-5''), 113.3 (C-2''), 111.5 (C-5'), 109.0 (C-5), 70.9 (OCH2-Ph), 61.0 (7-
OCH3), 60.1 (C-1), 56.4 (3''-OCH3), 56.1 (6-OCH3), 56.1 (4'-OCH3), 52.4 (NCH2-CH2-Ar), 44.5 
(C-3), 42.3 (2-NCH3), 40.2 (C-α), 35.1 (NCH3), 34.4 (NCH2-CH2-Ar), 23.4 (C-4) 
IR (ATR): ṽ [cm-1] = 2932, 2837, 1595, 1509, 1263, 1134, 1022, 806 
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Purity (HPLC, method c) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C37H44N2O6 + H]+ 613.3272, found: 613.3269 
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(±)-8-(N-Ethoxy-(6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)-N-ethoxy-6,7-
dimethoxy-1-(3’-benzyloxy-4’-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (95) 
 
 
 
 
 
C42H48N2O10 
MW = 740.33 g/mol 
Carbamate 58 (118 mg, 0.162 mmol) and paraformaldehyde (10.0 mg, 0.330 mmol) were 
condensed following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) 
using TFA as catalyst. The reaction was completed after 6 h. Purification by flash column 
chromatography (30% acetone in hexanes, Rf = 0.19) gave 95 as a white solid. 
yield: 36.0 mg, 0.104 mmol, 47%, white solid 
mp: 61.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.45 – 7.37 (m, 2H, 2'''-H, 6'''-H), 7.36 – 7.31 (m, 
2H, 3'''-H, 5'''-H), 7.30 – 7.25 (m, 1H, 4'''-H), 6.73 (d, J = 8.2 Hz, 1H, 5''-H), 6.71 (s, 1H, 5'-H), 
6.67 (d, J = 2.0 Hz, 1H, 2''-H), 6.60 (dd, J = 8.1, 2.0 Hz, 1H, 6''-H), 6.51 (s, 1H, 5-H), 6.34 (s, 
1H, 8'-H), 5.36 (s, 1H, 1-H), 4.92 (s, 2H, OCH2-Ar), 4.33 (s, 2H, 1'-H), 4.10 (q, J = 7.1 Hz, 2H, 
'OCH2-CH3), 4.06 – 3.93 (m, 1H, 3-H), 3.87 (s, 3H, 6'-OCH3), 3.91 – 3.75 (m, 2H, OCH2-CH3), 
3.82 (s, 3H, 6-OCH3), 3.78 (s, 3H, 4''-OCH3), 3.63 (s, 3H, 7-OCH3), 3.60 (t, J = 6.0 Hz, 2H, 3'-
H), 3.30 (ddd, J = 13.1, 10.0, 4.9 Hz, 1H, 3-H), 3.13 (dd, J = 14.0, 3.7 Hz, 1H, α-H), 2.80 (dd, 
J = 13.7, 9.1 Hz, 2H, α-H, 4-H), 2.74 (t, J = 6.0 Hz, 2H, 4'-H), 2.53 (d, J = 16.5 Hz, 1H, 4-H), 
1.21 (t, J = 7.0 Hz, 3H, 'OCH2-CH3), 0.92 (br s, 3H, OCH2-CH3) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.6 ('C=O), 155.4 (C=O), 152.6 (C-6), 149.0 (C-
4''), 148.8 (C-3''), 148.2 (C-6'), 146.8 (C-7'), 145.3 (C-8), 140.6 (C-7), 137.9 (C-1'''), 132.3 (C-
1''), 130.3 (C-4a), 128.5 (C-4a'), 128.4 (C-3''', C-5'''), 127.7 (C-4'''), 127.6 (C-2''', C-6'''), 126.0 
(C-8a'), 124.2 (C-8a), 122.8 (C-6''), 117.3 (C-2''), 114.2 (C-5'), 113.6 (C-5''), 113.0 (C-8'), 109.8 
(C-5), 71.8 (OCH2-Ar), 61.3 ('OCH2-CH3), 60.9 (OCH2-CH3), 60.8 (7-OCH3), 57.0, 56.8, 56.5 
(6-OCH3, 6'-OCH3, 4''-OCH3), 52.2 (C-1), 45.3 (C-1'), 41.6 (C-3'), 39.9 (C-α), 37.6 (C-3), 28.6 
(C-4'), 28.1 (C-4), 14.7 ('OCH2-CH3), 14.3 (OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 2838, 1689, 1510, 1422, 1218, 1111, 1020, 763 
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Purity (HPLC, method b) = 95% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C42H48N2O10 + H]+ 741.3382, found: 741.3378 
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(±)-8-(N-Ethoxy-(1-isobutyl-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)-N-
ethoxy-6,7-dimethoxy-1-(3’-benzyloxy-4’-methoxybenzyl)-1,2,3,4-
tetrahydroisoquinoline (96)  
 
 
 
 
C46H56N2O10 
MW = 796.39 g/mol 
Carbamate 58 (50.0 mg, 0.0686 mmol) and 3-methylbutanal (10.0 µL, 0.0932 mmol) were 
condensed following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) 
using TFA as catalyst. After 4 h an additional amount of 3-Methylbutanal (10.0 µL, 0.0932 
mmol) were added. The reaction was completed after 12 h. Purification by flash column 
chromatography (10% ethyl acetate in dichloromethane, Rf = 0.27 (sc4 precursor) and Rf = 
0.24 (sc5 precursor) gave the title compounds as a white solid. 
sc4 precursor: 
yield: 27.0 mg, 0.0339 mmol, 49%, white solid 
mp 65.0 – 66.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.42 – 7.37 (m, 2H, 2'''-H, 6'''-H), 7.36 – 7.30 (m, 
2H, 3'''-H, 5'''-H), 7.30 – 7.23 (m, 1H, 4'''-H), 6.73 (d, J = 8.1 Hz, 1H, 5''-H), 6.67 (d, J = 1.9 Hz, 
1H, 2''-H), 6.66 (s, 1H, 5'-H), 6.60 (dd, J = 8.1, 2.0 Hz, 1H, 6''-H), 6.51 (s, 1H, 5-H), 6.29 (s, 
1H, 8'-H), 5.33 (s, 1H, 1-H), 4.92 (s, 2H, OCH2-Ar), 4.91 – 4.85 (m, 1H, 1'-H), 4.18 – 3.99 (m, 
3H, 'OCH2-CH3, 3'-H), 4.00 – 3.89 (m, 1H, 3-H), 3.84 (s, 3H, 6'-OCH3), 3.82 (s, 3H, 6-OCH3), 
3.78 (s, 3H, 4''-OCH3), 3.81 – 3.72 (m, 2H, OCH2-CH3), 3.63 (s, 3H, 7-OCH3), 3.32 (ddd, J = 
13.1, 9.7, 4.9 Hz, 1H, 3-H), 3.20 (tt, J = 10.7, 4.6 Hz, 1H, 3'-H), 3.13 (dd, J = 14.0, 3.9 Hz, 1H, 
α-H), 2.89 – 2.78 (m, 2H, α-H, 4'-H), 2.79 – 2.71 (m, 1H, 4-H), 2.60 (dt, J = 16.1, 4.1 Hz, 1H, 
4'-H), 2.51 (d, J = 15.9 Hz, 1H, 4-H), 1.60 (ddd, J = 13.9, 8.9, 5.4 Hz, 1H, α'-H), 1.56 – 1.48 
(m, 1H, CH(CH3)2), 1.33 – 1.22 (m, 1H, α'-H), 1.20 (t, J = 7.1 Hz, 3H, 'OCH2-CH3), 0.93 (br s, 
3H, OCH2-CH3), 0.85 (d, J = 6.4 Hz, 3H, CH(CH3)2), 0.81 (d, J = 6.5 Hz, 3H, CH(CH3)2) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.6 ('C=O), 155.4 (C=O), 152.7 (C-6), 149.0 (C-
4''), 148.8 (C-3''), 148.1 (C-6'), 146.5 (C-7'), 145.6 (C-8), 140.8 (C-7), 137.9 (C-1'''), 132.4 (C-
1''), 131.2 (C-8a'), 128.4 (C-3''', C-5'''), 127.9 (C-4a'), 127.7 (C-4'''), 127.6 (C-2''', C-6'''), 124.2 
(C-8a), 122.9 (C-6''), 117.4 (C-2''), 114.2 (C-5'), 114.2 (C-8'), 113.6 (C-5''), 109.8 (C-5), 71.8 
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(OCH2-Ar), 61.1 ('OCH2-CH3), 60.9 (OCH2-CH3), 60.8 (7-OCH3), 56.9, 56.8, 56.6 (4''-OCH3, 6'-
OCH3, 6-OCH3), 52.8 (C-1'), 52.3  (C-1), 46.4 (C-α'), 40.1 (C-α), 37.8 (C-3, C-3'), 28.2 (C-4), 
27.9 (C-4'), 25.0 (CH(CH3)2), 22.9, 22.5 (CH(CH3)2),14.6 ('OCH2-CH3), 14.4 (OCH2-CH3) 
IR (ATR): ṽ [cm-1] = 2927, 2836, 1689, 1509, 1423, 1256, 1109, 1023, 763 
Purity (HPLC, method b) = 98% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C46H56N2O10 + H]+ 797.4008, found: 797.4010 
 
sc5 precursor: 
yield: 27.0 mg, 0.0339 mmol, 49%, white solid 
mp: 57.0 – 58.5 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 7.42 – 7.36 (m, 2H, 2'''-H, 6'''-H), 7.36 – 7.30 (m, 
2H, 3'''-H, 5'''-H), 7.30 – 7.23 (m, 1H, 4'''-H), 6.73 (d, J = 8.1 Hz, 1H, 5''-H), 6.67 (s, 2H, 2''-H, 
5'-H), 6.59 (dd, J = 8.1, 2.0 Hz, 1H, 6''-H), 6.50 (s, 1H, 5-H), 6.37 (s, 1H, 8'-H), 5.41 (s, 1H, 1-
H), 4.92 (s, 2H, OCH2-Ar), 4.90 (d, J = 5.3 Hz, 1H, 1'), 4.18 – 4.10 (m, 2H, 'OCH2-CH3), 4.09 – 
3.94 (m, 2H, 3'-H, 3-H), 3.84 (s, 3H, 6'-OCH3), 3.82 (s, 3H, 6-OCH3), 3.90 – 3.71 (m, 2H, OCH2-
CH3), 3.78 (s, 3H, 4''-OCH3), 3.60 (s, 3H, 7-OCH3), 3.29 (ddd, J = 13.2, 9.9, 4.9 Hz, 1H, 3-H), 
3.21 (ddd, J = 13.6, 10.3, 4.6 Hz, 1H, 3'-H), 3.15 (dd, J = 14.0, 3.8 Hz, 1H, α-H), 2.90 – 2.74 
(m, 3H, α-H, 4'-H, 4-H), 2.63 (dt, J = 16.1, 4.2 Hz, 1H, 4'-H), 2.50 (d, J = 16.0 Hz, 1H, 4-H), 
1.67 – 1.48 (m, 2H, α'-H, CH(CH3)2), 1.33 – 1.22 (m, 1H, α'-H), 1.21 (t, J = 7.1 Hz, 3H, 'OCH2-
CH3), 0.91 (br s, 3H, OCH2-CH3), 0.85 (d, J = 6.4 Hz, 3H, CH(CH3)2), 0.81 (d, J = 6.5 Hz, 3H, 
CH(CH3)2). 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 155.6 ('C=O), 155.5 (C=O), 152.6 (C-6), 149.0 (C-
4''), 148.7 (C-3''), 148.2 (C-6'), 146.4 (C-7'), 145.5 (C-8), 140.7 (C-7), 137.9 (C-1'''), 132.3 (C-
1''), 131.2 (C-8a'), 128.4 (C-3''', C-5'''), 128.0 (C-4a'), 127.7 (C-4'''), 127.6 (C-2''', C-6'''), 124.2 
(C-8a), 122.9 (C-6''), 117.4 (C-2''), 114.4 (C-8'), 114.1 (C-5'), 113.6 (C-5''), 109.8 (C-5), 71.8 
(OCH2-Ar), 61.1 ('OCH2-CH3), 60.9 (OCH2-CH3), 60.7 (7-OCH3), 56.8, 56.6 (4''-OCH3, 6'-
OCH3, 6-OCH3), 52.9 (C-1'), 52.1 (C-1), 46.4 (C-α'), 39.9 (C-α), 37.9 (C-3, C-3'), 28.0 (C-4), 
28.0 (C-4'), 25.0 (CH(CH3)2), 23.0, 22.5 (CH(CH3)2), 14.6 ('OCH2-CH3), 14.3 (OCH2-CH3). 
IR (ATR): ṽ [cm-1] = 2922, 1692, 1511, 1424, 1256, 1112, 1023, 763 
Purity (HPLC, method b) = 98% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C46H56N2O10 + H]+ 797.4008, found: 797.4010 
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(±)-8-(N-Methyl-(6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)-N-methyl-6,7-
dimethoxy-1-(3’-benzyloxy-4’-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (sc3)  
 
 
 
 
 
 
C38H44N2O6 
MW = 624.32 g/mol 
Carbamate 102 (60.0 mg, 0.0811 mmol) was reduced following General Procedure 4. The 
reaction was completed after 4 h. Purification by flash column chromatography (ethyl acetate 
→ 1% triethylamine and 5% methanol in ethyl acetate, Rf = 0.24) affording the product as a 
white solid. 
yield: 50.0 mg, 0.0800 mmol, 99%, white solid 
mp: 47.5 – 48.0 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.39 – 7.35 (m, 2H, 2'''-H, 6'''-H), 7.34 – 7.29 (m, 2H, 3'''-
H, 5'''-H), 7.28 – 7.23 (m, 1H, 4'''-H), 6.76 (d, J = 1.7 Hz, 1H, 2''-H), 6.72 (d, J = 8.1 Hz, 1H, 5''-
H), 6.69 (dd, J = 8.1, 1.7 Hz, 1H, 6''-H), 6.67 (s, 1H, 5'-H), 6.52 (s, 1H, 5-H), 6.20 (s, 1H, 8'-H), 
4.98 (q, J = 12.0 Hz, 2H, OCH2-Ar), 3.86 (s, 3H, 6'-OCH3), 3.85 (s, 3H, 6-OCH3), 3.81 (s, 3H, 
4''-OCH3), 3.74 (dd, J = 9.8, 2.8 Hz, 1H, 1-H), 3.67 (s, 3H, 7-OCH3), 3.32 (s, 2H, 1'-H), 3.25 
(ddd, J = 13.2, 11.3, 5.1 Hz, 1H, 3-H), 2.91 (dd, J = 14.3, 2.7 Hz, 1H, α-H), 2.92 – 2.84 (m, 1H, 
4-H), 2.82 (t, J = 6.0 Hz, 2H, 4'-H), 2.79 – 2.64 (m, 3H, α-H, 3-H), 2.61 (t, J = 5.8 Hz, 2H, 3'-
H), 2.45 – 2.37 (m, 1H, 4-H), 2.36 (s, 3H, 2'-NCH3), 2.16 (s, 3H, 2-NCH3) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 152.0 (C-6), 147.8 (C-4''), 147.7 (C-3''), 147.4 (C-6'), 
145.9 (C-7'), 145.8 (C-8), 140.3 (C-7), 137.6 (C-1'''), 134.0 (C-1''), 130.3 (C-4a), 128.5 (C-3''', 
C-5'''), 127.8 (C-4'''), 127.7 (C-2''', C-6'''), 127.1 (C-4a'), 126.9 (C-8a'), 124.9 (C-8a), 122.0 (C-
6''), 115.4 (C-2''), 112.8 (C-5'), 111.9 (C-8'), 111.6 (C-5''), 109.0 (C-5), 70.9 (OCH2-Ar), 60.9 
(7-OCH3), 60.1 (C-1), 57.5 (C-1'), 56.4 (6'-OCH3), 56.2 (4''-OCH3 or 6-OCH3), 56.1 (4''-OCH3 
or 6-OCH3), 53.0 (C-3'), 46.1 (2'-NCH3), 44.4 (C-3), 42.3 (2-NCH3), 40.2 (C-α), 29.0 (C-4'), 23.4 
(C-4). 
IR (ATR): ṽ [cm-1] = 2932, 2836, 1605, 1511, 1450, 1258, 1219, 1112, 1010, 797 
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Purity (HPLC, method c) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C38H44N2O6 + H]+ 625.3272, found: 625.3263 
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(±)-8-(N-Methyl-(1-isobutyl-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)-N-methyl-
6,7-dimethoxy-1-(3’-benzyloxy-4’-methoxybenzyl)-1,2,3,4-tetrahydroisoquinoline (sc4-
sc5)  
 
 
 
 
 
C42H52N2O6 
MW = 680.38 g/mol 
Carbamate 96 (sc4 precursor: 25.0 mg, 0.0314 mmol and sc5 precursor: 22.0 mg, 0.0276 
mmol), was reduced following General Procedure 4. The reaction was completed after 4 h. 
Purification by flash column chromatography (ethyl acetate → 0.5% triethylamine and 5% 
methanol in ethyl acetate, Rf = 0.13) affording the products as a white solid. 
sc4: 
yield: 17.2 mg, 0.0253 mmol, 80%, white solid 
mp: 46.5 – 48.5 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.38 (d, J = 7.2 Hz, 2H, 2'''-H, 6'''-H), 7.36 – 7.22 (m, 3H, 
3'''-H, 4'''-H, 5'''-H), 6.78 (d, J = 1.6 Hz, 1H, 2''-H), 6.74 (d, J = 8.1 Hz, 1H, 5''-H), 6.71 (dd, J = 
8.5, 1.2 Hz, 1H, 6''-H), 6.63 (s, 1H, 5'-H), 6.53 (s, 1H, 5-H), 6.25 (s, 1H, 8'-H), 5.00 (q, 2H, 
OCH2-Ar), 3.86 (s, 3H, 6'-OCH3), 3.85 (s, 3H, 6-OCH3), 3.82 (s, 3H, 4''-OCH3), 3.79 (d, J = 
11.1 Hz, 1H, 1-H), 3.66 (s, 3H, 7-OCH3), 3.30 – 3.21 (m, 2H, 1'-H, 3-H), 3.16 – 3.06 (m, 1H, 
3'-H), 2.97 – 2.67 (m, 6H, α-H, 3'-H, 3-H, 4'-H, 4-H), 2.57 – 2.48 (m, 1H, 4'-H), 2.42 (dd, J = 
18.0, 3.7 Hz, 1H, 4-H), 2.36 (s, 3H, 2'-NCH3), 2.18 (s, 3H, 2-NCH3), 1.65 (dq, J = 13.2, 6.7 Hz, 
1H, CH(CH3)2), 1.52 (dt, J = 13.8, 6.9 Hz, 1H, α'-H), 1.19 (ddd, J = 13.8, 8.1, 5.4 Hz, 1H, α'-H), 
0.79 (d, J = 6.5 Hz, 3H, CH(CH3)2), 0.75 (d, J = 6.7 Hz, 3H, CH(CH3)2) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 152.0 (C-6), 147.8 (C-3''), 147.7 (C-4''), 147.2 (C-6'), 
146.0 (C-8), 145.9 (C-7'), 140.3 (C-7), 137.6 (C-1'''), 134.0 (C-1''), 131.1 (C-8a'), 130.2 (C-4a), 
128.5 (C-3''',C- 5'''), 127.8 (C-4'''), 127.7 (C-2''',C-6'''), 127.1 (C-4a'), 124.8 (C-8a), 122.0 (C-
6''), 115.4 (C-2''), 113.6 (C-8'), 112.8 (C-5'), 111.6 (C-5''), 109.1 (C-5), 70.9 (OCH2-Ar), 60.9 
(7-OCH3), 60.8 (C-1'), 60.1 (C-1), 56.3 (4''-OCH3, 6'-OCH3 or 6-OCH3), 56.2 (4''-OCH3, 6'-OCH3 
or 6-OCH3), 56.1 (4''-OCH3, 6'-OCH3 or 6-OCH3), 46.1 (C-3'), 45.1 (C-α'), 44.4 (C-3), 42.3 (2-
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NCH3), 42.1 (2'-NCH3), 40.2 (C-α), 25.2 (CH(CH3)2), 23.9 (C-4'), 23.4 (C-4), 23.2 (CH(CH3)2), 
22.5 (CH(CH3)2) 
IR (ATR): ṽ [cm-1] = 2927, 2840, 1606, 1508, 1454, 1259, 1113, 1013, 762, 696 
Purity (HPLC, method c) = > 99% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H52N2O6 + H]+ 681.3898, found: 681.3891 
 
sc5: 
yield: 15.3 mg, 0.0225 mmol, 81%, white solid 
mp: 71.0 – 72.0 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.39 (d, J = 7.0 Hz, 2H, 2'''-H, 6'''-H), 7.35 – 7.23 (m, 3H, 
3'''-H, 4'''-H, 5'''-H), 6.77 (d, J = 23.5 Hz, 3H, 2''-H, 5''-H, 6''-H), 6.63 (s, 1H, 5'-H), 6.53 (s, 1H, 
5-H), 6.18 (s, 1H, 8'-H), 4.98 (q, J = 12.0 Hz, 2H, OCH2-Ar), 3.87 (s, 3H, 6'-OCH3), 3.86 (s, 3H, 
6-OCH3), 3.82 (s, 3H, 4''-OCH3), 3.71 (s, 3H, 7-OCH3), 3.67 (dd, J = 9.6, 2.9 Hz, 1H, 1-H), 3.34 
– 3.21 (m, 2H, 1'-H, 3-H), 3.12 (ddd, J = 13.7, 9.6, 5.2 Hz, 1H, 3'-H), 2.99 (dd, J = 14.3, 2.8 Hz, 
1H, α-H), 2.92 – 2.68 (m, 5H, α-H, 3-H, 3'-H, 4-H, 4'-H), 2.52 – 2.36 (m, 2H, 4-H, 4'-H), 2.36 
(s, 3H, 2-'NCH3), 2.18 (s, 3H, 2-NCH3), 1.69 (dt, J = 13.7, 7.0 Hz, 1H, CH(CH3)2), 1.54 (ddd, J 
= 14.0, 8.3, 5.5 Hz, 1H, α'-H), 1.15 (ddd, J = 13.8, 8.6, 5.0 Hz, 1H, α'-H), 0.79 (d, J = 6.5 Hz, 
3H, CH(CH3)2), 0.76 (d, J = 6.6 Hz, 3H, CH(CH3)2) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 152.0 (C-6), 147.8 (C-4''), 147.7 (C-3''), 147.1 (C-6'), 
145.9 (C-7'), 140.4 (C-7), 137.6 (C-1'''), 134.0 (C-1''), 131.3 (C-8a'), 130.4 (C-4a), 128.5 (C-3''', 
C-5'''), 127.8 (C-4'''), 127.7 (C-2''', C-6'''), 127.0 (C-4a'), 124.7 (C-8a), 122.1 (C-2'' or 6''), 115.5 
(C-2'' or 6''), 113.2 (C-8'), 112.8 (C-5'), 111.5 (C-5''), 109.1 (C-5), 70.9 (OCH2-Ar), 61.0 (7-
OCH3), 60.6 (C-1'), 60.4 (C-1), 56.3 (4''-OCH3, 6'-OCH3 or 6-OCH3), 56.1 (4''-OCH3, 6'-OCH3 
or 6-OCH3), 45.7 (C-3'), 45.7 (C-α'), 44.6 (C-3), 42.4 (2-NCH3), 42.1 (2'-NCH3), 40.5 (C-α), 
25.2 (CH(CH3)2), 23.5 (C-4'), 23.4 (CH(CH3)2), 23.2 (C-4), 22.4 (CH(CH3)2). The resonance of 
C-8 could not be identified. 
IR (ATR): ṽ [cm-1] = 2927, 2835, 1606, 1508, 1451, 1257, 1216, 1113, 1013, 752 
Purity (HPLC, method c) = 94% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C42H52N2O6 + H]+ 681.3898, found: 681.3895
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N,N’-Bisnor-Muraricine bis(ethylcarbamate) (97)  
 
 
 
C34H40N2O9 
Mw = 620.27 g/mol 
Intermediate 66 (53.0 mg, 0.0871 mmol) and paraformaldehyde (5.2 mg, 0.174 mmol) were 
condensed following General Procedure 2 (intermolecular N-acyl Pictet-Spengler reaction) 
using TFA as catalyst. The reaction was completed after 2 h. Purification by flash column 
chromatography (20% ethyl acetate in dichloromethane, Rf = 0.14) gave the title compound as 
a white solid. 
yield: 36.8 mg, 0.0593 mmol, 68%, white solid 
mp: 91.0 – 93.0 °C 
1H NMR (400 MHz, Tcl2, 100 °C) δ [ppm] = 6.80 – 6.75 (m, 2H, 10-H, 14-H), 6.68 (s, 1H, 5-H), 
6.61 – 6.57 (m, 2H, 11-H, 13-H), 6.51 (s, 1H, 5'-H), 6.03 (s, 1H, 8-H), 4.95 (t, J = 6.6 Hz, 1H, 
1-H), 4.41 (d, J = 17.1 Hz, 1H, 1'-H), 4.29 (d, J = 17.1 Hz, 1H, 1'-H), 4.13 (q, J = 7.1 Hz, 2H, 
'OCH2CH3), 4.04 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.87 (s, 3H, 6-OCH3), 3.88 – 3.82 (m, 1H, 3-
H), 3.82 (s, 3H, 6'-OCH3), 3.62 – 3.57 (m, 1H, 3'-H), 3.59 (s, 3H, 7'-OCH3), 3.34 – 3.25 (m, 1H, 
3-H), 2.91 (dd, J = 13.6, 6.0 Hz, 1H, α-H), 2.79 – 2.72 (m, 4H, α-H, 4'-H, 4-H), 2.61 (dt, J = 
16.0, 5.2 Hz, 1H, 4-H), 1.23 (t, J = 7.1 Hz, 3H, 'OCH2CH3), 1.17 (t, J = 7.1 Hz, 3H, OCH2CH3) 
13C NMR (101 MHz, Tcl2, 100 °C) δ [ppm] = 156.0 ('C=O), 155.5 (C=O), 154.4 (C-12), 152.4 
(C-6'), 148.5 (C-6), 146.2 (C-7), 145.9 (C-8'), 140.6 (C-7'), 130.6 (C-10, C-14), 130.4 (C-9), 
130.2 (C-4a'), 129.3 (C-8a), 128.6 (C-4a), 120.2 (C-8a'), 115.4 (C-11, C-13), 114.9 (C-8), 113.9 
(C-5), 109.8 (C-5'), 61.4 ('OCH2CH3), 61.2 (OCH2CH3), 60.7 (7'-OCH3), 56.9 (6-OCH3), 56.6 
(6'-OCH3), 56.3 (C-1), 42.3 (C-α), 41.5 (C-1'), 41.5 (C-3'), 39.1 (C-3), 28.9 (C-4'), 4', 28.2 (C-
4), 14.7 ('OCH2CH3), 14.7 (OCH2CH3) 
IR (ATR): ṽ [cm-1] = 2925, 2855, 1670, 1612, 1513, 1425, 1236, 1108, 1023, 823, 769  
Purity (HPLC, method b) = 76% (λ = 210 nm) 
HRMS (ESI): m/z calcd for [C34H40N2O9 + H]+ 621.2807, found: 621.2806 
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Racemic muraricine (rac-34) 
 
 
 
 
C30H36N2O5 
Mw = 504.26 g/mol 
Muraricincarbamate 97 (35.0 mg, 0.0564 mmol) was reduced following General Procedure 4. 
The reaction was completed after 3 h. Purification by flash column chromatography (10% 
methanol and 2% triethylamine in ethyl acetate, Rf = 0.22) gave the title compound as a beige 
solid. 
yield: 8.0 mg, 0.0158 mmol, 23%, beige solid 
mp: 63.0 – 65.0 °C 
1H NMR (400 MHz, CDCl3) δ [ppm] = 6.66 (s, 1H, 5-H), 6.60 (d, J = 8.0 Hz, 2H, 10-H, 14-H), 
6.53 (d, J = 8.0 Hz, 2H, 11-H, 13-H), 6.47 (s, 1H, 5'-H), 4.83 (s, 1H, 8-H), 3.89 (s, 3H, 6-OCH3), 
3.80 (s, 3H, 6'-OCH3), 3.83 – 3.76 (m, 1H, 1'-H), 3.58 (dd, J = 10.5, 3.0 Hz, 1H, 1-H), 3.39 (s, 
3H, 7'-OCH3), 3.41 – 3.31 (m, 3H, α-H, 3-H, 4'-H), 3.29 – 3.22 (m, 1H, 1'-H), 3.12 (dd, J = 11.0, 
5.4 Hz, 1H, 3'-H), 3.03 – 2.93 (m, 2H, 3-H, 4-H), 2.87 – 2.75 (m, 1H, 4-H), 2.70 (d, J = 16.6 Hz, 
1H, 4'-H), 2.62 (s, 3H, 2-NCH3), 2.61 (s, 3H, 2'-NCH3), 2.53 (t, J = 11.8 Hz, 1H, α-H), 2.47 – 
2.38 (m, 1H, 3'-H) 
13C NMR (101 MHz, CDCl3) δ [ppm] = 156.4 (C-12), 152.1 (C-6'), 147.6 (C-6), 144.2 (C-7), 
144.1 (C-8'), 138.9 (C-7'), 130.9 (C-10, C-14), 129.7 (C-9), 129.0 (C-4a'), 126.1 (C-8a), 125.6 
(C-4a), 118.8 (C-8a'), 118.3 (C-11, C-13), 115.1 (C-8), 111.9 (C-5), 108.2 (C-5'), 65.2 (C-1), 
60.2 (7'-OCH3), 56.2 (6-OCH3), 56.1 (6'-OCH3), 53.0 (C-1'), 52.4 (C-3'), 45.6 (2'-NCH3), 45.5 
(C-3), 41.8 (2-NCH3), 39.6 (C-α), 28.2 (C-4'), 24.6 (C-4). The NMR data are mainly in 
accordance with literature[119]. 
IR (ATR): ṽ [cm-1] = 2925, 2850, 1611, 1512, 1453, 1259, 1118, 1064, 834, 796 
Purity (HPLC, method c) = > 99% (λ = 210 nm)  
HRMS (ESI): m/z calcd for [C30H36N2O5 + H]+ 505.2697, found: 505.2697 
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3,4-Dimethoxy-2-((6-methoxy-2-methyl-3,4-dihydroisoquinolin-1(2H)-one-7-
yl)oxy)benzaldehyde  (99) 
 
C20H21NO6 
Mw = 371.14 g/mol 
Thalifoline 47 (0.368 g, 1.77 mmol) and 2-bromo-3,4-dimethoxybenzaldehyde (48, 0.435 g, 
1.77 mmol) were reacted following General Procedure 3 (intermolecular Ullmann coupling). 
The reaction was completed after 48 h. The crude product was purified by flash column 
chromatography (40% EtOAc in dichloromethane, Rf = 0.22), yielding the desired product (99) 
as a light yellow solid.  
yield: 0.323 g, 0.87 mmol, 49%, light yellow solid 
mp: 129.0 °C  
1H NMR (500 MHz, CDCl3) δ [ppm] = 10.10 (d, J = 0.9 Hz, 1H, CHO), 7.70 (d, J = 8.9 Hz, 1H, 
6'-H), 7.31 (s, 1H, 8-H), 6.87 (d, J = 8.8 Hz, 1H, 5'-H), 6.74 (s, 1H, 5-H), 3.98 (s, 3H, 6-OCH3), 
3.94 (s, 3H, 4'-OCH3), 3.69 (s, 3H, 3'-OCH3), 3.51 (t, J = 6.7 Hz, 2H, 3-H), 3.06 (s, 3H, NCH3), 
2.95 (t, J = 6.7 Hz, 2H, 4-H)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 188.2 (CHO), 164.2 (C-1), 159.4 (C-4'), 151.7 (C-6), 
151.6 (C-2'), 147.6 (C-7), 141.4 (C-3'), 133.7 (C-4a), 124.4 (C-6'), 123.4 (C-1'), 122.2 (C-8a), 
115.0 (C-8), 110.3 (C-5), 109.0 (C-5'), 60.9 (3'-OCH3), 56.3, 56.2 (4-'OCH3, 6-OCH3), 48.2 (C-
3), 35.0 (NCH3), 27.7 (C-4)  
IR (ATR): ṽ [cm-1] = 2932, 2852, 1677, 1643, 1588, 1495, 1454, 1180, 1110, 1020, 819, 773 
Purity (HPLC, method c) = 90% (λ = 210 nm)  
HRMS (ESI): m/z = calcd. for [C20H21NO6 + H]+ 372.1442, found: 372.1439 
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Berbanine (35) 
 
 
 
C22H22N2O5 
Mw = 394.15 g/mol 
Diaryl ether 99 (0.150 g, 0.404 mmol) and aminoacetaldehyde dimethyl acetal (48.4 μL, 0.444 
mmol) were dissolved in anhydrous toluene (5.0 mL) and a small number of molecular sieves 
4 Å was added. The mixture was heated at 100 °C for 4 h under nitrogen atmosphere. After 
cooling to room temperature, the mixture was filtered to remove the molecular sieves and the 
solvent was evaporated in vacuo. The oily residue was suspended in trifluoroacetic anhydride 
(TFAA, 5.0 mL) at 0 °C and added dropwise to a mixture of boron trifluoride acetic acid complex 
(112 µL, 0.808 mmol) in 2.0 mL TFAA at 0 °C. The reaction mixture was allowed to warm up 
to ambient temperature and stirred for 18 h. The mixture was poured into ice-water, basified 
with 25% aqueous NH3 (pH 12-14) and extracted with CHCl3 (3 x 50 mL). The combined 
organic phases were dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (5% MeOH and 2% NEt3 in EtOAc, Rf  = 
0.17) to give the title compound as a white solid.  
yield: 75.2 mg, 0.191 mmol, 47%, white solid 
mp: 126.0 °C  
1H NMR (400 MHz, CDCl3) δ [ppm] = 9.16 (s, 1H, 1'-H), 8.40 (d, J = 5.7 Hz, 1H, 3'-H), 7.50 (d, 
J = 5.7 Hz, 1H, 4'-H), 7.20 (s, 1H, 8-H), 6.99 (s, 1H, 5'-H), 6.78 (s, 1H, 5-H), 4.04 (s, 3H, 6-
OCH3), 4.01 (s, 3H, 6'-OCH3), 3.85 (s, 3H, 7'-OCH3), 3.49 (t, J = 6.9 Hz, 2H, 3-H), 3.01 (s, 3H, 
NCH3), 2.95 (t, J = 6.7 Hz, 2H, 4-H)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 164.3 (C-1), 156.9 (C-6'), 151.8 (C-6), 147.5 (C-7), 146.7 
(C-1'), 143.4 (C-3'), 143.0 (C-8'), 142.1 (C-7'), 134.0 (C-4a'), 133.7 (C-4a), 122.3 (C-8a), 119.6 
(C-8a'), 119.3 (C-4'), 114.9 (C-8), 110.4 (C-5), 102.7 (C-5'), 61.3 (7'-OCH3), 56.5 (6-OCH3), 
56.2 (6'-OCH3), 48.3 (C-3), 35.1 (NCH3), 27.8 (C-4)  
IR (ATR): ṽ [cm-1] = 2934, 2848, 1736, 1691, 1642, 1604, 1492, 1471, 1333, 1252, 1183, 
1114, 1014, 849, 773 
Purity (HPLC, method c) = 96% (λ = 210 nm)  
HRMS (ESI): m/z = calcd. for C22H22N2O5 [M+H]+ 395.1602, found: 395.1596 
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Berbanine ·HCl (35 ·HCl) 
 
C22H23ClN2O5 
Mw = 430.13 g/mol 
Berbanine (35, 23.0 mg, 0.0583 mmol) was dissolved in 2 mL 1,4-dioxane and treated with an 
excess of HCl (4.0 M in 1,4-dioxane). The resulting precipitate was vacuum filtered over a 
Buchner funnel and washed with diethyl ether. The desired product was obtained as a yellow 
solid.  
yield: 23.3 mg, 0.0542 mmol, 93%, yellow solid 
mp: 186.0 – 188.0 °C   
1H NMR (400 MHz, CDCl3) δ [ppm] = 9.22 (d, J = 5.3 Hz, 1H, 1'-H), 8.32 (br s, 1H, 3'-H), 7.96 
(d, J = 6.2 Hz, 1H, 4'-H), 7.20 (s, 1H, 5'-H), 7.19 (s, 1H, 8-H), 6.81 (s, 1H, 5-H), 4.13 (s, 3H, 6'-
OCH3), 4.01 (s, 3H, 6-OCH3), 3.93 (s, 3H, 7'-OCH3), 3.54 (t, J = 6.7 Hz, 2H, 3-H), 3.04 (s, 3H, 
NCH3), 2.98 (t, J = 6.8 Hz, 2H, 4-H)  
13C NMR (126 MHz, CDCl3) δ [ppm] = 164.0 (C-1), 162.1 (C-6'), 151.7 (C-6), 146.3 (C-7), 145.0 
(C-7'), 143.5 (C-8'), 139.4 (C-1'), 137.1 (C-4a'), 135.1 (C-4a), 131.1 (C-3'), 122.7 (C-4'), 122.3 
(C-8a), 119.5 (C-8a'), 114.8 (C-8), 110.9 (C-5), 103.0 (C-5'), 61.5 (7'-OCH3), 57.2 (6'-OCH3), 
56.5 (6-OCH3), 48.2 (C-3), 35.2 (NCH3), 27.8 (C-4) 
IR (ATR): ṽ [cm-1] = 3390, 2923, 2622, 2064, 1605, 1477, 1397, 1257, 1179, 1116, 1016, 
851, 772 
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Berbidine (36) 
 
 
C23H28N2O5 
Mw = 412.20 g/mol 
Berbanine (35, 0.040 g, 0.101 mmol) was dissolved in acetone (1.0 mL) and iodomethane (63 
µL, 1.01 mmol, 10 eq.) was added. The mixture was stirred at 45 °C for 3.5 h. After cooling to 
room temperature, the volatiles were removed in vacuo. The obtained methiodide was 
dissolved in 1.5 mL of a mixture of 4% water in MeOH (vol %)), the mixture cooled to 0 °C  and 
sodium borohydride (19.2 mg, 0.507 mmol, 5 eq.) was added in portions. The reaction was 
stirred for 1 h, while it was allowed to warm to room temperature. The solvent was removed in 
vacuo, the residue quenched with water (20 mL) which was basified with a 2M NaOH solution 
(pH 12-14). The aqueous phase was then extracted with CH2Cl2 (3 x 20 mL). The combined 
organic layers were dried over anhydrous Na2SO4 and the solvent was removed in vacuo. 
Purification of the crude product by flash column chromatography (5% MeOH and 2% NEt3 in 
EtOAc → 7.5% MeOH and 2% NEt3 in EtOAc, Rf  = 0.28) yielded berbidine (36) as a white 
solid.  
yield: 36.5 mg, 0.089 mmol, 88%, white solid 
mp: 113.0 °C (ref.[158]: 128 - 130 °C)  
1H NMR (400 MHz, CDCl3) δ [ppm] = 7.23 (s, 1H, 8-H), 6.71 (s, 1H, 5-H), 6.53 (s, 1H, 5'-H), 
3.98 (s, 3H, 6-OCH3), 3.82 (s, 3H, 6'-OCH3), 3.64 (s, 3H, 7'-OCH3), 3.50 (t, J = 6.7 Hz, 2H, 3-
H), 3.45 (s, 2H, 1'-H), 3.05 (s, 3H, 2-NCH3), 2.93 (t, J = 6.7 Hz, 2H, 4-H), 2.87 (t, J = 6.0 Hz, 
2H, 4'-H), 2.66 (t, J = 6.0 Hz, 2H, 3'-H), 2.38 (s, 3H, 2'-NCH3)  
13C NMR (101 MHz, CDCl3) δ [ppm] = 164.5 (C-1), 152.1 (C-6'), 151.7 (C-6), 146.9 (C-7), 144.8 
(C-8'), 139.8 (C-7'), 132.8 (C-4a), 129.9 (C-4a'), 122.3 (C-8a), 121.2 (C-8a'), 114.1 (C-8), 110.3 
(C-5), 109.4 (C-5'), 61.0 (7'-OCH3), 56.4 (6-OCH3), 56.1 (6'-OCH3), 52.4 (C-3'), 52.3 (C-1'), 
48.4 (C-3), 45.9 (2'-NCH3, 35.1 (2-NCH3), 29.1 (C-4'), 27.8 (C-4). The NMR data are mainly in 
accordance with literature[159-161].  
IR (ATR): ṽ [cm-1] = 2931, 2837, 1733, 1643, 1604, 1495, 1451, 1339, 1280, 1186, 1116, 
1070, 1013, 815, 774 
Purity (HPLC, method c) = 97% (λ = 210 nm)  
HRMS (ESI): m/z = calcd. for [C23H28N2O5 + H]+ 413.2071, found: 413.2064  
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7.1 SUPPLEMENTARY MATERIAL 
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Figure 22. Antiproliferative effects of racemic muraricine (rac‐34) and tetrandrine (1) on hepatocellular carcinoma 
(HepG2, A), colorectal adenocarcinoma (HCT‐15, B) and bladder carcinoma (T24, C) cell lines. Proliferation is 
shown as percentage of vehicle control after subtraction of the zero value. Line graphs display mean ± SEM of 
three independent experiments.   
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7.2 ABBREVIATIONS 
 
Å Ångström  
APCI atmospheric pressure chemical ionziation 
ASAP atmospheric pressure solids analysis probe 
ATR attenuated total reflectance 
Bn benzyl 
calcd calculated 
COSY homonuclear correlation spectroscopy 
CoV coronavirus 
CTB cell titer blue 
DCM dichloromethane  
δ chemical shift in ppm 
DEPT distortionless enhancement by polarization transfer 
DMF dimethylformamide  
DMSO dimethylsulfoxide 
EI electron ionization 
eq. equivalent 
ESI electron spray ionization 
EtOAc ethylacetate 
EtOH ethanol 
FCC flash column chromatography 
GC gas chromatography 
h hour 
HepaRG  hepatic stem cells 
HepG2 human hepatocellular carcinoma cells 
HMBC heteronuclear multiple bond correlation 
HMQC Heteronuclear multiple-quantum correlation 
HPLC high performance liquid chromatography  
HSQC heteronuclear single quantum correlation 
HR high resolution 
HUVEC  human umbilical vein endothelial cells 
Hz Hertz 
IC50 inhibitory concentration 
IR infrared 
J coupling constant 
λ wave length 
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LDA Lithiumdiisopropylamid 
MERS middle eastern respiratory syndrome 
MeOH methanol 
(m)mol (milli)mole 
mp melting point 
MS mass spectrometry 
Mw molecular weight 
NMR nuclear magnetic resonance 
NOESY nuclear Overhauser effect spectroscopy 
PBMC  peripheral blood mononuclear cells 
P-gp P-glycoprotein 
p-TsOH para-toluolsulfonic acid 
Rf   retardation factor 
rt room temperature 
SARS severe acute respiratory syndrome 
Tcl2 deuterated tetrachloroethane 
TFA trifluoroacetic acid 
TFE trifluoroethanol 
TfOH trifluoromethanesulfonic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TPC two pore channel 
VCR vincristine 
VCR-R CEM  vincristine-resistant acute lymphoblastic leukemia cells 
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